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A persons DNA is constantly under threat from damage caused by environmental 
factors, as well as the normal replication processes it performs whilst generating new cells. If 
the damage is serious enough it can kill the cell or lead to the formation of cancer, in order to 
protect the cells from death or cancer the cells have a series of repair pathways it employs in 
a variety of situations. 
DNA-PK is an enzyme that works in the Non-Homologous End Joining Pathway 
repairing DNA double strand breaks that can be caused by factors such as Ionising 
Radiation, UV light and chemotherapy drugs. If a high-resolution structure was produced it 
could be used to help with the development of drugs to be used in combination with existing 
cancer therapy to make them more effective. This study will show the work performed to 
attempt to generate soluble correctly folded protein to serve these structural purposes. 
DNA undergoes replication in order to produce new cells. This involves a large raft of 
proteins, all of which have specific functions. One particular protein is involves in the 
removal of a small RNA primer, whose role is the initiation of the replication process but also 
has to be removed from the final DNA sequence. Flap Endonuclease 1 (FEN 1) is the protein 
charged with this task. This study will use the Archeon Pyrococcus abyssi as a model organism. 
It is an organism that thrives under high pressure and high temperature, as well as having a 
DNA replication system analogous to ours, however much simpler.  
 xx 
Abstract
Genomic stability refers to an organism’s ability to maintain and pass forward its 
genetic information. There are a raft of proteins and pathways whose sole purpose is 
maintaining this stability through swiftly replicating DNA as well as accurately repairing 
damage caused through contact with endogenous and exogenous DNA damaging elements. 
This study will focus on the structural aspects of two proteins that play a part in different 
areas of genome maintenance.  
Flap Endonuclease 1  (FEN 1) works in DNA replication, where it is tasked with 
removing a small RNA flap that is created during Okazaki fragment formation. This flap 
removal is essential to mature these fragments into one continuous strand of nascent DNA. 
Using the archeon Pyrococcus abyssi (Pab) as a model system has the advantage of possessing 
simple replicative machinery, whilst bearing striking similarities with the human system. Pab 
is a hyperthermophilic, piezophile meaning it thrives in conditions of high temperature and 
pressure.  
DNA-dependent protein kinase (DNA-PK) is a holoenzyme that plays a role in the 
Non Homologous End Joining (NHEJ) pathway by repairing DNA double strand breaks 
(DSB’s). In cancer therapy, a patient is exposed to DNA damaging elements, leading to an 
ever-increasing population of DSBs. If an inhibitor of DNA-PKcs were introduced along 
with this therapy it could potentiate its effect, as the cancerous cells will be less able to repair 
the damage. The aim of this part of the study is to determine a protocol to generate pure, 
soluble, correctly folded protein for the purposes of biophysical characterisation and X-ray 
crystallographic structural studies.  




1.1 Genome Instability & Cancer 
1.1.1 – DNA damage 
The genetic information contained within a cell is under the constant threat, both 
internally and externally, of damage to its integrity. Endogenous damage can come from 
maintenance processes such as transcription and replication that can occasionally produce 
faulty products, whereas exogenous damage can come from ultraviolet (UV) light and 
ionising radiation (IR), as well as certain cytotoxic chemicals. If the damage that is caused is 
not repaired rapidly and efficiently, this can lead to mutations, compromising the integrity of 
the genome as well as the survival of the cell. 
The levels of DNA damage have been estimated in humans to be in the region of 
10,000 to 1,000,000 events per day per cell (1). DNA damage such as this falls primarily into 
three categories. Firstly, there can be chemically induced alteration of the nucleotides in the 
DNA sequence and secondly, there can be mutations that arise due to errors in the 
replicative process. Finally the chemical alteration of the DNA backbone can occur. 
Nucleotide alteration can itself occur as a result of a multitude of factors. These can 
include oxidation, where the DNA is damaged by reactive oxygen species (ROS) produced 
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during normal metabolic processes within the cell. One common product of DNA oxidation 
in mammals is the guanine analogue 8-hydroxyguanine (OH8Gua)1 (2).  
Another nucleotide alteration is alkylation, whereby the nucleotide is modified, usually 
through the addition of a methyl group. One prevalent methylation event is the alteration of 
guanine, forming 6-O-methylguanine. This modification stops the guanine binding with its 
traditional pyrimidine partner cytidine, but with the alternative pyrimidine thymine. This 
creates a DNA mismatch that can lead to a permanent mutation if not repaired correctly (3).  
 
Figure 1.1 - Chemical structure of guanine as well as two products of its modification. 
Oxidation can lead to addition of a hydroxyl group to position 8 of the guanine, forming 8-
hydroxyguanine; Alkylation can cause modification of the carboxyl group at position 6, forming 
6-O-methylguanine. 
Hydrolysis of the bases can also occur, leading to deamination, depurination and 
depyrimidation. This then leaves an unpaired base, which can be repaired through base 
excision repair (BER) (4). Another means by which the nucleotides can be chemically altered 
is through the formation of either inter- or intra-strand crosslinks. This is the formation of a 
covalent bond between two nucleotides affecting the ability of this portion of the sequence to 
take part in transcription and replication (5). Several pathways working in collaboration with 
one another usually repair this type of cytotoxic damage, BER and homologous 
recombination (HR) (6).  
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Figure 1.2 – Illustration of an interstrand crosslink between guanine and cytosine. This 
covalent link between nucleotides abrogates further downstream processing such as 
replication and transcription (7).   
Both polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene, commonly 
found in coal tar, and heterocyclic aromatic compounds (HACs) such as dibenzacridine, 
commonly found in cigarette smoke, are generated in the environment and are attributed to 
an increased incidence of cancer (8). Their reactive metabolites can covalently bind to 
nucleotides leading to the formation of depurinic adducts, an example of which can be seen 
in figure 1.3(B), with similar effects to nucleotide hydrolysis (8). 
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Figure 1.3 - (A) Dibenzacridine, an example of a heterocyclic aromatic compound; 
Benzo[a]pyrene, an example of a polycyclic aromatic hydrocarbon. (B) Figure published by 
Formenton-Catai et al describing the oxidative metabolic pathway of benzo[a]pyrene that leads 
to the formation of a DNA adduct with guanine (9). 
DNA damage, as a result of replication, can lead to nucleotides being either added, 
deleted or mutated spontaneously (10). Depending on the nature of the nucleotide alteration, 
it could be relatively innocuous, but it could be quite damaging to the cell. If a nucleotide 
  Chapter 1 
 5 
were added early in a protein coding exon sequence of DNA and not subsequently repaired, 
it would lead to a frame shift, thus permanently changing all amino acids synthesised 
downstream of the alteration.  
Chemical alteration of the DNA backbone is a significant type of DNA damage, and 
can potentially be the most destructive to the cell. The covalent bonds in the backbone of the 
DNA can be broken down when they come into contact with exogenous factors such as IR 
and certain chemotherapeutic drugs (11). This can lead to the formation of single strand 
breaks (SSBs) or, if the intensity of the radiation or concentration of drug is high enough, 
double strand breaks (DSBs). DSBs can be extremely cytotoxic and it has been shown that 
even one unrepaired DSB can be sufficient to trigger cell death (11, 12). If they go 
unrepaired they can lead to permanent cell cycle arrest and death, either through apoptosis 
or loss of genomic material (13). If they go on without sufficient repair, gene deletion can 
occur, along with chromosomal abnormalities, translocation and loss, all of which have been 
linked with cancer (11, 13) . 
DSBs are also an integral part of endogenous cellular processes. A key example of this 
occurring is V(D)J recombination (variable, diverse, joining gene segments). This is the 
process of generating antigen-binding diversity within developing B- and T- lymphocytes. 
These gene segments are flanked by recombination signal sequences, made up of conserved 
regions that ensure accurate segment joining. Further randomisation is generated through 
combinations of small deletions as well as insertions of either random or complementary 
nucleotides. The occurrence of these small deletions is believed to be due to the formation of 
DSBs, the repair of which occurs by the same pathways used when the cause of the DSB is 
exogenous (12, 14). 
With a vast array of repair processes to both detect and repair damage to the DNA, a 
considerable majority of the threats to genome integrity are removed or repaired. Some 
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damage eludes repair and can have a variety of phenotypes. If a cell were to pass on any 
DNA damage, this damage would be fully incorporated into the nascent strand and therefore 
would be undetectable with the canonical repair processes and therefore not be able to be 
repaired, remaining a permanent part of the genome from that point. This can potentially be 
extremely toxic to the cell and so safeguards are in place to stop the cell cycle from 
continuing at the point DNA damage has been detected. 
1.1.2 – Carcinogenesis  
If a mutation is caused either to an oncogene, tumour suppressor gene, or a gene 
involved in the DNA repair pathway, it can lead to the formation and progression of cancer. 
An oncogene is dominant in its nature and is formed when a normal gene, termed a ‘proto-
oncogene’, is mutated resulting in the cell becoming cancerous (15, 16). The proto-oncogene 
is often a gene that forms proteins affecting cell division and differentiation. The mutated 
proto-oncogene then encodes for increased expression of the resultant series of proteins, 
which can lead to the cell being unable to initiate or proceed with apoptosis, a trait 
commonly seen in cancer (16). Tumour suppressor genes (TSGs), such as p53, are genes that 
code for proteins that function in a variety of ways. Firstly they repress certain cell cycle 
proteins, leading to inhibition of cell division. Some TSGs code for cell adhesion proteins 
that work to prevent cellular dispersion, and therefore metastasis (17). A mutation in any of 
these genes can therefore inhibit their ability to perform their primary function.  
The final result of a cellular system that contains depleted numbers of functioning 
TSG products, and over-expressed oncogene products, is a heterogeneous tumour cell 
population that has no growth regulation and undergoes replication without restraint, all the 
while failing to respond to archetypal apoptosis signals (16). 
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1.2 DNA Damage Repair 
1.2.1 – Overview of DNA repair pathways 
1.2.1.1 - Mismatch repair  
As mentioned previously, a nucleotide mismatch can occur in a variety of manners, 
but the pathway for their repair is thought to be conserved across both prokaryotes and 
eukaryotes. The mismatch repair (MMR) pathway has been well characterized in E. coli, but 
the mammalian pathway is less understood. Homologues for the key components have been 
determined, such as MutS, which is responsible for mismatch recognition and binding as well 
as binding to insertion/deletion loops, which evade repair by proofreading nucleases. These 
roles are performed in Eukarya by MutSα (Msh2/Msh6 heterodimer) and MutSβ 
(Msh2/Msh3 heterodimer), where MutSα binds preferentially to the mismatches and single 
insertion/deletion loops, and MutSβ binds to 2-4 base pair insertion/deletion loops (18). At 
this point the parent and daughter strands are discriminated from one another and the 
protein ExoI excises the mismatched portion of the daughter strand. The single strand 
binding polymerase Polδ and DNA ligase resynthesise and re-ligate the repaired DNA (19). 
1.2.1.2 - Base excision repair 
As previously mentioned, BER plays a key role in the repair of nucleotide hydrolysis 
and inter-strand crosslinks, but it is in fact most abundantly used to repair adduct formation 
as a result of both PAHs and HACs (20, 21). The pathway is initiated when the damage is 
detected by one of 11 distinct glycosylases, the choice of which relates to the specific lesion 
type. Once bound the glycosylase excises the affected base, leading to the formation of an 
abasic site (AP-site), which undergoes incision by an endonuclease APE1 (Human AP 
Endonuclease). The DNA polymerase, Polβ, then processes the subsequently formed DNA 
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ends, which are then ligated together with DNA Ligase I. This is termed the single 
nucleotide-BER pathway. When a longer portion of nucleotides, between 2 and 10, need to 
be removed, the long-patch BER pathway is employed. This uses the same factors as 
mentioned previously, with the notable addition of both PCNA and FEN 1. This pathway is 
preferentially chosen in proliferating cells, where the choice of polymerase also changes from 
Polβ to Pol δ/ε (22). 
1.2.1.3 - Double strand break repair 
The safeguards against DNA damage mentioned previously are cell cycle checkpoints 
and in terms of DSBs they work to halt the transition from one phase to the next. When a 
DSB is detected, it triggers the DNA damage response (DDR), a process that works to 
maintain genomic stability by a variety of pathways including DSB repair, cell cycle arrest 
and apoptotic signal transduction (23).  
Figure 1.4 shows the mammalian cell cycle. The point in the cell cycle determines the 
DSB repair pathway choice for its repair. If the damage is detected either in G0 or G1 then 
the DSB will be predominantly repaired using the non-homologous end joining (NHEJ) 
pathway. If however the damage is detected in the G2 phase, homologous recombination 
(HR) will be employed. This preference for HR is due to having a newly synthesised 
homologous strand very close to the damaged DNA as replication has just concluded. With 
no homologous strands nearby in G0 or G1 the NHEJ pathway is preferred (23, 24). The 
proteins highlighted in the figure are known to play roles as checkpoint proteins, halting the 
cell cycle when aberrant DNA is detected. 
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Figure 1.4 - A schematic of the mammalian cell cycle. It begins in the Gap 1 (G1) phase 
where the cells physically grow in size and prepare for the impending DNA synthesis. A 
checkpoint exists here to ensure no DNA damage is present. Gap 0 (G0) is a resting state of 
the cell, where it leaves the cell cycle and takes part in no further growth or replication. The 
synthesis (S) phase then begins and is where DNA replication occurs. A secondary gap 
phase then occurs (G2), where the cells continue to grow once more. Again a checkpoint is 
in place here to ensure all newly synthesised DNA is correct, ready for mitosis. The mitosis (M) 
phase then begins, here all cell growth stops and focus is changed to division into two 
daughter cells. There is also a checkpoint midway through mitosis to ensure division is 
proceeding correctly (25, 26). 
1.2.2 – Homologous Recombination 
During either S or G2, the checkpoint kinase Chk1 plays a key role in halting cell cycle 
progression when a DSB is detected, either as a result of an exogenous factor such as IR, or a 
DNA replication error such as a stalled replication fork (27). Once hindered in G2, HR 
begins with the MRN (Mre11, Rad50, Nbs1) complex detecting the DSB and signalling for 
Rad52 to resect, in a 5’-3’ direction, the DNA strands away from the break site. At this point 
these overhangs invade an adjacent double helix, with which it shares sequence homology 
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(12). Rad51 helps with the strand invasion and DNA polymerase then extends the strands. 
Resolvase A then cleaves the interwoven DNA strands, known as Holliday junctions, into 
crossover and non-crossover products. Crossover products involve exchange of the 
homologous strand by cutting the inner strand of one Holliday junction and the outer strands 
of another. Non-crossover products are formed when both Holliday junctions are cut in the 
same plane. After the junction has been resolved the backbone is reformed using DNA 
Ligase (12, 28). 
1.2.3 – Non-Homologous End Joining 
As mentioned previously, when the cell cycle progression is halted in either G0 or G1 
then the DSB will be predominantly repaired using the non-homologous end joining (NHEJ) 
pathway. The halting of the cell cycle whilst in either G0 or G1 has been shown to be 
performed by p53 and this signal is sent by DNA dependent protein kinase (DNA-PK) 
catalytic sub unit (DNA-PKcs) (29). A schematic of the pathway can be seen in figure 1.5. 
Whether the source of the DNA damaging element is endogenous or exogenous the first step 
is detection of the break. This is performed by the heterodimer Ku70/80. It is made up of 
two sub units, firstly Ku70, which has a MW of 69 kDa in humans and Ku80, which has a 
MW of 83 kDa in humans (30). The Ku70/80 forms a dyad symmetrical molecule and binds 
to the DNA in a tight ring formation at a break site (31, 32), in a non-structure specific 
manner, meaning that it can interact with blunt end DNA as well as DNA with both 5’ and 
3’ overhangs. The sequence is also not important to the binding (33) due to its inherent mode 
of action.  
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Figure 1.5 - A schematic of the non-homologous end joining pathway. It involves the break 
recognition by Ku70/80 and the subsequent recruitment of DNA-PKcs, which acts to 
phosphorylate both itself and downstream factors such as Artemis, XRCC4, XLF and Ligase 
IV that are essential for the repair of DSBs. 
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Although the Ku heterodimer is the factor involved in the DSB detection and DNA-
PKcs recruitment, DNA-PKcs has been shown to bind to the DNA ends in its absence, when 
at high concentrations, however the activity of DNA-PKcs is diminished in the absence of 
the Ku heterodimer (33, 34). It has also been shown that the DNA ends are required in order 
to elicit an interaction between the Ku70/80 and DNA-PKcs.  
The DNA-PKcs is recruited via a helical domain present on Ku80 (32), at which point 
it interacts with both the Ku70/80 as well as the DNA (33, 35). It has been shown that the 
DNA-PKcs is truly DNA dependent due to the fact that in the absence of DNA, there is no 
catalytic activity (36). This DNA-PKcs binding to the Ku70/80 forms the complexed, active 
holoenzyme DNA-PK. The recruitment and binding of DNA-PKcs to the Ku70/80 triggers 
the translocation of Ku70/80 approximately 10bp (one helical turn) inward from the break 
allowing the DNA-PKcs to access the break site (37). The next protein that is recruited is 
Artemis, which has been shown to possess 5’-3’ exonuclease activity on its own, but works as 
an endonuclease when complexed with DNA-PK. It uses this functionality to remove any 5’ 
or 3’ overhangs present at the break site, preparing them for ligation (38). This endonuclease 
activity is dependent on both DNA-PK autophosphorylation and the phosphorylation of 
Artemis by DNA-PK (39). After Artemis has resected the overhangs present, terminal 
hydroxyl groups remain on both the 5’ and 3’ ends, which cannot be ligated to one another. 
Polynucleotide kinase (PNK) is then recruited to the break site and it also plays a role in 
preparing the ends of the repaired DNA for ligation by replacing these hydroxyl groups with 
5’ and 3’-phosphate groups, which requires the presence of both DNA-PKcs and X-ray cross 
complementing gene 4 (XRCC4), the latter of which also binds at this point (40).  
The XRCC4/Ligase IV/XLF complex is involved in ligating the repaired ends of the 
DNA together. Each of these proteins has been shown independently to interact with other 
proteins involved in the NHEJ pathway, already bound to the break site. The C-terminus of 
DNA Ligase IV has been shown to interact with Artemis whilst in complex with DNA-PK 
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(41, 42). The XRCC4/Ligase IV complex has been shown to interact with Ku70/80 both in 
the presence and absence of DNA-PKcs, but in its presence the interaction is considerably 
enhanced (42, 43). It occurs by DNA Ligase IV and Ku70/80 directly interacting with one 
another whilst the XRCC4 acts to stabilise the entire complex. XRCC4-like factor (XLF) is 
also present in the complex and is thought to promote NHEJ through regulating the activity 
of the XRCC4/Ligase IV complex (44). 
Once the damage has been repaired, the DNA-PKcs has to break away from the 
complex. This is achieved through autophosphorylation at the ABCDE cluster, triggering a 
conformational change in the protein, abrogating any affinity for the DNA (Fig. 1.6 ) (45, 
46). 
1.3 DNA-Dependent Protein Kinase 
DNA-PKcs is a serine/threonine protein kinase that is a member of the 
PhosphatidylInositol-3-OH Kinase (PI3K)-related Kinase family (PIKK) and it consists of a 
single polypeptide chain of 4128 amino acids, providing the main functionality to the DNA-
PK complex (47). Other members of this family include ATM (Ataxia Telangiectasia 
Mutated protein), ATR (Ataxia Telangiectasia and Rad3 related protein) and mTOR 
(mammalian target of Rapamycin). ATM and ATR both play significant roles in signal 
transduction through the cell cycle checkpoints mentioned earlier (48) and mTOR also plays 
a role in cellular signalling, regulating cell growth and proliferation (49). 
It has been shown that cells containing mutations in DNA-PKcs have increased 
radiosensitivity, indicating its importance in the repair of DSBs as a result of IR. Its 
importance has also been shown with scid (severe combined immunodeficiency) mice, 
whereby DNA-PKcs is mutated, leading to it being unable to carry out the V(D)J 
recombination required to generate antibodies during development (11, 50). 




Figure 1.6 - Linear sequence and conserved domains of DNA-PKcs: Red - Caspase-3 
cleavage site; Green - Two functionally relevant autophosphorylation clusters, PQR (S2023-
S2056) and ABCDE (T2609-T2647) (51, 52); Orange – FKBP-12 Rapamycin associate 
protein domain; Beige – Ataxia Telangiectasia mutated protein domain; Cyan – 
Transformation/Transcription domain-associated protein domain – All three of which form the 
FAT domain; Purple – Catalytic domain that is a member of the PI3K family. 
 
Highlighted in figure 1.6 are two functionally relevant autophosphorylation clusters 
(PQR and ABCDE) within the sequence. Present at D2020 is the Caspase 3 cleavage site. 
DNA-PKcs is a substrate for Caspase 3 prior to apoptosis (53). The FAT (FRAP, ATM, 
TRRAP) region of residues spans residues S2883 to S3539. The FRAP (FKBP12-Rapamycin 
Associated Protein) also known as mTOR (mammalian Target Of Rapamycin) plays a key 
role in cell cycle progression (54). ATM (ataxia telangiectasia mutated protein) plays a role in 
the phosphorylation of downstream factors such as the histone H2AX, which is triggered in 
response to the detection of DNA DSB’s (55). TRRAP (TRansformation/tRanscription 
domain-Associated Protein) is a ’pseudokinase’, lacking the conserved residues required for 
successful ATP binding and turnover. It works by recruiting several histone acetyltransferase 
complexes to chromatin, to be used during transcription, replication and repair of the DNA 
DSB (56). 
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The kinase (catalytic) domain codes for the region that binds ATP in order to confer 
its enzymatic activity and phosphorylate the Ku70/80. It is also one of the regions where the 
DNA-PKcs can autophosphorylate and dissociate from the newly repaired DNA double 
strand. The catalytic domain is directly connected to the C-terminal end of the sequence 
(FATC). It has been shown to be essential to the function of the enzyme, as a mutation 
present in the T-loop, a phosphorylation site within the kinase domain at T3950, leads to 
total loss of function (57). 
Initial in depth structural analysis using a combination of negative stain electron 
microscopy (EM) and cryo-EM led to the determination of a 13 Å structure from Rivera-
Calzada et al (58)  They determined binding modes and orientations between DNA-PK and 
double stranded DNA. They corroborate the finding that the DNA-PKcs interacts with the 
DNA ends triggering a significant increase in catalytic activity. The evidence for which was a 
conformational change, brought about by the DNA binding. The mechanism of this DNA 
binding involved bringing the palm and head regions of the protein within close proximity of 
one another. The palm region of the EM structure was determined to map to the N-terminal 
HEAT repeat region of the protein, with the head region containing the C-terminal catalytic 
domain (58). 
 
Figure 1.7 – 13Å three dimensional cryo-EM structure of DNA-PK published by Rivera-
Calzada et al (58) showing 90° rotated views of  the reconstructed volume. (i) – Nucleus 
within the head region (ii) – large globular region, (iii) – tubular structure, (iv) – distal claw (v)  - 
proximal claw (vi) – curved stalk. 
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The EM studies also found that the DNA bound within the central cavity, with one 
end of the DNA binding within the inner portion of the HEAT repeats, between the head 
and palm of the protein. This work also correlates with the putative DNA binding domain 
present in the 6.6 Å structure highlighted in figure 1.7 (47, 58). 
 
Figure 1.8 - Annotated crystal structure from Sibanda et al (47) showing the poly-alanine chain 
structure solved to 6.6 Å for DNA-PKcs. PDB ID: 3KGV. Figure prepared using Pymol (59). 
 
The structure seen in figure 1.8 is a 6.6 Å representation of DNA-PK, isolated and 
purified to near homogeneity from HeLa S3 cells. At this resolution, side chain information 
cannot be determined. This meant that the structure was made up of alanine helices placed 
within the visible rods of electron density. It does show however that it is approximately 160 
Å in length, with a central ring diameter of approximately 120 Å (47). The position of the 
kinase domain within the structure was determined by superimposing the kinase structure of 
PI3Kγ onto the head/crown region (47). The sequence of the PI3K/PI4K region from 
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DNA-PKcs was aligned to the same region from PI3Kγ using the online software Clustal 
Omega, and the result indicated that the two regions share 32% sequence identity (60).  
Highlighted in cyan is the putative DNA binding domain. The green and magenta regions of 
the structure represent the HEAT repeats that are arranged anticlockwise from the pink gap 
region shown in the structure and circumnavigates the entire structure before reversing 
direction on the other side. This gap is theorised to be the point at which the two portions of 
repeats could move apart allowing for the release of DNA-PKcs from the DNA (61), this 
being the structural change mentioned previously that is brought about by 
autophosphorylation. 
As previously mentioned, the catalytic activity of DNA-PKcs is essential to confer its 
activity but its exact role is not yet fully understood (62). The DNA-PKcs has been shown to 
phosphorylate each of the factors involved in NHEJ, but it has also been shown that none of 
these phosphorylation events are essential for the pathway to proceed. The only 
phosphorylation events that have been shown to be necessary are, in fact, the 
autophosphorylations (36, 37).  
Autophosphorylation occurs at many of the sites throughout the sequence, which will 
be discussed in chapter 3, however there are some sites that are very important to the 
progress of NHEJ. One of the first sites to be phosphorylated is T2609, which is found within 
the ABCDE cluster and this site promotes end processing during NHEJ (36, 37). It is also the 
site that, once phosphorylated, triggers the conformational change required to dissociate 
from both the Ku70/80 and the repaired DNA (36). There are two phosphorylation sites 
that serve to inhibit repair via NHEJ. The T3950 loop as well as T946, present within the JK 
cluster that, when phosphorylated, both inhibit NHEJ and promote HR, however the former 
does this through inactivation of the DNA-PKcs, whereas the latter does not inactivate the 
enzyme (37, 63). 
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The EM studies mentioned previously also indicate an importance of these 
autophosphorylation sites throughout the structure in the various clusters (32, 58). The 
researchers determined that, based on the placement of these sites within the structure, they 
cannot be accessed via the active site of their respective molecule. This then lead to the 
conclusion that the sites have to interact with an alternative DNA-PKcs molecule in a trans 
orientation. This is thought to be the interaction that brings the two broken ends of DNA 
into close proximity with one another in order for further processing of the DSB by 
downstream NHEJ factors (32, 58). 
DNA-PK has also been shown to play a role in the protection of the ends of telomeres. 
After DNA replication it is found to bind to the telomere ends forming a protective terminal 
structure in order to prevent end-to-end fusions. The activity of DNA-PK on the telomere 
has been shown to only act on the product of leading strand synthesis rather than lagging 
strand synthesis when single chromatids are involved (64, 65). The activity of DNA-PK in 
this pathway has been shown to be solely possible due to the kinase activity of the enzyme, 
due to the fact that DNA-PKcs knockouts were not as compromising to chromosome end 
protection as a kinase inhibitor of DNA-PK (64, 66). These end-to-end fusion products have 
been shown to contribute significantly to chromosomal instability.  
1.3.1 – A link between DNA-PK and cancer. 
At the point a cell becomes cancerous its growth is rapid and unregulated. Although 
traditional cell cycle checkpoints can be faulty, the cancerous cells do employ DNA repair 
pathways such as NHEJ to repair DSB’s. Due to the high proliferative rate of cancer cells, 
any introduction of DNA lesions through various cancer therapies has a higher probability of 
being repaired. In cancer therapy, a patient is exposed to either IR for radio-therapeutic 
purposes or to cytotoxic drugs for chemotherapeutic purposes. Both of these elements are 
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cytotoxic, promoting the formation of lesions, which will eventually lead to the formation of 
an ever-increasing population of DSB’s.  
Experiments have been conducted on DNA-PKcs, where mutations within the kinase 
domain were introduced, subsequently leading to the failure of the pathway to restore the 
DSB back to a fully functional DNA double helix [9]. If a small molecule inhibitor were 
formulated to either occupy or block the catalytic domain, then it would stop the DNA-PKcs 
performing its functions of both phosphorylation and recruitment, effectively stopping the 
DNA-PKcs being a functioning part of the NHEJ pathway. Due to the fact that it is such an 
integral part of the pathway this inhibition would also halt the full repair pathway, 
significantly hindering the cell being able to repair the DNA DSB’s thus potentiating the 
effect of the therapy. 
1.3.2 –DNA-PK Inhibition  
DNA-PKcs is an interesting target to study in terms of potential use in combination 
with existing chemo- and radio-therapies. By inhibiting DNA-PK, its role within NHEJ, as 
well as V(D)J recombination, is inhibited. The former of which makes the cells prone to 
synthetic lethality. Whereby if the product of gene A is knocked out, which in this example 
can be DNA-PK, normal cells can survive due to the presence of various other factors and 
repair pathways that allow the cell cycle to continue. In cancer cells however, mutations in 
the DSB repair mechanisms already exist causing genomic instability. If the same product in 
these cells is then knocked out, the lack of alternative repair mechanisms mean the cell is 
considerably more likely to die.  
1.3.2.1 – Small molecule catalytic inhibitors 
An ATP-analogue inhibitor will competitively inhibit ATP binding, thus restricting the 
downstream phosphorylation required in the NHEJ pathway. This particular mode of action 
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however can lead to significant selectivity issues as all of the approximately 500 various 
kinases coded for within the human genome require a similar binding mode of ATP. To 
date, several small molecule inhibitors of DNA-PKcs have been formulated through 
combinatorial chemistry with widely varying results (67, 68). Wortmannin is an example of a 
non-specific DNA-PK inhibitor (68), but this trend can be further expanded upon with 
results published by Bain et al (69) indicating that over two previous studies, totalling 38 
different supposedly specific kinase inhibitors, a high number of these affected too many 
alternative kinase targets to be accurately called specific. Hollick et al (68) however claim to 
have found, through their use of structure activity relationships (SARs) a compound, 
NU7442, that is highly specific to DNA-PK with a half maximal inhibitory concentration 
(IC50) of 14nm, based on the inhibition of serine phosphorylation. 
This use of SARs and homology modelling in drug design has been utilised due to a lack of 
any accurate structural information. This is due to the fact that the highest resolution 
published structure, as previously mentioned is 6.6 Å (47), which is far too low, in terms of 
resolution, to determine any interactions a potential drug candidate would have with side 
chains present within the kinase domain. With more detailed structural information, at a 
higher resolution, rational structure-based drug design could be implemented. This would 
then lead to a more effective use of time and resources in the production of small molecule 
inhibitors. 
1.3.2.2 – Inhibitory peptides 
One negative aspect of catalytic inhibition of DNA-PK is the inadvertent inhibition of 
its role within alternative pathways, such as the V(D)J recombination pathway, reducing 
diversity within the cellular immune system. By working on an alternative inhibition target 
this can theoretically be negated. As mentioned previously, the autophosphorylation at both 
the ABCDE and PQR clusters of DNA-PKcs is integral to its function within NHEJ. Sun et 
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al have generated a series of small peptides that are theorised to bind to the ABCDE cluster 
present in DNA-PKcs. By binding at this point all subsequent phosphorylation events are 
inhibited, with T2647 being postulated as one of the most important phosphorylation sites. 
They do also theorise that the inhibitory peptides could be competing with DNA-PKcs 
substrates blocking their access to the kinase. (70).  
1.4 Archaea 
Life on Earth can be categorised by where on the phylogenetic tree it belongs. The 
tree is constructed based on the three domains of life, the Eukarya, the Prokarya and the 
Archaea (71) and this classification is determined based on ribosomal RNA (rRNA) genes 
and how they relate to one another (72, 73). The kingdom of archaea can then be divided 
into the two main recognised phyla: Crenarchaeota, which can be described as thermophilic, 
some existing at temperatures exceeding 110 °C, with a tendency to act as sulphur 
reductants (74); and Euryarchaeota, which is a considerably broader phylum, containing 
significantly more morphologies (71, 74). Archaea are a group of prokarya that bear strong 
resemblance to bacteria in their physical size and shape, but at the molecular and genetic 
levels they differ. Firstly they can be characterised by an ability to thrive under extreme 
conditions. These extreme conditions can include low or high pH (acidophiles and 
alkalophiles respectively), temperature (hyperthermophiles), pressure (piezophiles), salinity 
(halophiles), and often, this is in combination with anaerobic conditions.  
Secondly, at the genetic level, archaea actually have many features in common with 
eukaryotes. In the context of DNA, Eukarya posses a nucleus that houses the cell’s genetic 
information, whereas prokarya do not encapsulate their DNA, instead it is present 
throughout the cellular matrix. The prokaryotic genomes are considerably smaller than the 
genomes of Eukarya. As a result the DNA is small enough to be contained within a single 
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circular chromosome. This is in contrast to the eukaryotic DNA that is linear and too large 
to fit within the nucleus without being packaged, firstly around a nucleosome and then coiled 
around itself in a series of loops forming `chromosomes. That being said, the majority of 
Archaeal proteins involved in replication, transcription and translation have homology to 
their eukaryotic counterparts, whereas their relationship to the bacterial proteins are far 
more distant (75).  
1.4.1 – Pyrococcus Abyssi 
The research presented in this thesis was performed using FEN 1 from the 
euryarcheon Pyrococcus abyssi (Pab). Pab is a hyperthermophilic piezophile, meaning that it 
thrives under high pressure and high temperature. Originally discovered 2 km below sea 
level in the North Fiji basin, in the south-west Pacific ocean, it grows in temperatures ranging 
from 67ºC to 102ºC and at pressures ranging from atmospheric pressure to an optimum 
pressure of 20 MPa (0.2 kBar) and an optimum temperature of 96ºC (76). Studying archaea 
such as Pab can help to ascertain what genotypic and phenotypic aspects of the organism are 
required to enable it to exist in conditions that would kill other organisms. In the context of 
this research, comparing both ambient pressure and high-pressure X-ray crystal structures, 
what structural changes can occur within the specific DNA replication protein, Flap 
Endonuclease 1 (FEN 1), that allow the organism to not only survive, but thrive. 
1.5 DNA Replication 
DNA replication is the process whereby the genetic information in a proliferating cell 
is copied from a template strand to form two newly synthesised daughter strands, identical to 
the original sequence. It is a vitally important step in the life of a cell and faithful and 
accurate replication is necessary to ensure the correct genetic information is passed to 
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daughter cells. Errors can occur during this process, and the repair pathways mentioned in 
chapter 1.2 are present to ensure that mistakes made during replication are not made 
permanent for future generations. 
DNA replication occurs when a series of proteins come together to form what is 
termed the replisome, a complex molecular machinery that actually performs the replication. 
The replication itself can be broken down into three processes. Firstly comes the initiation 
step. This begins at the origin of replication (oriC), with the formation of a pre-replication 
complex, which plays a role in the recruitment of further downstream proteins. The next 
stage is elongation, where the new daughter strands are synthesised, using the initial DNA as 
a template. This synthesis only ever occurs in a 5’-3’ direction, which means that the leading 
strand (with 5’-3’ polarity) is synthesised in a continuous manner, but the lagging strand (with 
3’-5’ polarity) has to be synthesised in a discontinuous manner, maintaining the correct 
directionality. This discontinuous synthesis makes use of short fragments of RNA-primed 
DNA, known as Okazaki fragments. The RNA primers present on these fragments are then 
removed and the two adjacent fragments are ligated to one another in a process known as 
Okazaki fragment maturation. The final step in replication is termination, occurring when 
the replisome encounters a termination site within the sequence, stopping the replication fork 
from proceeding any further. 
1.5.1 – Replication in Prokaryotes 
Extensive research has been carried out to determine how DNA replication occurs in 
prokaryotes using E. coli as a model organism. There is one origin of replication termed the 
oriC, which is a unique 245 bp sequence in the genome that directs assembly of the replisome 
onto the DNA to generate the replication fork (77). A DNA unwinding element (DUE) is also 
present at the oriC. This is a binding site for DnaA, whereby a DnaA-ATP complex 
multimerises and then melts the DNA allowing the helicase DnaB to access the DNA via the 
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helicase loader DnaC (78). At this stage the primase DnaG synthesises the RNA primers for 
both the leading strand, and for the Okazaki fragments needed for lagging strand synthesis. 
The polymerase holoenzyme Pol III HE then assembles the new DNA strand (79). 
 
1.5.2 – Replication in Eukaryotes 
DNA replication in eukaryotes is considerably more complicated and diverse than 
bacterial replication.  There are a variety of factors that make this the case; firstly there is a 
larger network of associated proteins and complexes required. Eukaryotic cells take part in 
the cell cycle shown in figure 1.4, whereas bacteria use a far simpler mechanism of binary 
fission. In binary fission the DNA is first replicated and the two strands migrate to opposing 
sides of the cell, in the absence of spindles. Once migrated, the cell lengthens and the plasma 
membrane constricts in the central portion of the cell forming a new, genetically identical 
cell. The genetic information of a eukaryotic cell is replicated once per cell cycle. This 
replication occurs during the S phase, but there are several steps that are essential to the 
replication that occur during the G1 resting phase.  
The first step that occurs early in the G1 phase, analogous to prokaryotic replication, is 
the formation of the pre-replication complex (pre-RC). This involves a complex of factors 
including the heterohexamer origin recognition complex (ORC) as well as the proteins: cell 
division cycle 6 (CDC6); Chromatin licensing and DNA replication factor 1 (CTD1) and the 
heterohexamer mini-chromosome maintenance (MCM). They bind to oriC sites present in 
the genome. In bacteria there is one oriC however in eukaryotes there are as many as several 
thousand on each chromosome (80). This is simply due to the size of the eukaryotic genome. 
An example is the human genome, which is approximately 3.2 billion bp, compared with the 
genome sequence for E.coli, which is approximately 4.6 million bp.  
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The transition from G1 phase to S phase begins directly after the formation of the pre-
RC, at the point at which a pair of kinases, cyclin-dependent kinase (CDK); and Dbf (Dumb-
bell former) dependent kinase (DDK), activates it. This activation results in MCM mediated 
DNA unwinding and binding of both replication protein A (RPA) and DNA polymerase, 
which work to initiate DNA synthesis (80, 81). 
1.5.3 – Components of the archaeal replicative machinery 
The archaeal replicative process shares aspects with both the eukaryotic and bacterial 
systems. Some archaea have one origin of replication, like bacteria, as is the case with Pab, 
which was also the first origin to be determined (82). Other archaea can have more, like 
Eukarya, such as Sulfolobus solfataricus, which has two (83),  or Methanocadococcus jannaschii,, 
which has multiple origins (84).   
The origins are large AT-rich stretches of DNA that are essential for function. They 
are frequently found in close proximity to the genes encoding for the archaeal homologues of 
both CDC6 and Orc1, mentioned previously as initiator proteins required for formation of 
the ORC, responsible for the formation of the pre-RC (84, 85).  
In the context of Pab, the ORC bind to the single origin using the catalytic activity 
derived from its AAA+ ATPase domain. As mentioned previously, eukaryotes bind the 
MCM at the pre-RC, mediated by the CDC6 within the ORC. This pathway has not been 
resolved in archaea, but Shin et al postulate that based on their sequence similarity, the 
archaeal homologue CDC6-2 does in fact mediate the loading of MCM on to the ORC (86). 
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Figure 1.9 – A model of the architecture of the archaeal DNA replicative machinery. The MCM helicase unwinds the DNA allowing for the leading 
strand to be synthesised continuously whilst the lagging strand is synthesised discontinuously. Here the formation of the okazakisome is initiated, 
where PCNA mediates interactions between the DNA and the polymerase, lengthening the DNA, the FEN 1, cleaving the displaced RNA flap, and the 
ligase, sealing the nick between adjacent Okazaki fragments.  
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The GINS (Go-Ichi-Ni-San – five-one-two-three in Japanese) complex is directly 
involved in the interaction between the MCM and the primase. Unlike in eukaryotes, where 
the primase DnaG directly interacts with the helicase DnaB, in archaea there has been 
shown to be no interaction between the primase and the helicase MCM (87). Due to the fact 
that polymerases, such as PolB1, are unable to generate new DNA de novo, they require the 
use of a primed sequence. Both the small and large primase sub units are responsible for 
generating these short sequences of RNA that initiate the polymerases on both the leading 
and lagging strands. 
The Okazaki fragments then undergo maturation, a process that involves removal of 
this RNA flap. FEN 1, mediated by its interaction with the proliferating cell nuclear antigen 
(PCNA), performs this flap removal. Another protein that interacts with PCNA is the ligase, 
that seals the nick between adjacent Okazaki fragments leading to a continuous strand of 
nascent DNA (88). RPA binds to the single stranded portions of the DNA, as shown in the 
figure in order to protect it from nuclease attack or chemical modification during the 
replicative process. It is a heterotrimer, made up of three monomers that are approximately 
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 Replication Components Replication Mechanisms 













RPA, pol ε, 
pol α, pol δ 
FEN 1, Dna2, 
DNA Ligase 
Occurs inside nucleus, 
many origins of 









Occurs in cytoplasm, 
single origin of replication, 











FEN 1, Dna2, 
DNA Ligase 
Occurs in cytoplasm, 
various levels of replication 
origins, very rapid 
replication.  
Table 1-2 - Highlighting the similarities and differences in the process of DNA replication 
across the three domains of life. 
1.5.4 – Flap Endonuclease 1 
FEN 1 is a highly conserved structure specific endonuclease that works by removing 
any un-annealed 5’ flaps present as a result of lagging strand DNA synthesis. The maturation 
of Okazaki fragments and the role of FEN 1 is functionally conserved across eukaryotes, 
prokaryotes and archaea (90). The Okazaki fragments observed in both Pab and other 
Eukarya are the same length (82) and taking this into consideration makes Pab an excellent 
model to study DNA replication, since the replication machinery is simpler but shares many 
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similarities with both Eukarya and bacteria. FEN 1 has been shown to be essential to survival 
of the cell. Homozygous knockouts have been shown to be lethal in mice and heterozygous 
knockouts have been shown to lead to rapidly accelerated tumour growth due to incorrect 
DNA replication (91). Traditional endonucleases are sequence specific, but FEN 1 requires a 
branched DNA structure, with a single 3’ unpaired nucleotide, overlapped with a sequence 
of 5’ unpaired DNA that can vary in length, but if it is longer than 5 to 7 nucleotides, RPA 
will bind and this portion of the nucleic acid will have to be cleaved via Dna2 before FEN 1 
can perform its function (92). This particular pathway, involving the use of RPA as a single 
stranded binding protein and Dna2 mediated cleavage, is termed the ‘long flap’ pathway 
(93). PolB1 displaces the RNA primer used to initiate the synthesis of the upstream Okazaki 
fragment, and this displacement leads to the formation of the ‘double-flap’ required as a 
structure for optimal FEN 1 binding (94). FEN-1 then works by cleaving this substrate after 
the first base pair preceding the 5′ flap to remove the flap and create a nicked DNA product 
(94, 95). 
Occasionally, in eukaryotes, FEN 1 can dissociate from the PCNA-FEN 1-DNA 
ligase-DNA complex, which in turn leads to polδ mediated flap lengthening (93, 96). If this 
newly lengthened strand is complementary with itself, it can in fact form a hairpin structure 
that cannot be repaired either by the long flap pathway or the short flap pathway (a pathway 
that does not require intervention from either RPA or Dna2). These hairpins have been 
shown in vitro to actually be un-wound by the helicase Pif 1 allowing the polymerase to 
resynthesise a new Okazaki fragment by displacing anything present on the affected portion 
of DNA. It is currently unknown if this also occurs in vivo (93, 97). 
As mentioned previously, in section 1.2.1.2, BER is used to repair oxidised and 
alkylated nucleotides present in genomic DNA. BER can be subdivided into single nucleotide 
BER (SN-BER) and long patch BER (LP-BER), the difference being the size of the portion of 
DNA undergoing repair (98). In LP-BER, the DNA polymerase adds anything from 2 to 15 
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nucleotides, displacing the damaged DNA strand, in the same manner as it displaces the 
RNA primer during Okazaki fragment maturation. This displacement leads to the 
generation of a 5’ single stranded flap, that is a substrate for FEN 1 (98). The FEN 1 then 
cleaves this flap in the same manner as in Okazaki fragment maturation leading to DNA 
ligase sealing the nick and producing a repaired DNA product.  
1.5.5 –Effects of a high-pressure system 
At the high pressures that Pab thrives at, the pressure is initially exerted on the cell wall 
and membrane, which can potentially shield the internal cellular components from these 
extremes. When pressure is applied to a system, there has to be a change in the volume of 
that system to maintain equilibrium. The Gibbs free energy (G) can be defined by the 
following equation: 
 
Where H is enthalpy of the system, T is temperature (in kelvin), S represents the 
entropy of the system, E is the internal energy, p is the pressure and V is the volume. 
Le Chatelier’s principle states that in a given system, upon the introduction of an 
external stimulus, a change in another aspect of the system has to occur to oppose the 
external stimulus and maintain equilibrium. The equation above states that in order for the 
equilibrium to be maintained, a shift toward an increase in pressure will ultimately lead to a 
decrease in overall volume (99). 
When pressure is exerted onto a protein, there are several aspects of the protein that 
can be altered including the density and the elasticity (100). Under pressure elasticity, the 
ability of a system to undergo a gradual and reversible change in its shape or density, the 
protein volume will decrease to levels lower than at ambient pressure, which theoretically 
G = H −TS = E + pV −TS
  Chapter 1 
 31 
could hinder the protein from functioning. However under the same pressure solute motility 
increases relative to ambient pressure, which in theory could enhance the enzymatic ability 
of the protein (100). Production and abundance of internal cavities could also be intrinsic in a 
proteins ability to perform at high pressure. Functional assays would need to be performed at 
high-pressure to determine if the protein was in fact being subjected to the pressure, or 
whether the cell wall and membrane were shielding internal components from this pressure. 
In the context of FEN 1 in Pab, One such assay could involve the use of either a radio- or 
fluorescently- labelled DNA strand that, upon successful cleavage from the engineered ‘flap’, 
could be detected. This assay could be performed both in vivo and in vitro at both ambient 
pressure and at optimum pressure for Pab, to determine where the pressure is acting in this 
particular system. 
1.6 Scope of this Thesis 
1.6.1 – DNA-PKcs 
The principal aim of this research was to determine a high resolution X-ray crystal 
structure of human DNA-PKcs, both apo and in complex with a variety of established and 
novel inhibitors, for the purposes of rational structure-based drug design. This thesis will 
discuss the work performed with this aim in mind, but ultimately working toward generating 
a soluble, correctly folded, stable protein for the purposes of biophysical and structural 
characterisation. Chapter 3 will delve into further detail regarding the attempts made to 
increase the solubility of the protein, as well as further attempts at construct manipulation to 
achieve this same goal. It will also go into further detail regarding the eventual denaturation 
and refolding of inclusion bodies and an eventual optimised protocol, with the subsequent 
aim of future work being scale-up of the protocol leading to structure determination.  
  Chapter 1 
 32 
1.6.2 – FEN 1 
The aim of this portion of research was to determine an X-ray crystal structure for 
FEN 1 from Pyrococcus abyssi. Being from an archaeal system, the replicative machinery is 
similar to that of eukaryotes, but simpler, making it an ideal system to greater elucidate the 
structure and function of FEN 1. Another reason that Pab is a good model system is due to its 
behaviour as a piezophile. Taking advantage of this trait could potentially allow for the study 
of proteins at high pressure, more specifically performing high-pressure macromolecular 
crystallography (HPMX) to determine any changes from ambient to high pressure structures, 
possibly indicating reasons for thriving in these conditions. This thesis will go into further 
detail regarding some biophysical characterisation as well as direct comparisons with 
homologs from both other archaea such as Sulfolobus solfataricus and Pyrococcus furiosus  and 
from human. Chapter 4 will cover these details as well as the work carried out in an attempt 
to co-crystallise Pab FEN 1 with DNA to determine its binding mode in vitro. This thesis will 
also shed light on preliminary high-pressure X-ray crystallography experiments, possible 
implications of this research and what it could mean in the future for the field of HPMX as a 
whole. 
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Chapter 2  
Materials & Methods 
2.1 Materials 
2.1.1 – Media 
All liquid media was stored at room temperature until required for use in experiments, 
at which point it was incubated at the desired temperature prior to supplementation with 
additives: Either antibiotics, cultures or inducing agents. All media was autoclaved prior to 
use. Solid media was obtained through the addition of agar to stocks of the aforementioned 
liquid agar. Table 2.1 contains ingredient information for all media used throughout the 
study. 
2.1.2 – Antibiotics & Inducers 
Antibiotics used throughout this study include Ampicillin/Carbenicillin, 
Chloramphenicol, Tetracycline and Kanamycin in various combinations. The formulations 
for stock solutions of each of these antibiotics can be found in Table 2.2. When the use of an 
inducer was required, the chemical Isopropyl-β-D-1-thiogalactopyranoside (IPTG) was used. 
Its stock formulation can also be found in Table 2.2. 
 
	










1.2% Bacto-tryptone, 2.4% yeast extract, 0.4% Glycerol, 10% 0.17M 
KH2PO4 and 0.72M K2HPO4 
LB Agar 1 % Bacto-tryptone, 0.5 % yeast extract, 1 % NaCl, 1.5 % Bacto-agar; 
pH adjusted to 7.5 with NaOH 
SOC 
2% Bacto-tryptone, 0.5% yeast extract, 0.5% 5M NaCl, 0.25% (v/v) 
1M KCl, 1% (v/v) 1M MgCl2, 1% (v/v) 1M MgSO4, 2% (v/v) 1M 
Glucose 
Auto-Induction 
1% Bacto-tryptone, 0.5% yeast extract, 0.33% (NH4)2SO4, 0.68% 
KH2PO4, 0.71% Na2HPO4, 0.05% Glucose, 0.2% α-lactose, 0.015% 
MgSO4, 0.003% Trace elements 
Table 2-1 - A list of media used throughout this study and their corresponding compositions. 




Acronym Solvent Stock Concn 
Working 
Concn 
Ampicillin Amp H2O 100 mg ml-1 100 μg ml-1 
Carbenicillin Carb H2O 100 mg ml-1 100 μg ml-1 
Chloramphenicol Cam Ethanol 50 mg ml-1 50 μg ml-1 
Kanamycin Kan H2O 50 mg ml-1 50 μg ml-1 
Tetracycline Tet Ethanol 12.5 mg ml-1 12.5 μg ml-1 
Isopropyl-β-D-1-
thiogalactopyranoside IPTG H2O 1 M 1 mM 
Table 2-2 - A Table of antibiotics and inducing agents at both stock and working 
concentrations (Concn) that were stored at -20°C until required. 
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2.1.3 – Purification resin 
All resin and pre-packed columns used throughout this study was purchased from GE 
Healthcare and used according to their guidelines, unless otherwise stated.  
2.1.4 – Crystallization reagents 
For the purposes of screens testing various crystallisation conditions, various 
manufacturers were used. These included Molecular Dimensions HT-96 format, MIDASTM, 
Morpheus®, JCSG-plus screens. They also included Hampton Research Crystal Screen 1 & 
2. AstraZeneca in-house screens were also used. The ‘Original MRC Crystallization Plate’ 
(SWISSCI) was used for all small scale screening in a sitting drop conformation. Larger scale 
hanging drop experiments were performed using 24-well Linbro plates (Hampton Research) 
with siliconised glass cover slides (Hampton Research).  
2.1.5 – Enzymes  
Restriction Enzymes used throughout the study were all purchased from New England 
Biolabs (NEB). GoTaq® and pWo polymerases were purchased from Peqlab. All were used in 
accordance with their corresponding manufacturer’s guidelines. 
Lysozyme, lyophilized from chicken egg white, was purchased from Sigma Aldrich 
and used, unless otherwise stated, according to their guidelines. 
Trypsin for the purposes of peptide mass fingerprinting was kindly provided by Dr 
Andy Cronshaw, University of Edinburgh, and used in accordance with his protocols. 
2.1.6 – Oligonucleotides 
Oligonucleotides were either purchased from Sigma Aldrich or from GeneArt. Both 
came in dry form and were resuspended in nuclease free H2O to a stock concentration of 
100µM unless otherwise stated. 
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2.1.7 – Buffers 
All buffers and solutions were stored at room temperature unless otherwise stated. All 
reagents and chemicals were added to double distilled, sterile H2O (Milli-Q®) 
EDTA 
0.5M stock solutions were prepared and adjusted to pH 8 using concentrated NaOH, 
and then filtered through a 0.22μm filter membrane for storage. 
Inoue Transformation Buffer 
10.8g MnCl2.4H2O, 2.2g CaCl2.2H2O, 18.6g KCl, made up to 800 mL with filter 
sterilised H2O stored at -20°C until required for competent cell production. 
TAE (50x) Buffer 
2M Tris base, 0.05M EDTA and 5.7% (v/v) glacial acetic acid made up to 1000 mL 
with filter sterilised H2O stored at room temperature until required. The working 
concentration of TAE was 1x. 
TGS (10x) Buffer 
60.4g Tris base, 288g Glycine, 20g Sodium dodecyl sulphate (SDS) made up to 2 L 
with distilled water and filter sterilised. The working concentration  of TGS buffer was 1x. 
Western Blotting Buffer 
60.4g Tris base, 288g Glycine made up to 2 L with distilled water and filter sterilised. 
The working concentration was 1x. 
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2.2 Methods 
2.2.1 – Molecular Biology 
2.2.1.1 – Plasmid Purification 
In order to generate the purified plasmid DNA, it first had to be isolated from the 
bacterium. The E. coli strain that contained the desired plasmid was grown overnight in 5 
mL of LB broth at 37°C. The plasmids were then extracted using a QIAprep® spin miniprep 
kit from Qiagen, using 250µL buffer P1, 250µL buffer P2 and 350µL N3, according to their 
guidelines. The plasmid DNA bound to the purification column was eluted using 50 μL 
nuclease free H2O that had been heated to 70°C and then once eluted, it was stored at -20°C 
until required. 
2.2.1.2 - Polymerase Chain Reaction 
All polymerase chain reactions (PCR) were performed using a thermal cycler. Either 
GoTaq® Flexi DNA polymerase (Promega) was used, or in situations where the product was 
proceeding further with cloning, a polymerase possessing 3’-5’ exonuclease activity, (pWo – 
Promega) was used. All reactions were performed according to the enzyme manufacturer’s 
guidelines. The melting temperature (Tm) of the oligonucleotides used was calculated by 
their respective manufacturers and unless otherwise stated, annealing temperatures were 5°C 
below the lowest Tm in the reaction. 
2.2.1.3 – Cloning 
The purified DNA product of the PCR reaction was then digested by restriction 
endonucleases, used according to their manufacturer’s guidelines. This digested DNA was 
then run on a 0.8% agarose gel (further information in section 2.2.2.2) at which point the 
desired band was excised and purified using a QIAquick Gel Extraction Kit (Qiagen) prior to 
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ligation. When linearising vector DNA, 1µL Calf Intestinal Phosphatase (CIP) (NEB) was 
added at the start of the reaction and again after 60 minutes in order to remove 5’ 
phosphates from the digested DNA. This was in order to remove background caused by the 
vector ligating with itself forming an ‘empty vector’, resulting in false positives. Ligation was 
performed with T4 Ligase (NEB) overnight at 16°C. Ligation products were then 
transformed into competent E.coli XL1-blue strain (endA- recA- hsdR). endA- refers to a lack of 
endonucleases improving the quality of the miniprep DNA. recA- means the cells are 
recombination deficient, thus improving the stability of the insert. hsdR refers to a mutation 
preventing the cleavage of cloned DNA via the EcoK endonuclease system. Once transformed 
these cells could then act to propagate the plasmid DNA.  
2.2.1.4 – Expression Vector 
All DNA-PKcs constructs produced were ligated into the expression vector pTWO-E. 
This vector is a modified pET17-b vector (Novagen, Merck Chemicals) that contains an 
additional PreScission protease cleavable N-terminal 6xHis tag, designed for optimal 
expression in E.coli. 
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Figure 2.1 (A) - Vector map of pET17-b, the vector that pTWO-E is built upon. The 
modifications take place at the start of the multiple cloning site (MCS) highlighted, indicating 
the difference between the two vectors. All cloning performed using this vector made use of 
the restriction site NdeI for the.digestion/ligation (101). 
2.2.1.5 – BigDye® DNA Sequencing 
The sequencing was performed at the GenePool, University of Edinburgh 
(https://www.wiki.ed.ac.uk/display/GenePool/Home). The plasmid DNA was sent with 
either the forward primer, (T7 or construct specific), or with the reverse primer (STO720 or 
construct specific) at which point the GenePool facility would perform the PCR and carry 
out the sequencing reaction using a BigDye® terminator v3.1 cycle sequencing kit (Applied 
Biosystems) according to the manufacturer’s guidelines. Samples were then analysed using an 
ABI PRISM 3100-Avant Genetic Analyser. 
2.2.1.6 – Codon Optimised DNA 
All codon optimised DNA used throughout this study was designed using GeneArt’s 
online software ‘GeneOptimizer®‘ to modify codon usage from Homo sapiens to E.coli  
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2.2.1.7 – Annealing DNA 
All oligos were provided by Sigma Aldrich and were resuspended to a final 
concentration of 300 µM. The three strands that were required to form the structure specific 
‘flap’ were the upstream, downstream and template, further details of which will be discussed 
in chapter 4. The downstream and template strands were combined in a 1:1 ratio with 
annealing buffer (50 mM Tris-HCl pH 8.8, 50 mM NaCl, 1 mM DTT) and placed in a 
thermal cycler at 90°C for 5 minutes at which point the temperature dropped to 85°C. At 
this point an equivalent amount of upstream oligonucleotide was added (for a final ratio of 
1:1:1) and it was left for another 5 minutes. This continued at 75°C, 70°C, 65°C all with 5 
minute intervals at which point the thermal cycler was set to 10°C and this was the end of 
the annealing process.  
2.2.2 – Microbiology 
2.2.2.1 – Competent Cell Production 
A scraping of a previous stock of the competent cells required was taken and plated 
onto a fresh LB agar plate with the appropriate antibiotic (or lack thereof) and grown for 18-
24 hours at 37°C.  
One colony was then removed from the plate and used to inoculate 25 mL SOC 
media in a 100 mL flask. This culture was then incubated for 6-8 hours at 37°C in an InFors 
HT Multitron shaking incubator at which point three individual 1 L flasks were inoculated 
with this starting culture. These flasks contained 250 mL LB media. The first flask was 
inoculated with 10 mL starting culture, the second flask had 4 mL added and the third had 2 
mL added. All were then allowed to grow overnight at 18°C. 
The following morning the OD600 measurements were taken and were monitored until 
one of the flasks had an OD600 of 0.55. At this point the corresponding flask was removed 
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and placed in an ice bath for 10 minutes. Cells were then harvested at 4000g using an 
Eppendorf 5810 R Centrifuge for 10 minutes at 4°C. The media was removed and the tube 
containing the whole cell pellet was inverted on paper towel to remove any excess media. 
The cell pellet was then resuspended in 80 mL ice cold Inoue Buffer and the centrifugation 
was repeated along with the drying of the pellet. 
The cells were then resuspended in 20 mL ice cold Inoue Buffer. At this point 1.5 mL 
DMSO was added and the mixture kept on ice for 10 minutes. 100 μL aliquots were then 
dispensed into sterile micro-centrifuge tubes and flash-frozen in liquid N2. The cells were 
then stored at -80°C until further use. 
2.2.2.2 – Heat Shock Transformation 
An aliquot of the desired strain of cells was removed from the -80°C freezer and 
allowed to thaw on ice for 20 minutes. A 1 μL aliquot of miniprep DNA corresponding to the 
desired construct was taken and placed into a fresh 1.5 mL eppendorf tube and left on ice. 
The competent cells were then added to the miniprep DNA and allowed to incubate on ice 
for 30 minutes. The cell/DNA mixture was then placed into a water bath at 42°C for a 
specific length of time, which varied according to the cell strain used. The times used were 
chosen based on manufacturer’s guidelines. A list of cell strains used throughout this study 
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recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ́ 
proAB lacIqZ∆M15 Tn10 (Tetr)]. 
45” 
DH5α 
fhuA2 lac(del)U169 phoA glnV44 Φ80' lacZ(del)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 20” 
Rosetta pLysS F- ompT hsdSB(rB- mB-) gal dcm (DE3) pLysS (camR) 30” 
BL21star 
F- ompT hsdSB (rB-mB-) gal dcm rne131 
(DE3) 
30” 
BL21gold F– ompT hsdS(r – m –) dcm+ Tetr gal λ(DE3) endA Hte 30” 
BL21-AITM F– ompT hsdSB(rB–, mB–) gal dcm araB::T7RNAP-tetA 30” 
Table 2-3 - List of cell strains used throughout this study. 
 
After heat shock the cells, now containing the plasmid DNA, were then allowed to 
incubate on ice for a further 15 minutes. At which point 500 μL SOC media was added and 
the cells were incubated at 37°C for 60 minutes in a shaking incubator. After this period 200 
μL and 400 μL of the mixture were plated onto two fresh LB agar plates with corresponding 
antibiotic and placed, inverted, in a stationary incubator set at 37°C for 18-24 hours. Plates 
were then stored at 4°C for a maximum of 1 week. 
2.2.3 – Electrophoresis 
2.2.3.1 – SDS-PAGE 
Sodium Dodecyl Sulphate–Polyacrylamide Gel Electrophoresis (SDS-PAGE) was 
performed using tanks manufactured by either BioRad or Invitrogen. They were run at 
constant amperage of 50 mA for various lengths of time. When casting gels, 10%, 12%, 15% 
or 20% acrylamide was used. Solutions contained filter sterilised H2O, Acrylamide at the 
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given concentration, Tris-HCl (1M at pH 8.8 resolving) (1.5M at pH 6.8 stacking), 10% 
SDS, 10% Ammonium Persulphate (APS), Tetramethylethyldiamine (TEMED). Pre-cast 
gels were either Any kDTM Mini-Protean® TGXTM (Biorad) or Novex® 4%-12% Tris-Glycine 
1.0 mm mini gels (Invitrogen). Protein standards were either Precision Plus ProteinTM Dual 
Colour Standard (Biorad) or SeeBlue® Plus2 Pre-Stained Standard (Invitrogen). After 
running the gels they were stained with InstantBlue protein stain (Expedeon) for 30 minutes 
and destained in filtered, sterilised H2O. 
2.2.3.2 – Agarose Gel Electrophoresis 
Agarose gels were run at constant amperage of 50 mA for various lengths of time. The 
gels were cast at either 0.8% or 1% w/v agarose in 1x TAE buffer. Electrophoresis running 
buffer consisted of 1x TAE buffer. DNA standard markers were either 1kb DNA Ladder 
(NEB) or 100bp DNA Ladder (NEB). Visualisation was performed using a high-sensitivity 
charged couple device (CCD) gel imaging system:  a GelDocTM XR+ System (Biorad). 
2.2.3.3 – Western Blot 
Western blots were performed immediately after analysis by SDS-PAGE. Membranes 
used to trap the proteins during transfer included Hybond-P PVDF membrane (Amersham), 
and Hybond ECL nitrocellulose membrane (Amersham). All transfers were performed using 
a PerfectBlueTM Tank Electro Blotter WebTM S (Peqlab) at 300 mA for 120 minutes in 
western blotting buffer. When using PVDF membrane, the membrane was incubated for 10 
minutes in 100% ethanol prior to running. Sponge and filter paper was used either side of 
the gel/membrane, both of which had been incubated in western blotting buffer forming the 
‘sandwich’.  
After running, the membrane was removed and placed into a solution of 5% w/v 
Skim Milk Powder (Sigma Aldrich) in Phosphate Buffered Saline with 0.2% v/v Tween 20 
(PBST) and incubated for 60 minutes at room temperature. At which point two washes were 
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performed with PBST only and then a solution of PBST in combination with a primary 
antibody was added to the membrane and another incubation of 60 minutes at room 
temperature was performed. If a secondary antibody was required the wash step was 
repeated and the new antibody added to a fresh PBST solution for further incubation. A list 
of antibodies used throughout the study can be found in Table 2.4.  
If the antibody was conjugated to alkaline phosphatase (AP) then the membrane was 
developed with SigmaFastTM BCIP®/NBT (Sigma Aldrich) tablets resuspended in PBST (1 
tablet / 10 mL PBST) and imaged using GelDocTM XR+ System (Biorad). If the antibody 
was conjugated to Horseradish Peroxidase (HRP) then the membrane was developed with 
ECL Prime Western Blotting Detection Reagent (Amersham) and imaged using Kodak 
BioMax MR-1 X-ray film and a standard X-ray film developer. 
 
Antibody 1o / 2o Host Conjugation Stock Concn Working Concn 
α- 6xHis 1o Mouse 
AP/un-
conjugated 
1 mg/ml 0.5μg/ml 
α – DNA-
PKcs 
1o Rabbit un-conjugated 0.3 mg/ml 0.5μg/ml 
α – GST 1o Goat un-conjugated 1 mg/ml 0.5μg/ml 
α – goat 2o Donkey HRP 1 mg/ml 0.1 μg/ml 
α – rabbit 2o Mouse HRP 0.8 mg/ml 800 ng/ml 
α – mouse 2o Rabbit HRP 2 mg/ml 0.2 μg/ml 
Table 2-4 - List of antibodies used throughout this study. 
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2.2.4 – Protein Production 
After transforming the competent cells with the desired construct, a single colony was 
picked from the LB agar plate and used to inoculate 5 mL LB media with corresponding 
antibiotic, for selection purposes. This was then allowed to grow for 6-8 hours at 37°C in a 
shaking incubator. This culture was then used to inoculate 100 mL of LB media containing 
the same antibiotic, which was then grown overnight at 37°C.  
5 mL of this was taken and added to a 2 L conical flask containing 500 mL of media 
(TB, LB or AI) and antibiotic. The ratio of 1:4 volume of media: volume of flask was 
maintained throughout all experiments. The culture was then incubated for 1 hour at 37°C 
in the shaking incubator at which point the OD600 was measured, and measurements were 
taken repeatedly every 30 minutes to assess the doubling time of the organism. When the 
cells reach mid-logarithmic scale of growth and the optimal time to induce the growth of the 
protein, IPTG was added to a final concentration of 1 mM unless otherwise stated.  This 
phase of cell growth is determined by measuring the OD600. Depending on the media this 
value can vary and is affected by the maximum optical density that can be reached with the 
media. LB media has a maximum OD600 of between 2-3 and it is between 0.6 and 0.8 that 
logarithmic growth occurs. TB however can reach a maximum OD600 of between 5-8, and 
therefore the logarithmic scale extends much higher to between 0.6-1.2. Initial time course 
experiments determined the optimal induction time and this time (either 1 hour, 2 hours, 3 
hours, 4 hours or overnight) was then used for all subsequent experiments. 
Once the optimal induction time had been reached the cells were harvested using a 
Beckman Coulter Avanti J-30I High Performance Centrifuge at 8000g for 30 minutes at 4°C 
The pellets were then collected and stored at -80°C for future use. 
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2.2.4.1 – Buffer Scouting 
 When solubility was an issue with a target protein, the buffer constituents and 
parameters were subjected to buffer scouting to increase yields of soluble protein. In all cases 
the cell pellet was initially lysed in 20 mM HEPES pH 7.5, 200 mM NaCl, 10 % Glycerol, 5 
mM MgCl2 to determine a baseline level of solubility. At this point the buffer scouting would 
begin. Five different buffer constituents were chosen: HEPES (buffering range pH 6.8-8.2), 
Tris (buffering range pH 7.5-9.0), MES (buffering range pH 5.5-6.7), PIPES (buffering range 
pH 6.1-7.5) and CAPS (buffering range pH 9.7-11.1). These buffers were all made to a final 
concentration of 20mM and were chosen in order to cover pH ranges both more acidic and 
more basic than the theoretical pI of the protein, which for DNA-PKcs was 8.44. The NaCl 
(200mM), glycerol (10%) and MgCl2 (5mM), were all kept constant, as well as the 
temperature, all buffer scouting experiments were performed at room temperature. A 
successful buffer condition was defined as the one that had either the largest yield of soluble 
protein or the largest amount in the supernatant relative to its pellet fraction. 
2.2.4.2 – Cell Lysis 
When lysing cells with lysozyme, firstly the cell pellet was resuspended in 20mL buffer, 
determined after initial buffer scouting, at which point the lysozyme mixture was added, 
which consisted of Tris-HCl pH 8.0, 1.2% v/v 0.5 M EDTA pH 8.0, 1% w/v lysozyme 
lyophilized from chicken egg white (Sigma Aldrich). Once this lysis solution was added, the 
cell pellet/lysozyme solution was incubated with rotation for 60 minutes at room 
temperature. 
When lysing the cells via sonication the cell pellet was resuspended in the desired 
buffer and kept on ice. At which point it was placed in to a Soniprep 150 sonicator with the 
MSE 9.5 mm diameter probe inserted into the solution. With the cell suspension remaining 
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on ice, the cells were sonicated in 3 x 30 second bursts, with 30-second intervals in between 
unless otherwise stated. 
When using a French press, the Constant Systems Ltd 1.1 kW TS Cell Disruptor was 
used. After washing with filtered, sterilised H2O and detergent, the sample was placed into 
the reservoir and passed through the system according to the manufacturer’s guidelines. The 
lysed product was then collected. 
Prior to any cell lysis, cOmplete EDTA-free protease inhibitor cocktail (Roche) was 
added to the buffer according to the manufacturer’s guidelines. 
After all cell lysis, the mixture was clarified via ultracentrifugation at 25,000g for 60 
minutes at 4°C and the pellet and supernatant were separated for future analysis. 
2.2.5 – Protein Purification 
2.2.5.1 – Affinity  
All purifications with pre-packed columns were used alongside either an ÅKTAprime 
or ÅKTAexpress (GE Healthcare) and their associated software. All columns and 
purification systems were used according to the manufacturer’s guidelines.  
Ni-Sepharose:  
Affinity purification was performed either with resin not bound to a column matrix, 
which will be discussed further in Chapter 2.2.4.3, or with pre-packed Ni-Sepharose 1 mL 
and 5 mL ‘HisTrap’ Columns (GE Healthcare) when using a protein designed to have an N-
terminal 6xHis tag. 
The supernatant contained 10mM imidazole in order to minimise non-specific 
binding, and was passed over the pre-equilibrated column during the binding process. Two 
distinct wash steps were performed, firstly at 50mM imidazole, secondly at 100mM 
imidazole to further remove non-specific or weak interactions with Ni-sepharose resin. 
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At this point the elution stage began and this was performed with an increasing 
concentration of imidazole either via gradient or step-wise.  When performing gradient 
elution methodology, the initial imidazole was 100mM imidazole, increasing to 500mM over 
40 column volumes (CV). This then resulted in elution of the purified tagged protein to be 
later analysed by SDS-PAGE and western blot, at which point positive fractions were taken 
forward in the purification protocol.  
When a step-wise elution methodology was used, the imidazole concentration was 
100mM, with periodic increases in concentration over 10 CV, the intervals of which varied 
from 100mM to 200mM. 
Glutathione-Sepharose: 
When using an N-terminal GST tag, Glutathione-Sepharose 1 mL ‘GSTrap’ columns 
(GE Healthcare) were used. The competing ligand with this resin is reduced glutathione. 
The supernatant contained 10mM reduced glutathione in order to minimise non-
specific binding, in a manner similar to previously discussed affinity purification methods, 
and was passed over the pre-equilibrated column during the binding process. The wash step 
discussed in previous affinity purification methods was omitted when purifying GST-tagged 
proteins. 
Elution was performed with an increasing concentration of reduced glutathione 
competing ligand either via gradient or step-wise.  When performing gradient elution 
methodology, the initial concentration of reduced glutathione was 10mM, finishing at 20mM 
reduced glutathione, over 40 column volumes (CV). During this research gradient elution 
was the only method used when using this particular resin. All subsequent analysis was 
performed in the same manner as previous affinity chromatography experiments. 
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2.2.5.2 – Ion Exchange 
Anion exchange was performed with pre-packed 1 mL HiTrap Sepharose columns. 
Strong anion exchange resin Q was used along with weak anion exchange resin DEAE. 
Cation exchange was performed with the same 1 mL HiTrap Sepharose. However for weak 
cation exchange CM resin was used and SP resin was used as a strong cation exchanger. All 
columns were manufactured by GE Healthcare and used according to their guidelines.  
Making use of the theoretical isoelectric point (pI) of the protein at a given pH allows 
for prediction of binding to a particular ion exchange resin. Theoretically, when the pH of a 
solution is above the pI of the protein, the net surface charge on the protein will be negatively 
charged and therefore bind positively charged (anionic) resin and vice versa. Although this is 
not always the case binding affinity experiments were carried out on a small scale, which will 
be discussed further in Chapter 2.2.4.3. 
The supernatant was passed over a pre-equilibrated column at 20-50mM NaCl in the 
buffer, resulting in a weak ionic strength. Once bound, the salt concentration was raised to 
100mM to act as a wash step. At which point an increasing salt concentration was applied 
either in a gradient or step-wise fashion as mentioned previously. This increase in ionic 
strength of the buffer weakens the interaction of the protein to the resin and it is eluted at a 
given salt concentration.  Fractions were then analysed by SDS-PAGE and any containing 
the desired protein were pooled and taken forward through the remaining purification 
protocol. 
In some respects Heparin Sepharose can be identified as both an affinity resin and an 
ion exchange resin. DNA binding proteins will have an affinity for the resin but it will also 
act as a cation exchange column and bind positively charged molecules. 
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2.2.5.3 – Batch Purification  
Before developing the purification protocol, optimal binding affinity had to be 
determined, and this was done through the use of resin not packed in a column. Ni-
Sepharose, GST-Sepharose, Heparin Sepharose, Q-Sepharose, DEAE-Sepharose, CM-
Sepharose and SP-Sepharose were all purchased from GE Healthcare and used according to 
their guidelines. 
An amount of unbound resin that is stored in 20% ethanol was taken and dispensed 
either into an eppendorf tube or a falcon tube depending upon the scale of the experiment. 
Small scale experiments used 100µL resin, whilst the largest scale experiments used 1mL of 
resin. It was then centrifuged at 800g for 5 minutes and the 20% ethanol was removed. An 
equal amount of equilibrating buffer was then added to the resin and it was resuspended 
briefly before another round of centrifugation. This was repeated at least 3 times in order to 
full equilibrate the resin to the desired conditions.  
The protein sample was then applied to the resin and it was incubated for 20 minutes 
with rotation at either at 4°C. The tube was then centrifuged at 800g for 10 minutes and the 
flow-through collected. Wash buffer was then added in exactly the same manner. It was 
either identical to the loading buffer, or the concentration of competing ligand was increased, 
to either 100mM NaCl for ion exchange, 40-100mM imidazole for Ni2+ affinity 
chromatography or 10mM reduced glutathione for GST-affinity chromatography. After 
centrifugation this wash fraction was removed. 500µl elution buffer was then added to the 
resin. This buffer contained the highest concentration of competing ligand required to elute 
all of the adsorbed particles (1 M NaCl, 500 mM imidazole, 20 mM reduced glutathione). 
After incubation and centrifugation this sample was collected and all fractions were analysed 
via SDS-PAGE and western blot to determine the optimum binding conditions for the 
protein in question. 
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2.2.5.4 – Size Exclusion Chromatography 
All size exclusion chromatography (SEC) was performed on either a Superose 6 
10/300 GL pre-packed Sepharose column (GE Healthcare) or a Superdex 200 10/300 GL 
Sepharose column (GE Healthcare). All SEC was performed alongside either an 
ÅKTAprime or ÅKTAexpress (GE Healthcare) and their associated software. Both columns 
were used according to the manufacturer’s guidelines. 
Initially the column was equilibrated with 2 CV of buffer. This buffer changed 
depending on the preceding step. SEC performed after Ni2+ affinity chromatography 
contained 20mM HEPES, 50mM NaCl, 20mM imidazole. After ion exchange the buffer 
contained 20mM HEPES, 400mM NaCl. The protein solution was then concentrated to a 
final volume of either 200 μL. The loop was emptied with 3 loop volumes (LV) onto the 
column and then removed from the flow path. The flow rate was kept at 0.5 mL / minute for 
the entirety of the run. The protein present in the solution was then separated based on its 
hydrodynamic radius.  
A protein with a small hydrodynamic radius will access a considerably larger amount 
of the available pores present in the Sepharose beads than a protein with a large 
hydrodynamic radius. Therefore larger proteins are eluted more quickly than than the 
smaller ones due to having a shorter flow path. This then leads to separation of proteins 
according to their size and allows for the technique to be used as a polishing step to remove 
impurities such as oligomers or aggregates from the desired protein which, when eluted, 
should be contained within a suitable buffer at homogeneous size. The UV absorbance, 
measured in mAu (milli-Absorbance units), was used to identify peaks being eluted from the 
size exclusion column. 0.5mL fractions were collected and analysis of these fractions was 
then performed via SDS-PAGE and western blotting. This analysis allowed the 
determination of which fractions contained the purest target protein, which were 
subsequently collected, pooled and concentrated for further experimentation. 
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2.2.5.5 – Purification in Denaturing Conditions 
Throughout the study, some protein had to be obtained by attempting to solubilise 
proteins from inclusion bodies, present in the insoluble pelleted fraction after lysis and 
centrifugation. This involved several rounds of washing to remove as many impurities from 
the inclusion bodies as possible. These impurities included cell membranes and membrane 
proteins.  
Firstly the pellet and supernatant were separated as mentioned in Chapter 2.2.4.1. 
The pellet was then resuspended in the same lysis buffer at a ratio of 1:25 w/v (pellet : 
buffer). Resuspension was performed using a CAT X120 Homogeniser (Bennet Scientific 
Limited) to create a fully homogenous solution. This solution was then centrifuged at 25,000 
rpm for 30 minutes. 
This supernatant was then removed and kept for analysis. The pellet then underwent 6 
further wash steps with changes to the buffer each time. A wash being defined as 
resuspension of the pellet in buffer with the homogeniser mentioned previously, 
centrifugation to collect the inclusion bodies present in the pellet fraction and removal of the 
supernatant for analysis. Washes 2 and 3 used lysis buffer containing 0.1% (v/v) TritonTM X-
100 (Sigma Aldrich) in order to solubilise the membranes and membrane proteins. Washes 4 
and 5 used lysis buffer containing 1M NaCl and 0.1% (v/v) TritonTM X-100, in an attempt 
to try to remove nucleic acid contamination. 
The final wash used lysis buffer only. This was done to remove traces of detergent and 
normalise the salt concentration, so that they could not otherwise affect how the protein 
reacted to the denaturant. The final inclusion body pellet was resuspended in a solution of 
lysis buffer containing either 8M Urea (Sigma Aldrich) or 6M Guanidine Hydrochloride 
(Sigma Aldrich) to a final w/v ratio of 1:25. The pellet was fully resuspended using the 
homogeniser and left to incubate overnight at 4°C with rolling to fully denature all proteins 
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still remaining in the pellet. The denatured protein mixture was then centrifuged at 25,000 
rpm for 60 minutes and the solubilised fraction and pellet were separated.  
Samples were then analysed via SDS-PAGE and western blot before being taken 
forward for further purification and renaturing. 
2.2.5.6 – Refolding 
After denaturing the protein, the denaturant had to be removed from the buffer in a 
controlled manner as to allow the secondary and tertiary structures to form in the correct 
manner, leading to a stable, functionally active refolded protein. There were 3 methods of 
refolding employed during this research: ‘on-column’, dilution and dialysis. 
When the protein was refolded ‘on-column’, the protein-denaturant solution was 
loaded on to an equilibrated 10 mL HisTrap column at room temperature. At this point the 
concentration of denaturant was decreased over a shallow gradient of 60 CV, from either 
8M urea or 6M guanidine hydrochloride to a final concentration of 0 mM at a flow rate of 1 
mL/minute, allowing the protein to slowly fold into a secondary and tertiary conformation 
around the scaffold of the interaction of the 6xHis tag with the Ni-sepharose resin.  
When refolding was performed via dilution, it was done so as an intermediate step, and 
technically cannot be considered a refolding step as it is being performed in the presence of a 
denaturant, although at concentrations lower than their optimum for denaturing protein. 
This involved rapidly diluting a protein sample into a lower concentration of an 
experimentally determined alternative denaturant (2 M Guanidine), which could then be 
further processed by dialysis, thus removing this lower concentration of denaturant. Dilution 
of protein sample into refold buffer was performed using a Mosquito LCP® Liquid Handling 
Robot (TTP Labtech) for the small scale experiments, and with a pipette at the larger scale. 
The ratio of protein : refold buffer was 1:50, which equated to 24 nL protein : 1.2 µL refold 
buffer for initial screens, 100 µL protein : 5 mL buffer for the intermediate scale and 1 mL 
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protein : 50 mL buffer at the largest scale performed, all of which were performed at 18°C. 
The protein concentration at the initial stage of refolding was 5 mg/mL. The refolds were 
also performed both in the presence and absence of ligands to determine their effects. 
When refolding protein via dialysis, it was always performed with Dry Spectra/Por® 
regenerated cellulose membrane (Spectrum Labs) with a pore size of 6-8 kDa and varying 
flat widths depending on the final volume. All dialysis was performed at 4°C with stirring, at 
a ratio of protein : dialysis buffer of 1:500, with 50 mL protein, at 2 M guanidine, to 25 L 
dialysis buffer. This consisted of 20mM Tris, pH 8.1, 50 mM NaCl. There were a total of 4 
changes of dialysis buffer over the course of the experiment, with at least 8 hours in between 
changes to allow enough time for equilibration. This therefore reduced the concentration of 
denaturant from 2000 mM to approximately 32 pM. 
2.2.6 – Biophysical Characterisation  
2.2.6.1 – Dynamic Light Scattering  
Dynamic Light Scattering (DLS) was used during this study in correlation with SEC 
previously mentioned in order to determine the hydrodynamic size of the proteins being 
tested. Experiments were carried out on a Zetasizer Auto Plate Sampler (Malvern 
Instruments Ltd) and were done so according to the manufacturers guidelines.  
Samples were prepared to a final volume of 65 μL into a 384 well plate (Malvern 
Instruments Ltd), at more than one concentration. For the DNA-PKcs work the 
concentrations used were 0.25 mg/mL and 0.125 mg/mL. For the FEN 1 work the 
concentrations used were 18 mg/mL and 1 mg/mL. The plate was then inserted into the 
machine and allowed to equilibrate to a predetermined temperature of 25°C. A standard 
operating procedure was then created whereby the information for each sample (solvent 
constituents & protein) was uploaded to the software.  Each measurement was repeated a 
total of 3 times in order to generate reproducibility. The result for the experiment is a 
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measurement of the distribution of particle size within the solution in relation to both the 
intensity and volume, with the readout showing this distribution on a logarithmic scale, with 
particle sizes being shown as a diameter in nm. 
2.2.6.2 – Thermal Denaturation Assay 
Thermal denaturation assays were performed during this study to determine the 
thermal stability of the target protein. All assays were performed on an IQ5 ICycler (Biorad), 
a real time PCR (rt-PCR) machine whose use was dedicated to this assay. It, along with the 
coordinated computer software, was used according to the manufacturers guidelines. 
An iQTM 96-well PCR plate (Biorad) was used for the reactions. Each sample was 
placed into a well (in triplicate) to a final volume of 45 µL. 5 µL of 5x SYPRO® Orange 
protein stain (Invitrogen) was then added to a final concentration of 1x. 5x solution was 
made by combining 1 µL of stock 5000x SYPRO®  + 999 µL H2O. The starting temperature 
was set at 25°C, with a ΔT of 1°C / minute for initial screening experiments and a ΔT of 
0.5°C / minute for more accurate results. The SYPRO® Orange protein stain binds to 
hydrophobic regions on the surface of the protein, which emits fluorescence upon binding to 
these regions. As the temperature increases and the protein begins to unfold, more binding 
events occur leading to an increase in fluorescence, which is detected by the CCD-based 
optics within the iQ5. At the melting temperature of the protein this process occurs at a 
much faster rate, which can be observed as a peak on the readout, which is shown as relative 
fluorescence units (RFU) vs time as well as the negative first derivative of the fluorescence 
change (-dRFU/dT). 
Due to the fact that FEN 1 is a thermostable protein, the final temperature for all of 
the corresponding TDA experiments was set to the maximum level 95°C. The DNA-PKcs 
experiment temperatures didn’t need to be set as high as they were for FEN 1, but still 
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varied, details of this will be discussed further in the results section. Results were analysed by 
the IQ5 software for further interpretation. 
2.2.6.3 – Peptide Mass Fingerprinting 
Peptide mass fingerprinting was performed to confirm the identity of proteins being 
purified. After purification the samples were analysed via SDS-PAGE and western blot. The 
SDS-PAGE serves to identify an estimated size of the protein in relation to a given standard 
run alongside. Western blotting can then confirm the identity by using the antibodies raised 
against them. Although these techniques can show an approximate size, as well as the 
presence of a specific epitope, when using the appropriate antibody raised against it, it 
cannot provide an absolute mass or identity. This information can be obtained however 
through the use of peptide mass fingerprinting. All fingerprinting was performed using 
Matrix Assisted Laser Desorption/Ionisation – Time of Flight (MALDI-TOF) mass 
spectrometry. The matrix used was α-cyano-4-hydroxycinnamic acid (CHCA) and it works 
by rapidly absorbing UV energy, converting it to heat and vaporising the sample. These 
vaporised particles are then accelerated through a drift tube toward a detector. The time 
taken to travel this distance is proportional to the square root of their molecular weight. 
Firstly the test sample had to be prepared. The samples were analysed by SDS-PAGE 
and subsequently stained with Instant Blue protein stain. Instant Blue is used, rather than 
coomassie stain due to the lack of methanol in the solution that would otherwise fix the 
protein to the acrylamide gel rendering further treatment null. Once the band was stained it 
was excised using a scalpel as tightly as possible, with minimal excess of acrylamide as excess 
acrylamide can provide large peaks that can mask the peptide peaks in the trace.  
This gel piece was then incubated in 300 μL NH4HCO3 (ABC) in 50% acetonitrile 
(ACN) at room temperature for 30 minutes. This was then repeated 2 further times in order 
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to remove SDS. The band was then incubated in 300 μL 20 mM DTT, 200 mM ABC, 50% 
ACN at room temperature for 60 minutes in order to reduce the protein. 
The band was then washed 3 times in 300 μL 200 mM ABC, 50% ACN. Cysteines 
present in the protein had to then be alkylated using 100 μL 50 mM iodoacetamide (IAA), 
200 mM ABC, 50% ACN at room temperature in the absence of light for 20 minutes. A 
further 3 wash steps with 20mM ABC, 50% ACN were then performed. 
The band was then cut into 2 mm x 1 mm pieces and centrifuged at 13,000 rpm for 2 
minutes. The gel pieces were then completely submerged in 100% ACN until they turned 
white in colour, at which point the ACN was removed and the gel pieces were allowed to dry 
at room temperature. 
A solution of 29 μL 50 mM ABC with 1 μL 1 mg/mL trypsin (0.034 mg/mL final 
concentration) (Promega – provided by Dr Andrew Cronshaw) was then added to the dried 
gel pieces. This was kept at 4°C until the gel pieces swelled, at which point the eppendorf 
tube was placed at 32°C for 16-24 hours along with a blank containing the same solution of 
50 mM ABC with 1 μL trypsin but no gel pieces. 
After sample preparation 0.5 μL of the digestion solution was mixed with 0.5 μL of 
CHCA matrix solution and was spotted onto a stainless MALDI plate. The samples were 
then analysed on a Voyager DE-STR MALDI-TOF Mass Spectrometer (Applied 
Biosystems) and after using Data Explorer software (Applied Biosystems), the processed 
spectra were directly compared against entries within the National Centre for Biotechnology 
Information (NCBI) non-redundant database using the MASCOT Server (Matrix Science) to 
determine their identity. 
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2.2.7 – Crystallisation 
2.2.7.1 – Principles of crystallisation 
To determine the X-ray structure of a protein, one cannot rely on the scattering of X-
rays from electrons within the protein, simply due to it not being powerful enough to 
generate a signal. To overcome this, a protein can be grown into a crystal of repeating units 
thus amplifying the X-ray scattering. This amplification occurs due to the nature in which a 
crystal is formed. A crystal is made up of a structural motif, in this instance the protein, 
arranged in a lattice of regularly repeating units. These regularly repeating units are termed 
unit cells defined by three lengths and three angles (a, b, c, α, β, γ).  The unit cell will usually 
contain one or several copies of the molecule, termed the asymmetric unit (AU), which have 
symmetry elements applied to them in order to generate the unit cell. An example of the unit 
cell and AU can be seen in figure 2.2. 
 
 
  Chapter 2 
 59 
 
Figure 2.2 – Representation, using the amino acid Alanine, of the asymmetric unit and how it 
forms the unit cell, in this case containing a two-fold rotation axis perpendicular to the page, 
which in turn forms the crystal. Other rotation axes present within the crystal are also two-fold 
rotation axes. They indicate how one unit cell relates by symmetry to others within the lattice. 
The regularity of a crystal means that the X-rays interact with it, producing a 
discontinuous diffraction pattern, meaning that the scattered X-rays are only observed at 
distinct points, the individual waves of which are referred to as reflections and the intensity of 
each of which is measured. A perfect crystal will have all unit cells perfectly aligned with one 
another and the diffraction from each unit cell will be perfectly aligned with that from each 
of the other unit cells. This will then produce a mosaicity value of 0. The mosaicity is the 
width of the distribution of mis-orientation angles of all unit cells in a given crystal. A high 
mosaicity will result in broader spots. In reality there are almost always packing 
imperfections in the crystal as a result of either growth defects or flash freezing. The higher 
the mosaicity, the larger the spread of diffraction which means a greater angle of rotation is 
required to collect the full intensity for each individual reflection.  
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2.2.7.2 – Sitting & Hanging Drop 
There are a variety of crystal growth techniques, including liquid/liquid diffusion, 
sublimation and vapour diffusion. In the interests of brevity the only method to be discussed 
here will be vapour diffusion as this was the only crystal growth method used throughout the 
experiments. 
Figure 2.3 shows a schematic of the vapour diffusion technique using either tissue 
culture plates, or custom-made crystallisation plates. Initial screens made use of a Gryphon 
LCP® Liquid Handling Robot (Art Robbins), in a sitting drop conformation. In this 
experiment 100 nL of protein at a concentration of 2 mg/mL was combined with 200 nL of 
precipitant in the drop and 1 µL precipitant in the reservoir. Commercial screens used 
throughout these studies included Molecular Dimensions HT-96 format, MIDASTM, 
Morpheus®, JCSG-plus and Hampton Research Crystal Screens 1 & 2. Larger scale studies 
were performed with pipettes manually in a hanging drop conformation. Once the drops 
were set up the sitting drop plates were sealed using EasySealTM sheets (Molecular 





Figure 2.3 - Schematic showing the two vapour diffusion methods used throughout these 
experiments, hanging drop and sitting drop. Both of which work on the same principle. 
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When the drop was first set up, it had a concentration approximately half that of the 
reservoir, because the drop contains both protein solution and reservoir solution in a 1:1 
ratio. When changing this ratio the actual drop concentrations of protein and precipitant can 
vary. Equilibration then occurred, through the vapour phase, leading to an increase in the 
concentration of the precipitant in the drop to roughly equal that of the reservoir. This left 
the reservoir concentration practically unchanged due to the vast difference in volumes of the 
reservoir compared to the drop. The concentration of both the precipitant and the protein in 
the drop however have doubled due to the evaporation of water from the drop resulting in a 
smaller drop volume. This subsequent increase in concentration of both the protein and 
precipitant changes the internal environment of the drop, a change that can be visualised 
with a two-dimensional phase diagram, illustrated in figure 2.4: 
	
Figure 2.4 - A two-dimensional phase diagram. Below the first curved line, indicating the 
saturation point, is termed undersaturation, and above this curve is termed supersaturation. 
Supersaturation can then be divided into: the metastable zone - whereby supersaturation is 
too small and the nucleation rate is too slow to form crystals; the nucleation zone - where 
supersaturation is large enough that spontaneous nucleation can occur; and the precipitation 
zone – where crystals cannot form due to aggregates and precipitation forming faster than 
any crystals can form (102). 
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In a perfect scenario during the vapour equilibration, the concentration of the drop 
will increase so that it is no longer undersaturated but is concentrated enough to form 
spontaneous nucleation and small, nucleated crystals will begin to form. As they form the 
concentration of protein in the drop decreases moving into the metastable zone, allowing for 
the nucleated crystals to stabilise and grow larger into crystals that can be used to collect 
diffraction data. This movement is depicted by the arrow in figure 2.3. In practice however 
the variables are much more complicated and diverse and cannot be determined 
theoretically, they have to be determined in a trial-and-error methodology. In practice this 
trial-and-error methodology involves large scale crystal growth screens with iterative rounds 
of refinement to finally determine the optimum set of conditions to get suitable, reproducible 
crystals to be used for data collection. 
2.2.7.3 – Screening 
Initial screening experiments were performed to maximise the chances of successfully 
growing crystals. These screens allowed testing of a vast array of conditions whilst still using 
minimal amounts of protein. Both commercial and in-house crystal screens were used, the 
identities of which will be discussed in chapter 4. Using a Mosquito LCP® Liquid Handling 
Robot (TTP Labtech), unless otherwise stated, aliquots were taken from the 96-well Deep 
Well blocks containing the screen and placed into the corresponding wells in the 96-well 
MRC plate mentioned in the previous section. The plates were then sealed and left at 18 °C 
to allow the crystals to form. The drops were then examined via a light microscope to 
determine which conditions yielded good crystals or at least a good starting point for 
optimisation. 
2.2.7.4 – Optimisation 
Optimisation began with the conditions found through screening, as previously 
mentioned, that yielded nucleation that could be improved upon. This nucleation was in the 
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form of micro-crystals or needle-like crystals. Precipitation was used as a determination of 
poor conditions and was used to exclude crystallisation conditions from subsequent 
experimentation. This involved varying the concentrations of the various constituents within 
the precipitant solution (salt, buffer, precipitant) as well as the final concentration of the 
protein and other parameters such as the pH. All optimisation was performed using 24-well 
Linbro plates to increase the potential for greater numbers of crystals or physically larger 
crystals more suitable to testing due to their decreased susceptibility to X-ray radiation. All 
solutions were dispensed manually using standard single channel or multi channel pipettes. 
2.2.7.5 – Seeding 
The process of seeding involved taking a drop that contained high levels of 
microcrystals, and placing it into a 1.5 mL eppendorf tube. A glass capillary with a sealed 
end was then used to grind the crystals down. The eppendorf was then centrifuged at 13,000 
rpm for 60 seconds. This solution was then either used in this state or serial dilutions were 
produced in order to have a seeding stock. Further optimisation plates were then set up and 
the drops were set up in the same manner as previous with the exception that in this instance 
an equal measure of crystal stock was also added to the drop. 
2.2.8 – Principles of X-ray crystallography 
In order to determine the structural information from the protein crystal that has been 
grown, X-rays that have been passed through both a monochromator and collimator to get a 
fine beam of uniform fixed wavelength are shot at the crystal and subsequently diffracted. 
These diffracted X-rays then collide with a detector, which can measure the intensity and 
position of the diffraction pattern, which can then be used to determine the structure of the 
protein. 
This diffraction occurs due to parallel planes within the crystal. They are added 
constructively to one another to generate a single reflection, or spot on the diffraction 
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pattern. The conditions required for this constructive interference, and therefore a signal 
being detected at angle θ, is given by Bragg’s Law, which then relates the diffracted spot to 
the lattice parameters: 
𝑛𝜆 = 2𝑑!!"𝑠𝑖𝑛𝜃 
where λ is the wavelength of the X-rays used in the data collection and θ is the angle 
between the incident ray and the lattice planes mentioned previously, which is also equal to 
the reflection angle. dhkl refers to the interplanar distance, of direction hkl. This means that 
for constructive interference each wave must travel exactly one wavelength further than the 
wave next to it. According to basic trigonometry, this requires that the angle of incidence of 
the x-ray relative to the plane must be an equal integer multiple of the wavelength. 
During an x-ray diffraction experiment the wavelength is fixed, and for a set of planes 
within the crystal the interplanar distance is also fixed. As a result of this the crystal must be 
rotated to ensure conditions that satisfy Bragg’s law for all reflections. Visualisation of 
conditions that allow detection of reflections can be done with an Ewald sphere, which is a 
reconstruction of Bragg’s law in reciprocal space. The radius of this sphere is 1/λ from the 
crystal origin. The origin of the reciprocal lattice will lie on the incoming beam. A reflection 
from a particular plane will satisfy the conditions of Bragg’s law when the lattice point lies on 
the surface of this sphere. By rotating the crystal in real space, the reciprocal lattice also 
rotates, bringing new reflections into diffracting conditions.   
Physical parameters such as radiation damage can affect the intensity of the reflection. 
Symmetry related reflections should have identical intensities. To ensure this the data is all 
scaled, combining reflections from different images within the dataset and applying a scaling 
factor, and then merged into one dataset for further analysis.  
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The direction of the planes described above can be described by the Miller indices, 
which are written as h, k, l values. These values relate to where on the x, y and z axes the 
plane intercepts, an example of this can be seen in figure 2.5: 
 
Figure 2.5 - An illustration of a plane within an orthorhombic unit cell, and how its direction can 
be described by the miller indices 
Once the h, k, l values have been determined and the plane is known, the distance 
between the planes (dhkl) can be determined. An example of a calculation for a cubic system 
can be seen below: 
𝑑!!" =
𝑎
ℎ! + 𝑘! + 𝑙!
 
2.2.8.1 – The Phase Problem 
During an X-ray diffraction experiment, the data collected comprises the intensity of 
the reflections, whereas the phase information (αhkl) is lost. X-rays behave as waves and 
therefore have both amplitude and phase. The amplitude is defined as the maximum extent 
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of the wave whereas the phase is a particular point in the cycle of a waveform. The structure 
factor amplitude (|Fhkl|), is proportional to the square root of the intensity information 
collected but the point in the wave cycle cannot be collected. This is what is termed the 
‘phase problem’  
The relationship between these parameters can be seen in the equation below, where 
the ρ(xyz) relates to the electron density at point xyz in the unit cell and the unit cell volume 
is represented by V: 
 
Of the methods used to solve the phase problem, only one will be discussed in detail in 
this thesis, molecular replacement (MR). This was the sole method used to solve the phase 
problem in this research due to an abundance of suitable models to use. Other methods used 
include isomorphous replacement, anomalous dispersion and molecular replacement, all of 
which are briefly discussed in the appendices. 
MR is performed computationally, and usually requires a single, complete dataset. In 
order to perform MR, a PDB file is required that contains the atomic coordinates of an 
ensemble that resembles the target protein. 
In MR one of the first variables to determine is the solvent content of the crystal. The 
Matthew’s Coefficient is a means of determining the solvent content of a crystal and it is 
defined as the crystal volume per unit of protein molecular weight (VM). By studying 116 
crystal forms in 1968, and 226 in 1976, Matthews determined the range of solvent contents 
and determined a relationship between the solvent content and number of molecules in the 
AU (103, 104).  This value can be calculated after determination of the space group and unit 
cell dimensions, in conjunction with the molecular weight of the protein. Once a value is 
obtained, an estimate can be performed, based on probabilities, to determine the number of 
molecules of the protein within the asymmetric unit. This information is required when 
ρ(xyz) =1/V.Σ | F(hkl) | exp(iαhkl )exp(−2πi(hx + ky+ lz))
  Chapter 2 
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performing MR. The principle behind MR is that a Patterson map is generated for the 
search model that has been taken from an existing set of coordinates. This search model has 
to be rotated in three rotation angles, α, β, γ as well as three translation functions, tx, ty, tz. By 
performing the rotations first to determine the suitable angles, and only performing 
translations on fixed angles determined from the best results from the rotation function 
dramatically improves computational efficiency. Both the rotation and translation functions 
are more efficient in reciprocal space, therefore structure factors are calculated for the search 
model, where the associated phase with every reflection is set to 0. This is known as the 
Patterson function, the equations for which is shown below:  














A peak at ‘uvw’ in the Patterson map will correspond to a vector between atoms ‘xyz’ 
and ‘x+u’, ‘y+v’, ‘z+w’ in real space. The N atoms in a molecule will produce N2 peaks in 
the Patterson function, with a single peak at the origin corresponding to a vector between an 
atom with itself, i.e. with a vector of zero length. The search model Patterson function is 
compared to the experimental Patterson function, where successful orientations can be 
identified by overlapping peaks.   
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Figure 2.6 - Cartoon depicting the process of molecular replacement, where the search 
molecule (A), is first rotated to a position where theoretical and experimental values correlate. 
At which point the molecule is translated to the target molecule (A’) (105) 
Once these phases have been calculated and combined with the amplitude data 
generated during the data collection this will produce an approximate Fourier synthesis of 
the structure of interest that will then begin the necessary rounds of model building and 
refinement. The success of the MR can only be confirmed by analysis of the newly calculated 
phases by inspection of the electron density maps. That being said, there are two score 
functions that can be used as strong indicators for success, where a score is significantly 
higher than background, this is likely to be a unique, correct solution. 
The Log Likelihood Gain (LLG) score is a probability function that compares the 
likelihood of obtaining an input (experimental data) based on the outcome (the model, and its 
structure factor determined by its position) to an outcome based on a random distribution of 
atoms based on the Wilson plot. 
The Z-Score is a statistical test that measures how many standard deviations the LLG 
score is above or below the mean. A translational Z-Score above 5 is usually indicative of a 
correct solution (106), however rotational Z-Score is often poorer as the error is larger and 
several orientations are tested for each translational search. 
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2.2.9 – Data Collection 
2.2.9.1 – High Pressure Data Collection 
All data collection performed at the European Synchrotron Radiation Facility (ESRF, 
Grenoble, France) was at room temperature, using a Diamond Anvil Cell (DAC) (107). A 
schematic and picture of the DAC used can be found in Figure 4.32. The Detector used was 
a Mar555 (Mar Research) and all analysis was performed using XDS (108) and CCP4 (109, 
110). Samples were transported via 1 mm capillaries with precipitant surrounding the crystal. 
The capillaries were sealed using wax and housed within a refrigerated unit maintaining a 
constant 18ºC temperature until arriving at the beam-line. The DAC was then cleaned and 
loaded with a small ruby, which was used to accurately determine the pressure within the cell 
during the experiment. The crystal was removed from the capillary directly onto a glass slide, 
which could be easily accessed and viewed under a light microscope. This  crystal was picked 
using a loop and, simultaneously, 2 µL of precipitant was added to the sample chamber. The 
crystal was then dropped into the sample chamber and the DAC was moved under the 
microscope, at which point it had to be manipulated from the surrounding area to be 
successfully oriented within the chamber. Any bubbles present within the chamber were 
removed at this point using a fine needle. The cell was then closed, sealed and loaded onto 
the beam-line. 
The DAC was then aligned to the beam centre and further positioned so that the 
crystal was in the X-ray beam for data collection. An initial crystal was used for a 
compressibility experiment, to determine the pressure at which the crystal no longer diffracts 
X-rays. Once this final value was experimentally determined, a pressure at approximately 
50% the maximum was applied and used throughout the remaining data collection.  
Pressure was measured by firing a laser beam at a ruby within the DAC as the 
pressure was increased. Using a calibration curve first postulated by Mao et al (111) a 
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constant pressure was achieved, monitored and regulated throughout the experiment. This 
calibration curve was constructed because of an observable upward shift in the wavelength of 
the fluorescence emitted from a ruby present within the DAC that correlates with an increase 
in the pressure.  
Due to the position in which the DAC sits in relation to the beam, there was only a 90º 
rotation possible from -45º to +45º around the vertical axis. This meant that to collect a 
complete data set in order to produce a structure, more crystals had to be used, and they 
were placed within the sample chamber in as many varied positions as possible (112). 
The concept and data processing of high pressure X-ray diffraction are practically 
identical to that of ambient pressure X-ray crystallography. The differences lie in the actual 
data collection and limitations that result from this. Firstly the data is collected at room 
temperature. This is done due to the fact that temperature and pressure are proportional, as 
shown by the following equation: 
  
Where P = Pressure, V = volume, N = number of molecules, T = temperature and 
k=Boltzmann constant. This formula states  that with an increase in pressure, there is an 
associative increase in temperature, until equilibrium is reached. Therefore it is considerably 
more difficult to increase the pressure and maintain it, whilst simultaneously lowering the 
temperature to cryogenic levels rather than collecting at ambient temperature, although a 
lower temperature will greatly increase the lifetime of the crystal, as radiation damage from 
free radicals is greatly reduced.  
2.2.9.2 – Data Collection at the Diamond Light Source. 
All data collection performed at the Diamond Light Source Synchrotron, Oxfordshire, 
was done so on cryo-cooled crystals. The crystals were picked from their drop and if the 
PV = kNT
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polyethylene glycol (PEG) concentration was high enough then the loop containing the 
crystal was submerged in liquid N2. When the PEG concentration was lower in the 
precipitant, the loop containing the crystal was first passed through a solution of 
cryoprotectant to reduce the chances of damage to the crystal or the presence of ice-rings in 
the diffraction pattern.  
The loops, once frozen, were then placed into a ‘puc’ and transported via a dewar 
containing liquid N2 directly to the beam-line. Data collection was either performed in 
person or via remote access. Data processing was performed with MOSFLM (113) and CCP4 
(109). 
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Chapter 3  
DNA Dependent Protein 
Kinase Catalytic Sub unit  
3.1 Introduction 
DNA-PKcs is a protein consisting of 4128 amino acids that associates with the Ku 
70/80 heterodimer to form the active holoenzyme DNA-PK, which plays a vital role in the 
repair of DNA double strand breaks (DSBs) through the non-homologous end joining 
pathway. This chapter will discuss preliminary work aimed at producing soluble domains of 
the catalytic domain of DNA-PKcs. By obtaining soluble domains of DNA-PKcs, structural 
information could be determined experimentally, provided that the protein is properly folded 
and can be crystallised, allowing for x-ray diffraction and data collection. With key 
knowledge such as this, inhibitors with greater potency and specificity could be synthesised to 
adjunct existing chemo- and radio- therapies. Soluble domains could also be used to develop 
assays to greater elucidate the function of DNA-PKcs within the NHEJ as well as a more 
detailed picture of its interactions and interacting partners.  
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3.2 Protein Production 
3.2.1 – Construct Design 
Beginning at the N terminus and continuing through the entire sequence is a large 
portion of HEAT repeats. These repeats are overlaid with several other domains throughout 
the sequence. 
A series of constructs surrounding the kinase domain were designed, seen in figure 3.1.  
This construct design approach was utilised in order to determine the minimum sequence 
required to produce functional, correctly folded, soluble protein for the purposes of 
crystallisation and crystallography. The largest construct, A1, starts at P3600 and continues 
through to M4128. 
In reference to the domain map in figure 3.1, this construct begins 60 amino acids 
downstream of the FAT domain and continues through to the C terminus of the protein. 
Highlighted in red in figure 3.1 is the minimum kinase domain as predicted by the software 
’Phyre’ (114) and highlights the region from H3716 through to P4008. Phyre works by 
comparing a query sequence to known structures deposited in the protein databank (PDB), 
with a comparative ranking based on the confidence allowing accurate prediction of domain 
boundaries deduced from known similar structures. From S4096 through to M4128 is the 
FATC domain. Between M3796 and L3829 is a portion of the sequence that is present in 
many human cell lines, but not in HeLa cells due to the exon on the cDNA being absent 
(115). This ‘splice variant’ region has been removed in the E and F series of constructs to 
determine its effects, if any, on stability of the protein as well as its role in folding into 
secondary and tertiary structure as currently it has unknown function. 
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Figure 3.1- - Construct map showing the constructs designed and used throughout this 
study with reference to figure 1.3 indicating what regions of DNA-PKcs these constructs refer 
to. Cloning of constructs A1-D3 was performed by Hanaë Gourier (HG), while E1-F3 were 
cloned by the author using A1 as a template. Highlighted in red is the minimum catalytic 
domain determined by Phyre (114). Construct N was purchased through GeneArt based on 
domain boundaries published by Sajish et al (115). Constructs G-M have been included in 
the figure to indicate that these regions were initially tested in the interests of being thorough, 
however they did not progress past initial solubility studies. 
1 4128
FAT
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3.2.1.1 – E & F Series Production 
Both the E and F series of constructs were built by initially using the A1 construct as a 
template for the production of E1. A1 itself was designed and constructed by a previous 
member of the Spagnolo Lab, Hanae Gourier (HG). 
The first step in generating these constructs was the production of the two fragments 
either side of the removed splice variant portion. This was performed with 4 different 
primers (figure 3.2 and table 3.1) supplied by Sigma Aldrich.  




Primer Name Sequence 
1 Fw3600 (NdeI) 
5’ – GTGTGTCATATGCCTGTAAATAA 
       AAAAAACATTGAAAAATGTATGAA - 3’ 
2 Rv3796 (-) 5’ – GGAGGTCATGGGCACAACGCTATAGG – 3’ 
3 Fw3830 (-) 5’ – AGTGATCCCAGGGCACCGCC – 3’ 
4 Rv4128 (NotI) 5’ – AAAAAGCGGCCGCTTACATCCAGGG – 3’ 
Table 3.1 - A table showing the 4 primers used in this study to produce the E and F series of 
constructs. Primers 1 and 4 both contain restriction sites engineered into the primer, the 
identity of which is in parentheses. A dash in parentheses indicates no restriction site being 
used, for the purposes of blunt end ligation. 
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As mentioned previously, A1 was used as a template for the PCR reactions with Pwo 
polymerase to amplify both sides of the construct. Digestions on the 3600 and 4128 ends of 
the newly formed construct were performed with NdeI and NotI (New England Biolabs) 
respectively. The two blunt ends of the construct were ligated with T4 Ligase (Roche).  This 
ligation then produced a single fragment that was subsequently ligated into the pTWO-E 
vector discussed in chapter 2. Making use of the different restriction sites allows for correct 
orientation within the vector. The product of this ligation was then used directly to transform 
chemically competent XL1-Blue cells. A colony PCR was then performed to test the 
successful introduction of the sequence into the vector. The positive results of which were 
confirmed by sequencing. The remaining E and F series of constructs were then produced in 
a standard manner using E1 as the template rather than A1. 
3.2.1.2 – Overexpression Trials  
Initially, all constructs were first transformed into competent BL21* cells. Any 
constructs that didn’t produce viable cells after transformation were then discarded and only 
successful constructs were taken forward.  
A starter culture was produced for each of the successful constructs and an 
experimental culture was produced. An induction time course was performed to determine 
the optimum induction period prior to harvest. If any of the protein products were toxic to 
the cells, this would be observed by seeing a drop in the OD600 post induction. The final 
constructs that were taken forward after these initial experiments were: A1, A3, B1, B3, C2, 
D1, D2, D3 and E1. Although this is a high rate of decline, it was deemed that there were 
suitable levels of non-toxic proteins being taken through to solubility studies to warrant time 
being spent optimising this step in the protocol. An interesting observation to note is that the 
three most successful constructs taken forward were A1, E1 and D1. The likelihood is that 
the three of these constructs were so successful due to where in the protein they began and 
ended, which was at designated regions throughout the construct that are bona fide domain 
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boundaries, rather than within domains, such is the case for most of the remaining constructs 
in the map in figure 3.1. 
After this list of successful constructs was determined, further overexpression and 
solubility studies were performed, the results of which can be seen in figure 3.4. Based on the 
results seen in the figure, the A1, D1, E1 constructs were taken forward, as they showed an 
increased level of expression post-induction when compared to the other constructs tested. 
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Figure 3.3 – 12 % SDS-PAGE gels showing the results of growth trials on the positive DNA-
PKcs constructs. The arrows indicate bands present in the most successful constructs, A1, 
D1 and E1. U – Uninduced, I – Induced, P – Pellet, S – Supernatant. 
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The results in this figure indicate that there were varying levels of expression for these 
three constructs, however when using sonication as a means of cell lysis, the proteins were in 
fact insoluble. This could have been due to incomplete cell lysis, or possibly heat 
denaturation. To test these hypotheses, the lysis protocol was optimised. 
The first of these variations was to use lysozyme rather than sonication. This treatment 
is a lot milder than sonication and there are no heat associated denaturation issues. This 
however had no beneficial effect on increasing the solubility of the proteins. Alternative 
overexpression approaches were then tested. The first of these approaches was a decrease in 
the induction temperature, from 37 °C to 18 °C. After several attempts with all three 
constructs, all that was seen was a decrease in overall yield within the whole cell extract, but 
the relative amount of soluble protein remained at previous levels. 
Another variable tested was the final concentration of IPTG used to induce protein 
production. Initial experiments used a final concentration of 1 mM IPTG; this was reduced 
to final concentrations of both 0.2 mM and 0.1 mM. After testing this on all three constructs, 
no beneficial effects were seen in relation to solubility. This was then performed in 
combination with the reduced induction temperature mentioned previously, however this 
also failed to increase protein solubility. 
Lysis buffer optimisation was then performed to attempt to increase yields of soluble 
protein. 6 different buffers were tested. Firstly the buffering compound itself was changed, 
using either HEPES or Tris. The concentration of NaCl was also varied, in a range from 20 
mM to 500 mM. The pH was varied within the suitable buffering ranges of both the HEPES 
and Tris. Lastly the addition of 80 nM Dodecyl Maltoside (DM) as a detergent was tested.  
The buffer changes mentioned above, both on their own and in combination with one 
another did very little to aid with the solubility of the constructs. It was at this point that 
alternative constructs were designed and implemented, with the aim of generating soluble 
DNA-PKcs. 
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3.2.1.3 – Codon Optimisation 
The advantage of using E. coli as an expression system is the fact that it is cheap, quick 
and relatively straightforward to produce a protein recombinantly. A lot of commercially 
available vectors are also optimised for expression in E. coli. However, the frequency that the 
codons are translated in the ribosome by complementary tRNAs varies significantly between 
different organisms. This disparity in tRNA levels leads to a positive selective effect on 
constructs that result in faster and more accurate translation, thus leading to the 
aforementioned codon usage bias (116). A recombinant human DNA sequence will contain a 
degree of codons that are rarely used in E. coli and as such the translation levels will be sub 
optimal. Issues can then arise during protein synthesis. These issues can include: interrupted 
translation; frame shifting; mistranslational events; as well as inhibition of cell growth and 
protein synthesis (117). 
One way to overcome this issue is to generate a ‘codon optimised’, synthetic construct. 
The rare codons are replaced with ones that are used in abundance in E. coli (118).  
Codon optimised constructs for A1 and E1 were designed and purchased from 
Geneart, using their online software ‘GeneOptimizer®‘ to modify codon usage from Homo 
sapiens to E.coli (119). These codon-optimised constructs were subsequently tested for 
overexpression and solubility. Different media were tested, using LB, TB and Auto-induction 
media. The cell strain was also varied, testing BL21*, BL21-AI (Arabinose Inducible), and 
Rosetta pLysS cell strains. Then a variety of N terminal tags were also tested, including 
untagged, 6xHis tag, GST tag and a SUMO tag. The tags were incorporated into the 
construct through cloning into the pTWO-E vector, shown in figure 2.1. SUMO (Small 
Ubiquitin like Modifier) is a small protein that is covalently linked to the target protein that 
behaves akin to a post-translational modification. It is also believed that the SUMO tag 
prevents degradation of the protein by translocating it to an intracellular region low in 
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proteases (120, 121). GST tags have the potential to protect against intracellular protease 
activity and stabilise recombinant proteins.(122) 
Transformation of the cells was performed and an induction trial was performed. The 
results were viewed on several western blots, which can be seen in figure 3.5 and these results 
have been summarised into tabulated form, seen in table 3.2. The quality, measured by the 
levels of degradation products present in the sample, and quantity of protein, based on the 
expression levels quantified by both SDS-PAGE and the absorbance at 280 nm, were given a 
score and the better the conditions, the more ticks it was awarded.  
This experiment helped to remove LB as a growth medium, as well as both untagged 
versions of the constructs, which didn’t actually grow, a result which was seen after several 
repeated experiments. TB media was consistently better than any other media tested and was 
therefore used throughout the remaining experiments. Possible reasons for its superiority 
over other media could be due to the fact it is phosphate buffered preventing cell death due 
to pH changes, as well as the fact that it can reach much greater cell densities. Rosetta pLysS 
was chosen due to having consistent overexpression levels when compared to the other cell 
strains tested. 
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Table 3.2 - A list of the various conditions tested with the codon optimised constructs. Final conditions used A1 and E1 with a GST tag in Rosetta pLysS 
cells. 
 











No Tag NO GROWTH 
His ! !! !!! ! ! ! ✗ ✗ ✗ 
GST !!! !!! !!! ! ! ! ✗ ✗ ✗ 
SUMO !! !! !!! ! ! ! ✗ ✗ ✗ 
E1 
No Tag NO GROWTH 
His NO GROWTH 
GST !! !! !!! ! ! ! ✗ ✗ ✗ 
SUMO !! !! !! ! ! ! ✗ ✗ ✗ 
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Figure 3.4 - (A) Western blot developed with α-DNA-PKcs antibody showing the results of 
over-expression tests using GST-A1. Condition 1 used the BL21* cell strain, condition 2 
used the BL21-AI (Arabinose Inducible) cell strain, and condition 3 used the Rosetta pLysS 
cell strain. (B) Western blot developed with α-DNA-PKcs antibody showing the over-
expression results for His-A1. LB broth was not included due to already being determined an 
unsuitable medium. All blots in both (A) and (B) were developed on the same film, and 
incubated with the membrane for 60 seconds. Bands in both (A) and (B) are both 
considerably lower (around 55 kDa) than the 85.9 kDa of GST-A1 highlighted with the 
dashed red box. . 
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3.3 Protein Purification 
3.3.1 – Soluble GST-A1 
After determining the optimal growth conditions, both the GST-A1 construct and His-
A1 constructs were tested alongside one another but due to both the His-A1 and SUMO-A1 
being His-tagged they were grouped and written about in the section proceeding this. To test 
the solubility status of the target protein, the cell pellet was lysed with lysozyme, in 20 mM 
HEPES pH 7.5, 150 mM NaCl, 10 % Glycerol, 5 mM MgCl2, then subjected to further 
optimisation. The results of this lysis can be seen in figure 3.5.  
 
Figure 3.5 – 15% coomassie stained SDS-PAGE and western blot, developed with a-DNA-
PKcs antibodies showing the uninduced (U), induced, (I), pellet (P) and supernatant (S) 
samples for GST-A1. Lysis was performed with lysozyme and incubated with rotation for 60 
minutes at room temperature before clarification via centrifugation at 22,000 rpm for 60 
minutes. 
Figure 3.5 highlights the levels of expression observed for GST-A1. The SDS-PAGE 
shows that expression levels are low but the western blot does indicate a protein containing 
the epitope for an anti-DNA-PKcs antibody is being produced. The bands in this western 
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blot are resolving at approximately 55-60kDa, whereas the theoretical size for GST-A1 being 
85.9 kDa. This could be as a result of non-specific antibody binding. Other reasons could 
include abnormally fast migration of bands through the SDS-PAGE gel or even an untagged 
construct, as this is close to the size of the band being observed (60.4 kDa) 
In figure 3.6, the upper western blot (developed with α-DNA-PKcs antibody) is for the 
GST-A1 construct and the lower western blot (again developed with α-DNA-PKcs antibody) 
is the E1-GST construct. The one condition that had a good yield of soluble protein for both 
of the constructs was PIPES at pH 7. One interesting observation is the disparity between the 
band migration for both the A1 and E1 constructs. The GST-A1 construct seems to be 
present higher on the gel than it should be, greater than 98 kDa, even though the size of the 
protein is 85.9 kDa, whereas for GST-E1 the band is present ~64 kDa when its true size is 
82.3 kDa. This disparity can also be seen when comparing the results in figure 3.7 with those 
in figure 3.6, which also has bands present ~64 kDa. One reason for this could be 
degradation of the tag from lysis to analysis, however this is unlikely due to the lysis and 
preparation techniques being consistent. Another possible explanation could be cross-
reaction of the antibody against DNA-PKcs used for these western blots, although the 
epitope that these antibodies target is small and no E.coli proteins have sequence similarity to 
this region. 
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Figure 3.6 – Western blot developed with α-DNA-PKcs antibody showing the results of a 
buffer scouting experiment performed to increase solubility of GST-A1 (upper) and E1-GST 
(lower). U – uninduced, I – induced, odd numbers indicate a pellet fraction after lysis and even 
numbers represent the supernatant from that same lysis experiment. Highlighted in red 
indicate a pellet/supernatant pair for lysis performed in PIPES pH 7. Lane identities can be 
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Table 3.3 - A table showing the identity of each of the lanes present in the western blots 
shown in figure 3.6. Highlighted in red is the condition that was optimal for both constructs, 
which was then taken forward. 
 
Therefore PIPES at pH 7 was used for all subsequent experiments. A binding affinity 
assay was performed to determine the best resin to use for the purification of the construct. 
All subsequent results discussed in this chapter are for the GST-A1 construct. 
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3.3.2 – GST-A1 Protein Purification 
Figure 3.7 - Western blot, developed with α-DNA-PKcs antibody, showing the results of the 
binding affinity experiment with GST-A1. FT – flowthrough, W – wash, E – elution. 
500 µL of supernatant in PIPES pH 7 was added to 100 µL of pre-equilibrated resin, 
and allowed to incubate for one hour at room temperature, at which point the resin was 
washed and bound proteins were then eluted with the appropriate eluent for that particular 
resin. The samples were then loaded onto an SDS-PAGE gel for the purposes of a western 
blot. This blot can be seen in figure 3.7. 
Based on this experiment, the most effective resin to use was the strong anion 
exchange resin, Q, as it was the only sample with protein present in the eluate rather than 
the flow-through. As seen in the figure, the protein did not bind to its appropriate affinity 
resin. This could be due to the concentration of reduced glutathione being too high in the 
buffer used to equilibrate the column, as well as the sample buffer. However it is also 
migrating on the gel lower than expected, which strongly indicates a lack of the required N 
terminal GST tag. It could also indicate antibody cross-reactivity leading to the purification 
of an alternative, non-target protein. This point will be discussed further later in this chapter.         
Due to finding a resin that the protein bound to, the scale was then increased and subsequent 
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purifications were performed on a 1 mL Q Hitrap (GE Healthcare) column. The theoretical 
pI of GST-A1, as calculated by Protparam (123) is 8.77, therefore at pH 7 it should bind to 
an anion exchanger, concurring with the result observed.  
The overexpression scale was then increased. The pellet harvested from 1 L of culture 
was resuspended in 30 mL of PIPES buffer. After loading and washing the 1 mL Q Hitrap 
column, the protein was eluted with a salt gradient, from 200 mM NaCl to 1 M NaCl over 
40 column volumes. Results are shown in figure 3.9, the fractions that contained the peak 
highlighted were then analysed by SDS-PAGE and western blot, the results of which can also 
be seen in the figure. 
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Figure 3.8 - (A) Elution trace from 1 mL Q column. This particular trace is showing only the 
elution portion of the purification, with elution being performed by a salt gradient. The 
highlighted grey area indicates the fractions collected (12-25). The green line in the graph 
indicates the concentration of elution buffer (B) on a percentage scale, where 100% equates 
to 1M NaCl. (B) 15 % SDS-PAGE coomassie stained gel and western blot developed with α-
DNA-PKcs antibody showing these peak fractions. 
 
Fractions 17 – 24 were collected, although the bands were running lower than they 
should be for the A1 construct with a GST tag. The expected size of the GST fusion protein 
GST-A1
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was 85.9 kDa. When the tag is removed however the size of the protein is 60.4 kDa, which 
was the approximate size of the band. This could be either due to tag removal during the 
purification process, proteolytic degradation or an alternative ribosomal binding site. 
Although unavailable at the time of experimentation, an anti-GST antibody would have 
been useful to detect presence/absence of the GST tag throughout the process from 
induction to lysis and purification. After collection, the fractions were pooled and 
concentrated to a final volume of 500 µL. This sample was then loaded onto an s200 10/300 
GL size exclusion chromatography column (GE Healthcare). The results of this experiment 
can be seen in figure 3.10. 
The blue trace in the figure represents the GST-A1 sample. As a reference, the red 
trace represents the calibration of the column with Blue Dextran, a 2 MDa branched 
polysaccharide that is too large to access any of the pores present on the Sepharose within 
the column. The volume that this is eluted from the column is termed the ‘void volume’. 
As mentioned previously the GST-A1 is around 85.9 kDa, which is not large enough 
to elute in the void volume. GST tags however are known to dimerise but this resultant ~172 
kDa protein would still be small enough to pass through the column without being present in 
the void volume, as the largest protein size that can be accommodated by this column is 600 
kDa therefore tag dimerisation causing void volume elution cannot be the cause. 
The second GST-A1 peak shows no protein, based on the SDS-PAGE, and this is 
most likely free nucleic acid due to the 260nm / 280 nm ratio for samples 15, 16 and 17 
being around 1.95, 1.98 and 1.99 respectively. A protein sample that contains no nucleic 
acid contamination will have a 260nm / 280nm ratio of 0.5. 
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Figure 3.9 - Size exclusion chromatographic trace, using an S200 10/300 GL column (GE 
Healthcare) with a column volume of 24 mL. Below is the associated 15% coomassie stained 
SDS-PAGE and western blot developed with α-DNA-PKcs antibody for the purification of 
GST-A1. The grey areas indicate the fractions collected for analysis (7-10 & 15-17). 
GST-A1
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The 260 nm / 280 nm trace for fractions 8, 9 and 10 were all above 1.2, indicative of 
moderate levels of nucleic acid contamination. Therefore the formation of a protein / DNA 
complex could potentially be the reason for the protein being eluted in the void volume. One 
way to test if the tag dimerisation is in fact the reason for void volume elution was to perform 
a TEV cleavage assay, to remove the tag and then analyse the samples. 
The TEV cleavage assay was performed in 50 mM Tris-HCl pH 8, 0.5 mM EDTA, 
1mM DTT. 22 µL of the GST-A1, along with 1 µL of acTEVTM (Invitrogen), and 177 µL of 
reaction buffer were added into an eppendorf tube. The entirety of the reaction was 
performed at room temperature and after every hour 30 µL of the reaction mixture was 
removed and immediately denatured with SDS prior to running on a 12% SDS-PAGE gel. 
The results of this assay can be seen in figure 3.11. 
	
Figure 3.10 – Silver stained 15% SDS-PAGE and western blot developed with α-DNA-PKcs 
showing the TEV cleavage assay performed on GST-A1. The acTEVTM protease is 27 kDa 
and its migration region is highlighted in the figure ith the red dashed box (124). 
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Based on this figure, there has been no cleavage at the TEV site, which would 
normally be indicated by the band migrating faster due to a decrease in size, as well as the 
lack of appearance of a new band around 25.4 kDa. The experiment was varied several 
times in an attempt to improve the assay, however cleavage was never observed. No control 
has been included in this figure, however control experiments were performed, and indicated 
that the acTEV TM was in fact a functioning protease. This further points to the possibility 
that the protein being taken through the purification does not contain either a GST tag or a 
TEV protease site, and is therefore not the target protein. The molecular weight of the 
protein, based on its migration on the gel is correct for the protein without the tag. One 
interesting point to note is the disappearance of the signal corresponding to the protein in the 
overnight (ON) sample, compared with the 4 hour sample. This could be due to the protein 
being kept at room temperature overnight, leading to subsequent degradation. Several 
repeats of this experiment yielded similar results with no appearance of a lower band that 
would indicate successful cleavage. 
Dynamic light scattering (DLS) was then performed in order to determine an 
approximate size of the species, which could help to identify if it is a monomer, a dimer, with 
or without a GST tag or in fact in complex with DNA. 
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Figure 3.11 - DLS data showing the size distribution against both the intensity of the scattering 
signal and volume in per cent for GST-A1. The peaks are an average of four repeats that 
were performed at two concentrations; 0.25 mg/mL and 0.125 mg/mL. 
The main peak, visible in both graphs, had a mode diameter of 15.51 nm (s.d. 7.05 
nm), which produced a MW of 552 kDa, calculated by using the empirical mass against a 
size calibration curve automatically by the software (Malvern Instruments). This value is 
most likely due to the large and varied levels of aggregation, visible in the intensity peak, and 
not a true representation of the size of the protein in solution, or the protein in complex with 
DNA 
Peptide mass fingerprinting was then carried out using the protocol discussed in 
chapter 2 to determine a more accurate answer to the identity of the band. Using the same 
sample seen in the silver stained ‘input’ band seen in figure 3.11, a new SDS-PAGE 
experiment was performed and the prevalent band was excised and digested with trypsin, 
which cleaves after K or R residues within the sequence. The results of the fingerprinting can 
be seen in figure 3.13. 
The excised band was identified as a 60 kDa E. coli chaperonin. With 65% coverage, 
23 peptide matches and a protein score of 183, this information can be considered accurate. 
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A definition of the protein score is -10LogP, where P is the probability that the observed match 
is a random event. Any protein score above 70 has a statistical significance, with a p < 0.05. 
The fact that the main protein being purified is a chaperone indicates that the codon 
optimised GST-A1 required significant attention from the host chaperones in order to fold 
correctly and maintain this structure. Although no direct evidence for the protein ever being 
correctly folded is available, the presence of a chaperone throughout the procedure indicates 
attempts to fold the protein. The interesting aspect of this outcome however, is the fact that 
even though it was a chaperone it produced a signal when used in a western blot developed 
with α-DNA-PKcs. This could be due to the fact that they are co-migrating, seeing as they 
are similar sizes. The epitope for the antibody is for a portion of the FATC domain of DNA-
PKcs, which no homology to any portion of chaperonin. If they are maintaining a complex 
(85.9 kDa + 60 kDa with the GST tag or 60.4 kDa + 60 kDa without the tag) then this could 
in fact be the reason that the protein is being eluted in the void volume, but would not 
explain why only one was being seen in the SDS-PAGE gels or western blots. Another factor 
against this theory is the lack of peptides being observed that would map to the DNA-PKcs 
sequence, which, if they were co-migrating, would be detectable after the tryptic digest. 
A solution to this has not been determined and this will be discussed in more depth in 
the future work chapter of this thesis. In parallel to the GST-A1 work, studies were also 
performed on the two other constructs that performed well in Rosetta pLysS cells, grown in 
TB. These constructs were His-A1 and SUMO-A1. 
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Figure 3.12 – Graph highlighting the mass peaks and their associated intensity (%). The mass 
of these peaks relates to the peptides highlighted in the sequence coverage map. This map 
shows the sequence of a 60 kDa E. coli chaperonin being purified instead of the target 
protein. 
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3.3.2 – Soluble His-A1 & SUMO-A1 
The His-A1 and SUMO-A1 seen in table 3.1 had similar growth and expression levels 
to the GST-A1 and were taken forward simultaneously. Both tags were present on the N-
terminus of the protein and the SUMO tag also contained a 6xHis tag for identification and 
purification purposes, however this was downstream of the SUMO tag itself. The solubility 
was tested in PIPES buffer by using both sonication and lysozyme as lysis techniques, with 
the results being directly compared on an SDS-PAGE gel seen in figure 3.14. 
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Figure 3.13 – Coomassie stained 15% SDS-PAGE and western blot developed with α-6xHis 
antibody showing the expression and lysis experimentation results for both His-A1 and 
SUMO-A1. This antibody was chosen due to the tag being present on both constructs. α -
DNA-PKcs western blots were also performed with identical results, however these results are 
not shown. This experiment shows a direct comparison between sonication (Sonic) and 
lysozyme (Lys) as a means of cellular lysis. U – Uninduced, I – Induced, P – Pellet, S – 
Supernatant. The calculated molecular weight of His-A1 is 61.2 kDa and of SUMO-A1 is 
72.7 kDa. 
 
Directly comparing the results from His-A1 and SUMO-A1, only the 6xHis tagged 
construct actually produced protein. This result was verified through repeat experiments as 
His-A1            SUMO-A1 
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well as using α-DNA-PKcs rather than the α-His antibody results shown in the figure. The 
other observable, and repeatable, result from this experiment is the difference between the 
lysis techniques, with lysozyme treatment generating more soluble protein when compared to 
the sonicated sample.   
At this point, due to the construct containing an N-terminal 6xHis tag, a binding 
affinity experiment was performed using Ni-Sepharose not bound to a column. After an 
interaction had been determined, a larger scale experiment was performed, whilst 
maintaining the use of the resin.  
In the experiment described in figure 3.14, 500 µL of resin with 50 mL supernatant 
from 1 L of cell culture was used. The western blot, developed with α-DNA-PKcs, shows the 
His-A1 construct present in the supernatant, as well as coming off slightly at 100 mM 
imidazole, but with the majority of the protein being eluted at 500 mM imidazole.  
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Figure 3.14 – 15% coomassie stained SDS-PAGE gel and western blot showing the results 
of the batch purification of His-A1. Western blot developed with α-DNA-PKcs. Washes 1 & 2 
were performed with 20 mM imidazole. Washes 3 & 4 were performed with 100 mM 
imidazole. Elution was performed at 500 mM imidazole. The ‘Elution 1’ sample was 
concentrated to a final volume of 500 µL and loaded onto an s200 10/300 GL column (GE 
Healthcare). Red dashed box indicates predicted molecular weight. 
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Figure 3.15 - His-A1 size exclusion trace and 15% coomassie stained SDS-PAGE gel 
showing highlighted (grey) fractions 7 – 13. 
His-A1    Elution Volume (mL)
  Chapter 3 
 103 
The void volume for this column is ~ 7.8 mL, and this is the point at which the peak is 
being eluted from the column. This indicates that the protein is much larger than predicted. 
It could be due to soluble aggregates forming, greatly increasing the hydrodynamic radius. It 
could also be oligomerisation of the protein, however this is less likely with a 6xHis tag rather 
than the GST tag mentioned previously. What is more likely is in fact nucleic acid 
contamination because the 260 nm / 280 nm ratio for sample 10 is 1.91.  
In order to determine if these data were obtained as a result of nucleic acid 
contamination, experiments were performed with the aim of removing the nucleic acids from 
the protein.  
The first of these experiments was to incorporate a high salt wash into existing 
protocols. The resin was replaced with 1 mL HisTrap columns, which allowed for greater 
control and variation throughout the wash stages due to the fact it is used in combination 
with an ÅKTA purification system and subtle changes to the concentration of elution buffer 
can be made more accurately. The imidazole concentration in the lysis buffer was increased 
to 60 mM, and the concentration of NaCl in the wash step was increased to 1.5 M. The 
target protein was then eluted using a gradient of imidazole. Prior to running on a size 
exclusion column the 260 nm / 280 nm ratio was calculated and the values for the combined 
fractions was 1.97, implying that a salt wash did not remove any of the proposed nucleic acid 
contamination. 
A second purification step was then included to try and achieve this removal. Using 
the output of this last purification, a binding affinity assay was performed using ion exchange 
chromatography resin. Including strong and weak anion exchanging resin (Q and DEAE 
respectively), strong cation exchanging resin (SP) and Heparin. Firstly the salt concentration 
was reduced from 350 mM to 20 mM, for the binding step. An intermediate wash step at 
100 mM NaCl was performed and then the protein was eluted at 1 M NaCl. The results of 
this assay can be seen in figure 3.16. 
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The theoretical pI of this protein, according to ProtParam (123), is 9.16.  Based on this 
the protein should bind to an anion exchanger, which again is the result observed. There is 
clear binding for both the strong (Q) and weak (DEAE) anion exchange resins. The 
interesting difference between the two is that the DEAE actually separates the two bands that 
are migrating very close to one another, however the Q does not, most likely due to its 
strength as an anion exchanging resin. Strong anion exchange resins are charged over a large 
pH range whereas weak anion exchange resins remain charged over a much narrower pH 
range. This therefore allows for the two bands present in the input lane of figure 3.17, to be 
separated as the difference in their pI will be smaller than the difference of the range of 
charge between Q and DEAE resins. 
 
Figure 3.16 – SDS-PAGE gel, stained with coomassie, showing the results of an ion 
exchange binding affinity assay for His-A1. The input had a salt concentration diluted from 350 
mM to 20 mM. Lanes show the flow-through (FT), wash (W) and elution (E). The lower band 
of the two in the couplet (highlighted by the arrow in the Heparin flow through lane) was 
deemed to be the correct band and therefore DEAE resin was incorporated into subsequent 
purification steps. 
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An intermediate ion exchange step using DEAE resin was then incorporated into a 
larger prep after the existing affinity chromatography step. The output from the DEAE 
column was then concentrated to a final volume of 500 µL and loaded onto a pre-
equilibrated s200 10/300 GL column in order to determine if the ion exchange step served 
its purpose.  
The result in figure 3.17 shows the chromatographic trace for a size exclusion step 
introduced after the DEAE resin to determine the effectiveness of nucleic acid removal. The 
first peak was eluted at around 8 mL, which is the void volume for this column. The second 
peak begins being eluted at around 12 mL. Fractions were collected for both peaks and were 
analysed on an SDS-PAGE and western blot to determine their contents. These results can 
be seen in figure 3.19 
 
Figure 3.17 - Size exclusion chromatographic trace for the purification of His-A1 after previous 
anion exchange chromatography, shown in figure 3.16. 
 
His-A1
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 Fractions 8 and 9 contain the target protein and both relate to the void volume peak. 
Their 260 nm / 280 nm ratios are 1.97 and 1.99 respectively, indicating a failure of DEAE 
to remove the nucleic acid contamination. This could be due to the fact that at this pH, both 
the protein and the nucleic acid will have net negative charges and will therefore both bind 
to the resin. Future work could involve a repeat of this experiment at around pH 5, in order 
to generate a net positive charge on the surface of the protein, which in turn will serve as a 
separation technique between protein and nucleic acid. 
	




Figure 3.18 – 15% coomassie stained SDS-PAGE and western blot developed with α-DNA-
PKcs antibody, showing the fractions obtained during size exclusion chromatography step, 
shown in figure 3.18, after the protein had already passed over a weak anion exchange 
chromatography column (DEAE). Red dashed box indicates predicted molecular weight. 
 
The next technique employed to remove this apparent nucleic acid contamination was 
precipitation with polyethyleneimine (PEI). PEI is a cationic electrolyte at this pH and serves 
as an intermediate purification step that work by separating molecules based on their charge. 
In this instance the concentration of the PEI will be high enough to precipitate the nucleic 
acid whilst keeping the protein in the solution (125). 
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The final concentration of PEI used, after initial small-scale experimentation, was 
0.025 %. The PEI was combined with benzonase during the lysis of the cells and then the 
remaining protocol made use of the high salt wash mentioned previously. After the PEI 
treatment, the protein was subjected to ammonium sulphate (AMS) in order to precipitate 
the protein, removing any trace of PEI. Tests were performed to determine the optimal 
concentration of AMS relative to the protein by starting off at 0 M until it was saturated (3.5 
M). The optimal concentration determined and then used for this experiment was 3.2 M. 
Once the protein was precipitated, it was separated from the supernatant and resuspended in 
fresh lysis buffer for further treatment.  
This involved the sample being loaded onto an s200 10/300 GL column, where it 
eluted in the void volume. Due to the protein being precipitated from the lysate, this acted as 
an alternative to affinity chromatography and, once resuspended, the protein was loaded 
directly onto the S200 size exclusion column. The fractions collected from this purification 
can be seen in figure 3.17. The 260 nm / 280 nm ratio after the PEI treatment in the most 
concentrated fraction (8), was 1.74. This is an improvement on previous results of ~ 1.97 
however the problem is persistent enough to cause the protein to elute in the void volume. 
The western blot shown in this figure was developed with α-6xHis antibodies.  
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Figure 3.19 – 15 % SDS-PAGE and western blot, developed with α -6xHis antibodies, 
showing the results of size exclusion chromatography after treatment with AMS and PEI. + 
refers to a positive control for the western blot, which was a purified 6xHis tagged protein. 
Due to this step being unsuccessful, an alternative protocol was attempted using 
hydrophobic interaction chromatography (HIC). The rationale behind using this technique 
being that if increased hydrophobicity is induced artificially, through the introduction of a 
high ionic strength buffer, any nucleic acid contamination then present on the protein will 
not bind to the resin and flow through, thus allowing purified protein without the 
contamination to be eluted. The chemical used to induce hydrophobicity by exposing the 
hydrophobic amino acids that would normally be buried within the structure, was AMS. 
The concentration at which  the protein precipitates using AMS was determined when 
performing the PEI treatment. The optimal precipitation concentration was 3.2 M, but the 
highest concentration possible prior to any precipitation was 1 M. Once the AMS was added 
to the sample, it was then divided up into three aliquots and passed over different HIC resins. 
These were Butyl-S, Octyl and Phenyl. The difference between the resins is the length of the 
backbone, where the length of the backbone affects their efficacy, with longer chains binding 
to increasingly hydrophobic proteins. Shorter length chains attract less hydrophobic proteins 
and therefore may not succesfully purify the protein, however longer chains induce stronger 
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interaction of the protein to the resin and yields may decrease through protein not being 
eluted. The results of this experiment can be seen in figure 3.19. 
The SDS-PAGE gel shows that the target protein binds to all three resins. However 
none of them have served to purify the target protein away from the contaminant proteins 
present in the solution, nor have they managed to significantly remove the nucleic acid 
contamination. The input 260 nm /280 nm ratio was 1.97. The Butyl-S resin had a ratio of 
1.35, however the protein had a concentration of 0.08 mg/mL. The Octyl resin reduced the 
ratio to 1.91 and the Phenyl resin reduced it to 1.84. 
 
 




Figure 3.20 – 15 % coomassie stained SDS-PAGE gel and western blot developed with a-
DNA-PKcs antibodies, showing the results of an HIC binding affinity experiment. The results in 
the gel show the protein binding to all three resins with equal affinities whereas based on the 
western blot there is a strong affinity for the Butyl-S and a slightly weaker interaction with the 
Octyl resin, with no binding interaction with the phenyl resin. The 1M AMS lane refers to the 
input after treatment with 1M AMS in order to induce hydrophobicity. The arrow indicates 
which band was excised for subsequent mass spectrometry analysis. 
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The sample highlighted in figure 3.20 was analysed using another SDS-PAGE, with 
15 µL of sample loaded to allow for band excision and digestion with trypsin for peptide mass 
fingerprinting to be performed. Following the protocol discussed earlier, the experiment was 
performed and the results of this can be seen in figure 3.22. 
The sequence seen in the figure is for a chaperone called GroEL from E. coli. The 
protein score was 2078 with 157 matched peptides and sequence coverage of 73 %. The 
strength of this evidence is convincing and leads to the conclusion that when using both 
GST-A1 and His-A1 that are codon optimised, they are not stable enough to exist without 
the presence of a chaperone. This interaction is strong enough to exist far from the 
intracellular environment and is strong enough to withstand some very stringent purification 
conditions. These results will be further discussed in chapter 5. 
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Figure 3.21 - Graph highlighting the mass peaks and their associated intensity (%). The mass 
of these peaks relates to the peptides highlighted in the sequence coverage map. This map 
shows the sequence of an E. coli chaperone called GroEL being purified instead of the target 
protein. Sequence results show 73% coverage, with 157 matched peptides and a protein 
score of 2078.  
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3.3.3 – Alternative Constructs 
3.3.3.1 – Construct N (R3746-M4128)  
Due to the failure of a codon optimised approach, the next logical step to generate the 
desired soluble protein was to test proteins with alternative domain boundaries. Sajish et al 
(126) recently published work performed on a soluble DNA-PKcs construct with alternative 
domain boundaries to the ones used in this study. The soluble construct, Construct N, began 
30 amino acids downstream of the minimum kinase domain mentioned previously, at R3746 
and continued to M4128 in the FATC domain of DNA-PKcs.   
 
Figure 3.22 - (A) Construct schematic for A1, the construct used throughout these studies. 
(B) Construct schematic from Sajish et al showing the domain boundaries for their soluble 
DNA-PKcs (126). NT – N-Terminal, MD – Middle Domain, KD – Kinase Domain. 
 
Using this publication as a reference, three new constructs were designed and 
purchased from Geneart. The first construct was designed without a tag, the second 
construct contained an N-terminal V5 tag, a 14 amino acid long peptide derived from a 
small epitope, present on paramyxovirus of simian virus 5. The third construct contained a 
C-terminal 6xHis tag.  
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Initial over-expression tests were performed, using Rosetta pLysS cells, grown in TB 
medium and the results of this can be seen in figure 3.23. This cell strain and media 
combination was used due to high growth yields in previous experiments. 
	
Figure 3.23 – SDS-PAGE gels and western blots developed using α-DNA-PKcs antibody 
showing Induction trials using three constructs derived from the soluble construct shown by 
Sajish et al (126). The untagged construct has an expected MW of 43.5 kDa. The V5-tagged 
protein has an expected MW of 44.9 kDa and the 6xHis tagged protein has an expected 
MW of 44.4 kDa. Red dashed box indicates predicted molecular weight. 
 
The SDS-PAGE gels show low levels of over-expression but based on the western 
blots, developed with an α-DNA-PKcs antibody, there appears to be more significant over-
expression. That being said, the chemiluminescent detection method can be affected by 
exposure time, with longer times producing greater signal, possibly exaggerating absolute 
levels of expression. Future work would include a variety of exposure times to reduce this as a 
variable. The western blots show both the untagged and V5-tagged proteins with significant 
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levels of either a smaller contaminant product or breakdown product. Future work would 
include limited proteolysis experiments to determine definitive breakdown products as well as 
stable sub domains present within the protein.  
The 6xHis tagged protein was taken forward for further experimentation, due to lower 
levels of this smaller ‘contaminant’ band, and 2 hours was chosen as the optimum induction 
time. Initial solubility experiments showed distinct lack of solubility, concurrent with previous 
construct experiments. This was also true for a variety of lysis techniques  
All cell pellets were lysed using lysozyme at a final concentration of 1 mg/mL for 1 
hour at room temperature, at which point they were centrifuged at 22,000 g for 1. Based on 
the gel and western seen in figure 3.24, the lysis worked well with the vast majority of 
proteins present in the supernatant, however the target protein for each of the various 
conditions was always found in the pellet.  
 
Figure 3.24 – 15 % SDS-PAGE and western blot, developed with α -6xHis antibodies 
showing the results of a buffer scout attempting to generate soluble target protein. Red 
dashed box indicates predicted molecular weight. 
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These figures indicate that these construct boundaries have done little to improve the 
solubility.  
3.3.3.2 – pelB Leader 
The pelB leader sequence refers to a 22 amino acid sequence of pectatelyase B of 
Erwinia carotovora CE (127) that, when attached to a protein, encodes for the transport of the 
protein from the cytoplasm, to the periplasm between the inner and outer membranes  (128). 
Once there, the leader sequence is cleaved by signal peptidases present in the periplasm. 
 
Figure 3.25 - Cartoon detailing the cell envelope, between the cell wall and cell membrane in 
gram negative bacteria such as E. coli (129). 
 
One advantage of having a protein contained within the periplasm rather than the 
cytoplasm is that there are fewer proteases present that could potentially lead to proteolytic 
degradation. Another advantage is the fact that there are fewer chaperones present when 
compared to the cytoplasm. Due to the fact that this was such an issue for both 6xHis tagged 
and GST tagged codon optimised constructs discussed in the previous chapter, having a 
protein fold with fewer chaperones present could be beneficial. Yet another advantage is the 
fact that there are significantly fewer proteins present in the periplasm, and disruption of the 
outer membrane, whilst keeping the inner membrane intact, is a good means of keeping the 
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protein relatively pure before any further purification. This outer membrane lysis step was 
performed using osmotic shock using Tris-Sucrose-EDTA (TSE) buffer.  
	
Figure 3.26 - Schematic of the three pelB leader constructs that were designed: Purple – 
PelB leader sequence; Light green – TEV cleavage site; Dark green – PreScission cleavage 
site; Red – 6xHis tag; Blue – construct with boundaries R3746 – M4128. All three constructs 
were cloned into the pTWO-E vector seen in figure 2.1. 
 
In each of the constructs the pelB leader was at the N-terminus of the protein with 
either a TEV site upstream of the target protein (AZPelB1), a 6xHis tag upstream of the 
protein (AZPelB2), or a PreScission site as well as a 6xHis tag upstream of the target protein 
(AZPelB3). The presence of these cleavage sites should theoretically not be necessary due to 
the automatic leader cleavage by a signal peptidase but the efficiency of this cleavage is 
unknown and is negated by the presence of these cleavage sites. 
The first experiment performed was an over-expression test, to determine if the 
presence of the PelB leader affected the levels of protein production. The results can be seen 
in figure 3.27. Each of the proteins is expressed well, with 3 hours being the optimal time 
before the cells are harvested. 
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Figure 3.27 – 15% SDS-PAGE gels and western blots developed with α-DNA-PKcs antibody 
showing the expression experiments of constructs containing a PelB leader. AZPelB1 has an 
expected MW of 47.4 kDa, AZPelB2 has an expected MW of 46.6 kDa and AZPelB3 has an 
expected MW of 47.4 kDa. Red dashed box indicates predicted molecular weight. 
 
At this point the osmotic shock experiment was performed in order to disrupt the 
outer membrane of the cell, whilst keeping the inner membrane intact. This was performed 
using TSE buffer (200 mM Tris-HCl pH 8.0, 500 mM Sucrose, 1mM EDTA). Cell pellets 
were resuspended in 1 mL of this TSE buffer and kept on ice for 30 minutes at which point 
they were centrifuged at 16,000 g for 30 minutes at 4 °C. This supernatant then contained 
the periplasmic proteins. The results of this experiment can be seen in figure 3.29. The 
media sample was included in the gel due to the fact that some pelB leader sequences can be 
extremely efficient at the export of the protein, and occasionally export the protein through 
the periplasm and through to the media in which the cells are grown. 
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Figure 3.28 – 15% SDS-PAGE and western blot developed with α-DNA-PKcs antibody 
showing the results of testing the periplasmic expression of the three proteins. The lanes 
show uninduced (U), Induced (I), Pellet (P), Supernatant (S) and Medium (M). Red dashed box 
indicates predicted molecular weight. 
 
The figure shows that the pelB leader sequence has been ineffective in exporting the 
protein to the periplasm. Although there is a strong band visible in the SDS-PAGE at the 
correct apparent Mw that does not produce a western blot signal. This could potentially be 
the desired product with the C-terminal region, the epitope for the a-DNA-PKcs antibody, 
degraded. This would require further experimentation to validate. At this stage however it is 
unknown whether it is in a soluble form in the cytoplasm or whether it has also formed 
inclusion bodies. The next experiment therefore, was to test if the presence of the pelB leader 
had increased solubility, even though it failed to carry out its primary function. 
The pellet from this experiment was then taken forward and lysed via sonication with 
three 30 second bursts, each with 30 second intervals and then centrifuged at 20,000g for 60 
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minutes at 6°C. As well as the previous uninduced and induced samples, the fresh pellet and 
supernatant samples were analysed on an SDS-PAGE gel and western blot to determine if 
the pelB leader had any effect on solubility. 
	
Figure 3.29 – 15 % SDS-PAGE and western blot, developed with α-6xHis antibodies, testing 
the solubility of the pelB constructs post-sonication. The arrow indicates the protein band, 
based on the information seen in the western blot below. 
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What is apparent from the figure is the fact that although there were moderate levels 
of expression, and with the lysis being effective, the target protein is still insoluble, and is 
present only in the pellet fractions. 
This therefore means that soluble DNA-PKcs catalytic domain could not be generated 
using the alternative domain boundaries presented by Sajish et al (126). The authors of this 
paper make no reference to the yields of protein obtained through this protocol, although 
they imply that it is suitable for their cellular assays. After extensive attempts at improving 
the solubility, varying the vector, cell strain, buffer system, and making use of codon 
optimisation, all attempts at generating soluble protein failed. These results will be discussed 
further in Chapter 5. 
The next route to take in an attempt to produce soluble DNA-PKcs kinase domain 
was denaturing and refolding the expressed protein from inclusion bodies, which is normally 
performed through the addition of a chaotrope such as guanidinium hydrochloride or urea.  
3.4 Protein Denaturation 
Under native conditions a protein will fold into a conformation that is most 
thermodynamically stable in that environment. The conformation that it adopts is affected 
purely by the amino acid sequence, more specifically, the side chains they possess and how 
they interact with one another (130). The process of protein folding is a very rapid one, and it 
occurs during protein synthesis.  Secondary structure dynamics studies have shown that for 
single alpha helices and short polypeptides the folding to form entire helices can be 
completed in hundreds of nanoseconds (131). High concentrations of the new protein 
localised close to one another can lead to a protein misfolding, which can very easily lead to 
an insoluble product such as an inclusion body (132).  
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If the protein is forming inclusion bodies, by denaturing and refolding in suitable 
conditions, bio-active protein can be recovered (132). This therefore was the next course of 
action.  
When the proteins present in the cell pellet (target and host proteins alike) are 
resuspended in a chaotropic solution like urea, the chaotrope disrupts the hydrogen bonding 
network between water molecules and thus reducing the stability of the native state of a 
protein (133). The secondary structure is disrupted, with α helices and β strands no longer 
being ordered, but in fact adopting a randomly coiled conformation (134). The primary 
structure however is made up of covalent peptide bonds linking the amino acids, which 
cannot be broken down by the presence of such a chaotrope.  
Prior to any significant devotion of time to the denaturing and refolding of protein, 
and based on the discovery of chaperone purification in the previous chapter, the identity of 
the overexpressed protein that was due to be denatured needed to be determined. This was 
done with peptide mass fingerprinting. After induction, HIS-A1 samples were analysed by 
SDS-PAGE and stained with SimplyBlue Safestain (Invitrogen). At this point the band that 
correlated with the western blot signal was excised. This was then run on the MALDI-TOF 
and the results can be seen in figure 3.31. 
 
 




Figure 3.30 - Graph highlighting the mass peaks and their associated intensity (%). The mass 
of these peaks relates to the peptides highlighted in the sequence coverage map. This map 
shows a manually entered sequence for DNA-PKcs, more specifically His-A1. Sequence 
results show 75% coverage, with 226 matched peptides and a protein score of 8138. 
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What can be seen in the figure is the sequence for human DNA-PKcs – more 
specifically the manually entered sequence for the entirety of the A1 construct. It shows 75 % 
sequence coverage, with 226 matched peptides and a protein score of 8138, which confirms 
that the overexpressed protein is the target protein. Although coverage indicates the first 30 
residues are missing, this is most likely not the case due to the fact that the N-terminal 6xHis 
tag is being detected with immunoblotting and can therefore be assumed to be present. At 
this point further work can be performed with the knowledge that it is being done on the 
target protein rather than a contaminant or chaperone. 
3.4.1 – Urea 
Throughout this study both urea and guanidinium hydrochloride (GuHCl) were 
tested, but a decision was made early on that urea would be the chaotrope of choice and only 
the results of this will be discussed in the chapter. This decision rested on the fact that 
refolding with GuHCl was less reproducible than with urea and the fact that a lot of the 
analysis was performed with SDS-PAGE. When GuHCl comes into contact with SDS it 
precipitates, which causes the gel to run very irregularly making the analysis a lot more 
difficult, although this could have been avoided through precipitating any GuHCl present 
prior to performing any SDS-PAGE analysis. 
The levels of expression of the A1 construct were very high when using IPTG at a final 
concentration of 1 mM for an overnight induction, using TB as the growth media. This 
therefore meant that there was a lot of starting material to take forward, which would prove 
to be essential due to the high attrition levels commonly seen with denature/renature 
protocols. 
The cell pellets that were stored at -80 °C were taken forward and resuspended in a 
solution of 20 mM HEPES pH 7.5, 1 M NaCl, 10% glycerol, 5 mM MgCl2. Based on the 
mass spectrometry data shown in figure 3.31 the pellet was known to contain target protein 
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and was subsequently processed by being washed 5 times in lysis buffer either on its own or 
in combination with one of two detergents, Brij-35 and Triton x-100. This wash step was 
extremely useful as it served as a purification step by partially solubilising a series of host 
proteins and increasing the ratio of target protein to contaminant host proteins. The results 
of this pellet washing protocol can be seen in figure 3.31. 
 
Figure 3.31 – 15 %SDS-PAGE and western blot showing the result of pellet washing, as well 
as the denaturing of the pellet. Wash 1 consisted of buffer only. Washes 2 & 3 consisted of 
this buffer supplemented with 0.05 % Brij-35. Wash 4 contained the buffer supplemented 
with 0.1 % Triton X-100 and wash 5 was the buffer only.  
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After being washed 5 times in a the combination of solutions shown in the figure, the 
pellet was then taken and suspended in the wash buffer, supplemented with 8 M urea and 
incubated with rotation overnight. This solution was then centrifuged at 25,000 g for 2 
hours. The input pellet, solubilised pellet and remaining treated pellet can also be seen in 
figure 3.31. What is apparent is the appearance of a breakdown product significantly lower 
than the target protein after contact with urea. This was a frequent presence but was 
removed through purification. The other aspect of this result to be discussed is the presence 
of a small amount of DNA-PKcs still present in the pellet even after urea treatment. Even 
after significant rounds of refinement and optimisation this could not be improved upon. 
To purify this newly solubilised protein the N-terminal 6xHis tag was employed and 
bound, whilst in a denatured state, to  Ni2+ IMAC resin. Several rounds of optimisation were 
performed, firstly using 1 mL HisTrap columns and then 5 mL HisTrap columns (GE 
Healthcare). Both however had a significant amount of target protein present in the flow-
through. Final optimisation involved the use of 10 mL of Ni-Sepharose resin (GE 
Healthcare) loaded into an XK-16 column and equilibrated. This too had some degree of 
flow-through issues, which were negated by a second pass of the flow-through sample. The 
capacity for this resin is 40mg of His-tagged protein per ml of resin. This 10 ml column 
therefore could potentially allow for 400mg of protein per run, however this is calculated 
based on a folded, globular protein. A protein in a denatured state may occupy significantly 
more space whilst adsorbed to the resin, reducing its effective capacity. Further experiments 
at greater column volume could be tested in future, but were not included in this study due 
to the success of re-loading the flow through fraction from the first purification. The protein 
was purified in a denatured state in order to increase the likelihood of getting the protein to 
refold in the correct manner without any contaminants present inhibiting this process. 
The results of the optimised purification protocol can be seen in figure 3.33. The flow 
through issue is apparent from the FT sample from purification one. The flow through from 
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purification two shows a smaller amount of target protein not binding. All positive fractions 
from both runs were combined and concentrated to a final concentration of 5 mg/mL and 
stored in 100 µL aliquots at -80 °C ready for refolding experimentation. 
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Figure 3.32 - optimised purification protocol for His-A1 , in the presence of Urea. The red line in the graph indicates the concentration of elution buffer (B) 
on a percentage scale, where 100% equates to 1M NaCl. FT – Flow through, W1 – Wash 1, W2 – Wash 2, W3 – Wash 3.
His-A1                   Concentration
Elution Volume (mL)
His-A1                   Concentration
Elution Volume (mL)
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3.5 – Refolding 
The list of variables with a refolding experiment can be extensive, and can include the 
speed at which the denaturant is removed, whether an intermediate buffer is used, whether 
the refolding is done in solution or with the protein bound to a fixed structure such as IMAC 
resin, and whether or not an external ligand is added to the solution to act as a refolding 
scaffold. 
These variables all needed to be tested in order to improve the chances of achieving a 
correctly folded, stable, catalytically active protein. In order to test as many conditions as 
possible, increasing the likelihood of finding optimal refolding conditions, an in-house AZ 
screen was used. This was a compilation of 96 conditions including a variety of buffers, such 
as Tris, salts such as KCl, compounds such as L-Arginine, oxidants and reductants such as 
cystamine and cysteamine and the presence of chaotropes such as GuHCl. This screen was 
developed by AstraZeneca through both experimental discovery and literature searches for 
conditions that favoured refolding. 
3.5.1 – Batch 
The protein was thawed and a solution of either Adenosine 5′-(β,γ-imido)triphosphate 
(AMP-PNP) or AZ135XXX (a DNA-PKcs ATP analogue inhibitor developed within AZ 
that is still subject to confidentiality) was added to the protein prior to any refolding. This was 
done with the theory that a protein will refold more accurately around a known ligand than 
without any sort of scaffold. A sample of protein was also put into the screen without any 
ligand.  
The refolding experiment was performed on a micro-scale, involving a rapid 50-fold 
dilution with mixing at the nL scale. 24 nL of protein at 5 mg/mL in 8 M urea was added to 
1.2 µL of refold buffer containing the folding additive. This was performed three times (apo, 
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AMP-PNP, AZ135XXX). After the refold buffer was added to the 96 well plate a liquid 
handling robot added the protein to the drop, at which point the plate was sealed, agitated 
and left overnight to equilibrate. The plates were then imaged to determine the state of the 
solution after the overnight incubation. Only one observation was performed with the 
rationale being that most refolding will occur almost immediately due to the rapid 1 in 500 
dilution. The overnight period was also included prior to observation to ensure equilibration 
will have occurred. A condition that was deemed favourable was one that had a clear drop. If 
any precipitation was visible this condition was excluded from further analysis. This 
methodology does not preclude the possibility of clear precipitate, which is a distinct 
possibility. However it served as a starting point that could be up-scaled, and this could then 
determine the likelihood of a clear precipitate forming rather than correctly folded protein. 
Of the 96 conditions tested there were 3 clear optimal conditions that were taken 
forward, all of which required the use of a folding additive, either the AMP-PNP or 
AZ135XXX. When the protein was left to refold apo none of the conditions yielded clear 
drops. The three conditions chosen were: 
• B1 (100 mM MES pH 5.8, 2 M Guanidinium Hydrochloride) 
• B2 (100 mM MES pH 5.8, 1 M Guanidinium Hydrochloride) 
• D9 (500 mM Tris pH 8.0, 2 M Guanidinium Hydrochloride) 
All three conditions contain the chaotrope Guanidinium hydrochloride at either 1 or 2 
M concentration. It is theorised, based on the work of Rashid et al (135), that between 0.5 
and 1.5M guanidinium hydrochloride the protein actually exhibits a non-native intermediate 
state and is not fully denatured until approximately 4M. Therefore at these concentrations it 
can be supposed that the drop from 8M urea to 1-2M guanidine hydrochloride has brought 
the protein from a fully denatured state into an intermediate state, which is in a more stable 
position prior to dialysis, completing the refold into native structure. This will vary from 
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protein to protein and is something that will be tested in future work. This future work could 
involve taking the refolded protein and subjecting it to functional kinase assays in increasing 
concentrations of guanidinium hydrochloride to determine at which point the protein loses 
all functionality.  
The drops for each of these conditions can be seen in figure 3.34 (A). Shown in figure 
3.33 (B) is a drop for the condition G2 (100 mM MES pH 5.8, 900 mM Arginine). In this 
drop there is visible precipitation and this image has been included in the thesis as an 
example of a condition that was excluded due to not being suitable for induction of protein 
refolding.  
Due to the fact that these three conditions were successful for both the AMP-PNP and 
AZ135XXX, the decision was made to use only the AMP-PNP for further experiments. This 
was due to confidentiality issues, and the fact that if a crystal structure were solved with this 
ligand in the binding site, publication of these results could be prohibited, whereas with a 
commercially available compound like AMP-PNP, this would not be an issue. 
These experiments were then performed on a larger scale. The intermediate refolding 
buffer volume was increased to 5 mL and to maintain the same ratio of buffer : protein, an 
entire 100 µL aliquot of denatured A1 at 5 mg/mL with AMP-PNP was added, drop-wise, to 
the solution, whilst maintaining a rapid stirring. Upon addition of the entire 100 µL, the 
solution was rolled at 4 °C overnight in order to equilibrate. At this point the solution was 
centrifuged at 25,000 g for 1 hour and visible inspection was performed to detect the 
presence of any precipitate. The results of this experiment can be seen in figure 3.33 (C). 
This shows that these conditions remain favourable, even at a larger scale. At this point the 5 
mL of intermediate protein solution was dialysed into a buffer containing 20 mM HEPES 
pH 7.5, 150 mM NaCl, 5% Glycerol, 2 mM TCEP.  
During the dialysis experiment, the protein that was refolding under the ‘B1’ 
conditions (100 mM MES pH 5.8, 2 M guanidinium hydrochloride) precipitated, which was 
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a result that was repeated several times, each time with the same outcome. This condition 
was therefore excluded from future experiments and the remaining 2 conditions were used. 
The next step was to determine the stability of the protein within the 2M guanidinium 
hydrochloride solution for storage purposes. HIS-A1 in both conditions was taken and stored 
overnight at either 4 °C or -20 °C. Determining optimal storage conditions allows for large 
scale synthesis and storage to ensure reproducibility in terms of subsequent experimentation. 
This storage however, is something that can only be utilised when the preceding steps have 
been optimised and also shown to be reproducible. Based on the results seen in figure 3.33 it 
is visible that storage of either intermediate at either condition is just as 
favourable/detrimental to the overall yield of protein. 
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Figure 3.33 - (A) Small scale drops containing the refold buffer for the successful conditions. 
B1 contained 100 mM MES, pH 5.8, 2 M guanidinium hydrochloride. B2 contained 100 mM 
MES, pH 5.8, 1 M guanidinium hydrochloride and D9 contained 500 mM Tris, pH 8.0, 2 M 
guanidinium hydrochloride. (B) An example of a condition that leads to precipitation of the 
protein. G2 contained 100 mM MES, pH 5.8, 90 mM Arginine. (C) Larger scale refolding with 
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Figure 3.34 – 15% coomassie stained SDS-PAGE showing the results of testing both 4 °C 
and -20 °C as storage over a period of 24 hours. B2 contained 100 mM MES, pH 5.8, 1 M 
guanidinium hydrochloride and D9 contained 500 mM Tris, pH 8.0, 2 M guanidinium 
hydrochloride.  
 
All four of these samples were then dialysed, in parallel, into the same buffer 
mentioned previously. For the B2 sample the final concentration of GuHCl after dialysis was 
~0.1 pM and for the D9 sample it was ~ 0.2 pM. The contents of each of the membranes 
were then concentrated as much as possible. The results of this concentration can be seen in 
figure 3.36. 
What can be seen is the first instance of a difference between the two conditions. The 
B2 conditions have precipitated considerably more than the D9 conditions, however both 
have dropped their yields relative to their inputs (seen in figure 3.35). A significant drop in 
yield is to be expected during a refolding experiment due to the protein precipitating or 
incorrectly folding but variability on this scale does show that further optimisation can be 
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D9 conditions as a more controlled removal of the chaotrope may improve protein folding 
thus increasing the yield. 
 
Figure 3.35 – SDS-PAGE showing the results after dialysing from the intermediate refold buffer 
into a stable buffer for further testing. 
As a result of this experiment the protein refolded in the D9 conditions was passed 
over an equilibrated s200 10/300 GL column that had previously been calibrated using a 
combination of proteins found in the high and low molecular weight calibration kits (GE 
Healthcare). 
The purpose of the calibration curve is to determine the elution volume for a globular 
protein of a particular molecular weight. Once this has been determined for each of the four 
proteins used in the calibration a graph can be plotted, showing the correlation between the 
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log of the molecular weight (logMW) of the protein and the partition coefficient (Kav). This 
then produces a calibration trace (green) seen the graph in figure 3.37 and by plotting a 
trendline between each of the points, the logMW of the unidentified protein peak, and 
therefore the MW, can be calculated. 
 
Where Ve = the elution volume of the particular peak, Vo = the void volume of the 
column being used, and Vc = the volume of the column being used. The void volume for this 
column was determined experimentally by running a sample of blue dextran (2 MDa) down 
the column. It is too large to access any pores present on the matrix and therefore passed 
straight through the packed bed of the column. The value obtained was 7.8 mL (results not 
shown).  
The volume of the column can be calculated as follows: 
Vc =  π x r2 x h 
Vc = π x 52 x 0.3 
Vc = 23.6 mL 
As an example of the calculations performed, Conalbumin had an elution volume of 
15.60 mL: 
Conalbumin Kav = (15.6 – 7.8) / (23.6 – 7.8) 
Conalbumin Kav = 7.80 / 15.8 
Conalbumin Kav = 0.493 
This value was then plotted against the logMW of Conalbumin (75 kDa) = 1.875 
Kav = (Ve −Vo )
(Vc −Vo )
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These calculations were performed for each of the proteins and the results of this, as 
well as the calibration curve can be seen in figure 3.36. 
This was done as a control in order to determine if the product of the intermediate 
refold and dialysis folded into a globular protein of approximately the correct size. Using an 
s200 column such as this, the hydrodynamic radius can be determined and extrapolated, 
based on a calibration curve, to see if it behaves like a globular protein of the same size as is 
theorised.  
The computed molecular weight of the protein is 60.4 kDa, and it is running around 
this height on the SDS-PAGE gel seen in figure 3.35. 
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Figure 3.36- Size exclusion chromatography and associated analysis of the protein refolded in 
the D9 conditions. The green curve indicates the peaks for each of the calibration proteins 
used: Aldolase (158 kDa) at 14.3 mL; Conalbumin (75 kDa) at 15.6 mL; and Ovalbumin (43 
kDa) at 17.9 mL. The grey box indicates the peak that was analysed to determine its 
approximate molecular weight. The line of best fit has an R value of 0.961. 
 
Peak 1 seen in the trace is eluted at 7.8 mL, which has previously been determined to 
be the void volume of this column. This is most likely soluble aggregates that have formed as 
a result of the refolding process. There are also two peaks, 2 and 3, that merge with one 
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can be plotted on a trend line generated from the calibration curve to determine the 
approximate MW of the protein responsible for that peak. In this instance the Kav for the 
peak 3 of HIS-A1, assumed to be the correct peak for the protein, was 0.533. Based on the 
trend line this generated an exponential factor of 1.785, which equates to a MW of 60.9 kDa. 
Due to the calculated MW being 60.4 kDa, it is safe to say that this is in fact folding in the 
correct orientation and has not been subject to degradation. The small amounts of protein 
eluted from the column however meant that further SDS-PAGE analysis could not be 
performed and therefore this is merely supposition. In future work, when the scale is 
increased this can be validated through SDS-PAGE analysis as well as western blotting. 
The SEC trace shows the absorbance at 260 nm and 280 nm and what can be seen is 
that there still remains a 260 nm/280 nm ratio of ~1.8. This would indicate that there is 
nucleic acid contamination, which is unlikely, due to the stringent conditions the protein has 
passed through to get to this stage. An explanation to this result has not been experimentally 
determined, but one theory could be the presence of ATP, or more likely AMP-PNP which 
has a peak absorbance at 254nm, as this was required as a scaffold for the refolding of the 
protein.  
The biggest factor however is the yield, in that the peak size for the 280 nm trace is 
around 1.8 mAu. Dilution when running a size exclusion column is inevitable, but starting 
with 5 mg/mL, prior to refolding, has lead to an almost non-existent peak of approximately 
0.1 mg/mL. Although theoretically this amount of protein is enough for some small-scale 
experimentation to be performed, there is not enough for extensive screens as well as the 
necessary biophysical characterisation required.  
These values are representative of several attempts at this refolding experiment. Due 
to this the next logical step was to optimise the protocol and attempt to increase the final 
yield of solubilised, correctly folded protein. Initial optimisation involved replacing the 
dialysis step as it was during this step that the greatest drop in yield occurred and there could 
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theoretically be more effective ways to remove the intermediate denaturant. The first 
alteration was to directly replace this step of the refold with an on-column refold step. 
Whereby the drop-wise dilution from 8 M urea to the D9 solution was performed. At this 
point the ~50 mL of D9 containing the target protein was loaded onto a 5 mL Histrap (GE 
Healthcare) column. Once loaded the concentration of GuHCl was reduced from 2 M to 0 
over 20 column volumes. At this point the protein was eluted with the dialysis buffer 
mentioned previously, supplemented with 500 mM imidazole. Although theoretically this 
method would improve the likelihood of generating higher yields, in actual terms it was not 
reproducible, and after a large number of attempts changing a multitude of variables this 
particular method was deemed unsuccessful. 
Time constraints stopped any alternative attempts at optimising this refolding step to 
attempt to increase the final yields of protein after the refold. Although this is the case, the 
work performed to get to this stage sets up a platform for future work to enable either larger 
scale experiments or optimisation to generate refolded, soluble, catalytically active DNA-
PKcs kinase domain for the purposes of biophysical characterisation and X-ray 
crystallographic studies. 
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Chapter 4  
Flap Endonuclease 1 
This chapter of the thesis will go into detail on the determination of the X-ray crystal 
structure for FEN 1 from Pyrococcus abyssi, and will make comparisons with various other 
existing crystal structures. Results will also be discussed from initial high-pressure 
crystallography experiments performed at the ESRF in Grenoble, France. 
4.1 FEN 1 Structure at Ambient Pressure 
4.1.1 – Protein Production & Purification 
4.1.1.1 - Construct information 
The construct used throughout this study was for full-length Pab FEN 1 spanning from 
M1 to P343 with no tags present on either termini. A schematic of the construct, and its 
domain organisation is in figure 4.1. 
 
Figure 4.1 – Domain organisation of Pab FEN 1. The N-terminal domain (N-Domain) spans 
M1 to R98. The internal domain (I-Domain) spans from E116 to K258. The PCNA interacting 
protein motif (PIP), spans from K330 to F338. 
 
1! 343!





Protein MotifE116 – K258
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  Chapter 4 
 143 
The N terminal domain (N-domain) and the internal domain (I-domain) are both 
globular domains, the latter of which contains a conserved region that harbours the active 
site. It is also the region that forms a helical archway that is thought to play an important role 
in DNA binding (136, 137). The construct used was cloned by Rashed-Al-Naber into the 
pET3aTr overexpression vector (138) 
 
Figure 4.2 - pET3aTr vector map (138). Cassettes 1-4 allow the coexpression of up to 4 
genes in the one expression plasmid, which relates to projects other than those mentioned in 




4.1.1.2 - Expression conditions 
Athanasios Adamopoulos (AA) and Rashed-Al-Naber (RAN) optimised the over-
expression conditions. The conditions involved using transformed BL21* cells, induced and 
grown overnight. The SDS-PAGE gel shown in figure 4.3 shows both the results of this 
induction as well as the subsequent lysis. 
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Figure 4.3 – 15 % SDS-PAGE gel showing successful induction and lysis of FEN 1 
 
4.1.1.3 - Protein isolation 
An initial purification protocol was set up by AA, but was subjected to optimisation. A 
cell pellet was removed from storage at -80°C and fully resuspended in 20 mL lysis buffer (20 
mM HEPES pH 7.5, 300 mM NaCl) with protease inhibitors (Roche). It was then sonicated 
in 3 x 30-second bursts with 30-second intervals. After sonication the lysate was incubated for 
20 mins in a water bath at 70°C in order to denature the host E.coli proteins whilst keeping 
the target FEN 1 protein intact.  
The heated lysate was then centrifuged at 25,000g for 1 h separating the pellet and 
supernatant. The supernatant containing the soluble FEN 1 was then diluted with 180 mL 
20 mM HEPES pH 7.5, reducing the salt concentration from 300 mM to 30 mM. At this 
point the solution was loaded onto a 1 mL HiTrap Heparin column (GE Healthcare). The 
results of this can be seen in figure 4.4: 




Figure 4.4 - Chromatographic trace of the FEN 1 purification using a 1 mL Heparin column as 
well as the accompanying gel showing the contents of fractions 8 to 29, highlighted in grey in 
the trace. The green line in the graph indicates the concentration of elution buffer (B) on a 
percentage scale, where 100% equates to 1M NaCl. Fractions 9 – 21 contained pure FEN 
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Fractions 21 - 29 also contained the same protein, however the levels of contaminants 
are higher therefore these fractions were discarded. The concentrated sample was loaded 
onto a pre-equilibrated size exclusion chromatography column Superdex 200 10/300 GL 
(GE Healthcare) (Figure 4.5). 
 
Figure 4.5 - Chromatographic trace and associated 15% SDS-PAGE gel for the size 
exclusion chromatography experiment purifying FEN 1. The size exclusion step was 
performed in 20 mM HEPES pH 7.5, 400 mM NaCl. Fractions 15 – 19 were pooled. 
 
Elution Volume (mL)
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The NaCl concentration was set at 400 mM based on the concentration of salt during 
elution of the main peak collected in the heparin purification in figure 4.4. Pooled fractions 
were concentrated and the final concentration of the sample was tested using a NanoDrop 
2000 UV-Vis spectrophotometer (Thermo Scientific) measuring the absorbance at 280 nm as 
well as the 260 nm/280 nm ratio detecting potential nucleic acid contamination. 
Using the online software ProtParam from the Expasy Suite (123), the extinction 
coefficient of the protein was calculated as 35870. This was then used to calculate the 
concentration of the protein, which after the size exclusion step was 18 mg/mL. The 260 
nm/280 nm was measured to be 0.56. This indicates that the sample was free from nucleic 
acid contamination. After determining the concentration and purity, the sample was 
aliquoted and flash frozen by being dropped into liquid N2, and then stored in the -80°C 
freezer until further use.  
4.1.2 – Biophysical Characterisation 
4.1.2.1 – Size exclusion chromatography elution analysis 
The Superdex s200 10/300 GL column was calibrated according to the 
manufacturers guidelines in 20 mM HEPES pH 7.5, 400 mM NaCl, using four proteins 
from the low molecular weight calibration kit (GE Healthcare). This calibration curve was 
then used to determine the partition coefficient for FEN 1 in order to determine the 
molecular weight of the protein being eluted. The method for this is discussed in chapter 3. 
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Figure 4.6 - Calibration curve containing Conalbumin, Ovalbumin, Carbonic Anhydrase and 
Ribonuclease A, overlaid with the SEC trace shown in figure 4.5.  Below is a graph showing 
LogMW against Kav. The line of best fit has an R value of 0.910 
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Using an elution volume for the FEN 1 sample of 16.125 mL, and the equation 
mentioned in chapter 3 previously, a Kav value of 0.526 is obtained. Plotting this on the 
trendline seen in figure 4.6 shows a LogMW value of 1.592.  
101.592 = 39.1 kDa. 
This shows that the protein purified during the size exclusion chromatography, 
behaves in the same manner as a globular protein approximately 39.1 kDa in size. 
Due to the fact that the calculated MW of FEN 1 is 38.9 kDa this seems to indicate that the 
FEN 1 protein being purified is both globular and monomeric at this concentration. A 
sample of the protein was then subjected to further characterisation. If however the true 
oligomeric state of FEN 1 is in fact a dimer, the 400mM salt could potentially disrupt any 
potential electrostatic interactions. This could therefore artificially suggest a monomeric, 
rather than dimeric state.  
4.1.2.2 – Dynamic Light Scattering. 
Results discussed in the previous section indicate that the protein being purified is in 
fact a monomer. To strengthen the evidence of the oligomeric state of the protein dynamic 
light scattering (DLS) was performed in order to determine both the size of the molecule as 
well as the size distribution of the molecules within the solution. 
The technique makes use of the phenomenon whereby particles in solution will 
experience random motion known as Brownian motion. It is caused by the interaction of the 
protein with surrounding molecules affecting its trajectory. It is possible to model this motion 
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This equation shows the relationship between the particle size (hydrodynamic 
diameter (Dh)) and the values obtained for the diffusion coefficient (Dt). The kB is the 
Boltzmann constant (1.3806 x 10-23 JK-1) which is a constant indicating the relationship 
between energy (J) and temperature in kelvin (K). T is the temperature that is set manually. 
In the case of these experiments it was set at 25°C (298.15 °K). η relates to the dynamic 
viscosity of the solution. The buffer constituents were loaded into Malvern Instruments 
software and it determined the viscosity based on theoretical values.  
  Chapter 4 
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Figure 4.7 – Averaged DLS data for FEN 1 at two concentrations. (A) Shows size by intensity 
and (B) shows size by volume of FEN 1 at 1 mg/mL. (C) Shows the size by intensity and (D) 
shows size by volume of FEN 1 at 18 mg/mL. 
 
When analysing these results, (B) shows a smaller hydrodynamic diameter than any of 
the other three graphs, even comparing it directly to the FEN 1 at 1 mg/mL showing size 
against intensity (A). This shows a shift to the right indicating a larger hydrodynamic 
diameter. According to the mass distribution results the mode hydrodynamic diameter is 
5.12 nm (StD 1.35 nm) with an estimated molecular weight of 38.1 kDa. The mode is chosen 
as a means of averaging rather than the mean simply due to the fact that it is not affected as 
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much by larger molecules. The intensity of light scattering does not increase linearly with an 
increase in mass, a larger molecule will scatter considerably more than a smaller one (i.e. a 
dimer will have > 2x intensity than a monomer).  
According to the intensity distribution the mode diameter is 6.45 nm (StD 1.67 nm) 
with an estimated molecular weight of 57 kDa. This suggests that there is a small amount of 
dimer present but due to the mass results indicating solely monomer, the levels of dimer must 
be very small. 
The data represented in panels (C) and (D) correlate to one another a lot more than 
(A) and (B). This is most likely due to the increased prevalence of a higher order structure, 
most likely a dimer, at 18 mg/mL than at 1 mg/mL. The mode hydrodynamic diameter 
values for intensity was 6.75 nm, for mass it was 6.16 nm  (StD 0.81 nm and 0.79 nm 
respectively) showing again that these results correlate with one another more than (A) and 
(B). The estimated molecular weight by intensity was 58.8 kDa and by mass was 53.4 kDa. 
This could suggest that within the solution, at this concentration, there is a greater presence 
of dimer relative to the monomer, and higher than the values seen at 1 mg/mL which could 
indicate a concentration dependent oligomerisation. 
4.1.3 – Crystallisation 
4.1.3.1 – FEN 1 crystallisation 
An aliquot of FEN 1 was used for the purposes of growing crystals in order to 
determine an X-ray crystal structure of the protein. Crystallisation trials were performed 
with FEN 1 at a concentration of 3.1 mg/mL, with a 260 nm/280 nm ratio of 0.58. Using 
the Gryphon LCP liquid handling robot (Art Robbins Instruments), in a sitting drop 
conformation, 65 µL precipitant was placed into the reservoir. The drop in the well consisted 
of 100 nL of precipitant and 100 nL of protein solution. The first commercial screen to be 
tested was the Structure Screen 1 & 2 (Molecular Dimensions). The plates were stored at 
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18°C and were checked periodically every 24 hours for approximately 1 week, at which 
point they were checked once per week. 
After 48 hours the most promising conditions to yield crystals were A4 (100 mM 
sodium acetate, pH 4.6, 2 M sodium formate), B7 (200 mM zinc acetate, 100 mM sodium 
cacodylate, pH 6.5, 18% w/v PEG 8000) and C9 (200 mM magnesium chloride, 100 mM 
Tris, pH 8.5, 30% w/v PEG 4000). A typical example of crystals grown in these conditions 
can be seen in figure 4.8: 
 
Figure 4.8 – Grown in 100 mM sodium acetate, pH 4.6, 2 M sodium formate (A4). The 
crystals appear to be small, nucleated needles that were indicative of crystals grown in the 
other conditions tested. Each crystal is roughly 10-20 µm long. 
The crystals shown in this figure, although promising, are small and highly nucleated.  
Neither the crystal size nor the shape are suitable for data collection but are an excellent 
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starting point for optimisation. The optimisation began by varying the concentrations of the 
precipitant and buffer, a schematic of which can be seen in figure 4.9. 
 
Figure 4.9 - Schematic of the larger scale crystallisation screens expanding on A4 (100 mM 
sodium acetate, pH 4.6, 2 M sodium formate), B7 (200 mM zinc acetate, 100 mM sodium 
cacodylate, pH 6.5, 18% w/v PEG 8000) and C9 (200 mM magnesium chloride, 100 mM 
Tris, pH 8.5, 30% w/v PEG 4000) conditions varying both the precipitant and buffer 
concentrations above and below screen levels. Highlighted in green are the two most 
promising results to come out of this round of optimisation. These conditions are: E7 - 
200mM zinc acetate, 100mM sodium cacodylate, 20% w/v PEG 8000; F8 – 200mM zinc 
acetate, 200mM sodium cacodylate, 22% PEG 8000. 
After several more iterations and improvements around the conditions a final set of 
conditions were obtained. These conditions were used for larger scale experiments using 24-
well Linbro plates (Hampton Research), which made use of larger reservoir and drop 
volumes as well as a hanging drop vapour diffusion method rather than sitting drop used 
previously. The final conditions were 200 mM zinc acetate, 100 mM sodium cacodylate, 
11% w/v PEG 8000. FEN 1 at an initial concentration of 2.4 mg/mL was added to the drop 
and the crystals were left at 18°C to allow crystals to grow. After 14 days crystals had formed 
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that were large enough to be used for data collection. An image of these crystals can be 
found in figure 4.10: 
 
Figure 4.10 - Crystals grown after 14 days in 200 mM zinc acetate, pH 4.6, 100 mM sodium 
cacodylate, 11% PEG 8000, conditions obtained through several rounds of refinement. The 
crystals have an approximate length of between 40-50 µm. 
Crystals were used for data collection at beamline I04-1 at the Diamond Light Source 
Synchrotron. The beam-line makes use of cryogenic temperatures during the data collection 
to reduce X-ray associated free radical formation, which can damage the crystal and reduce 
the quality of the data. It can also improve the X-ray diffraction due to lower levels of 
thermal motion. The crystals shown in figure 4.10 were harvested using 0.5mm loops and 
cryo-cooled in liquid N2. 
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4.1.4 – Crystallography 
4.1.4.1 – Space Group Determination 
The crystals seen in figure 4.10 diffracted to 2.27Å resolution and a typical diffraction 
image can be seen in figure 4.11. The data were collated and processed using MOSFLM 
(113) in the space group C2221. The reflections were scaled using SCALA (109).  
Figure 4.11 - Typical X-ray diffraction pattern from a crystal shown in figure 4.10. The data 
diffracted to 2.27 Å 
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Data collection FEN-1 
Space group C2221 
Cell dimensions    
a, b, c (Å) 65.23, 86.40, 238.99 
     	α, β, γ (°) 90, 90, 90 
Resolution Range (Å) 50.26 - 2.27 
Rmerge 0.143 (0.317) 
I/σI 6.0 (2.7) 
Solvent Content (%) 43.1 
Molecules / AU 2 
Completeness (%) 96.1 (99.8) 
Redundancy 4.2 
Refinement  
Resolution (Å) 2.27 
No. Reflections 30549 
Rwork / Rfree 0.2160/0.2755 
No. Atoms 4507 
Protein 4345 
Water 162 
B-factors (Å2)  
Protein 14.38 
Water 16.62 
R.m.s deviations  
Bond lengths (Å) 0.008 
Bond angles (º) 1.143 
Ramachandran Plot  
Preferred 535 (98.7%) 
Allowed 542 (100%) 
Outliers 0 (0%) 
Table 4.1 – Crystallographic statistics for Pab FEN 1 
 
The Rmerge (Linear merging R-value) in the outer shell at this resolution was 0.317. 
The Rmerge is a measure of reliability of the data, comparing intensity measurements for all 
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of the reflections to an averaged intensity value, however this does not take multiplicity into 
consideration in so far as the more a particular reflection is measured, the more accurate the 
average intensity for that reflection will become. The I/σI, a statistic used to define a 
potential resolution limit, is a measure of how well spots can be defined compared to 
background. This signal to noise parameter can show when data has become too weak to 
accurately define its intensity. The value obtained for the I/σI in the outer shell at this 
resolution was 2.7, where an acceptable cut off for this is approximately 2.0.  
4.1.4.2 – Molecular Replacement of FEN 1 
 
Molecular replacement was performed using FEN 1 from Sulfolobus solfataricus (Sso) 
(PDB code: 2IZO) (139). Figure 4.12 shows a sequence alignment, performed with T-Coffee 
(138) between FEN 1 from Sso and from Pab. They share 57% sequence identity and it has 
been proposed that a solution can be derived using a model with as low as 30% sequence 
identity compared with the unknown protein (140). 
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Figure 4.12 - Sequence alignment of FEN 1 from Sso and Pab using the online software 
Clustal Omega and T-Coffee(60, 141). Highlighted in green is the region in Pab present in the 
structure absent in the Sso structure. Highlighted in yellow is the region present in Sso that is 
absent in the Pab structure. 
The program PHASER in the CCP4 suite (106, 109) was used to perform the MR, 
conducting the steps discussed in chapter 2.2.8.1. Firstly the program performed the cell 
content analysis, which generated a Matthew’s coefficient value of 2.16 Å3/Da, with 2 
molecules in the AU. After this was the anisotropy correction. Anisotropy is defined as 
having data that has a directional dependence, which can affect the overall quality of the 
346 
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data. PHASER corrects for overall anisotropy from the dataset. This was followed by both a 
fast rotation function as well as a fast translation function.  
One molecule was used as a search model, searching for 2 molecules in the AU, based 
on the Matthew’s coefficient. The fast rotation function was performed only once and this 
yielded a least-likelihood gain (LLG) score of 44.91 and a corresponding Z-score of 10.83. 
The fast translation function was also only performed once due only one solution coming out 
of the fast rotation function analysis. The top translation function (TF) score for this data set 
was 179.1 with a Z-score of 12.48. Packing analysis was then performed to ensure that as a 
result of the rotation and translation, there were no structural clashes. If a significant number 
of clashes were detected it would imply an incorrect MR solution.  
The output from PHASER was then used to perform TLS and restrained refinement 
using isotropic B factors, using the program REFMAC. 10 cycles of TLS refinement were 
performed, followed by 10 cycles of maximum likelihood restrained refinement to a 
maximum resolution of 2.27Å. The R factor after this round of refinement was 29.47%, with 
an R free of 37.25%.  
4.1.4.4 – Refinement & Model Building 
Refinement involves iterative rounds of positional improvement in both real and 
reciprocal space in order to comply more with the observed structure factors that were 
generated during the data collection increasing the overall accuracy All refinement was 
performed using REFMAC, part of the CCP4 suite (109, 142). There are several quality 
control methods that are used throughout the refinement process to ensure any model 
building and editing improves the accuracy. The first of these are the R factor and free R 
factor (Rfree), which are a means of measuring the agreement between the model that is 
being built, with the crystallographic data that was collected. 
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Where Fobs is the observed structure factor amplitude and Fcalc is the calculated 
structure factor amplitudes. The Rfree is calculated from a portion of data (around 5%) that 
is excluded from any refinement steps. It is then used as a marker against how the refinement 
process is proceeding. It is used to test how well the model predicts experimental changes in 
the structure without being used when fitting the model.  
Another example of a quality control indicator is the Pearson correlation coefficient 
(CC), which provides a direct assessment of relative proportions between the signal and noise 
and their contributions to the data for a particular resolution. The data is split into two ‘half’ 
data sets (CC1/2), each obtained by averaging half of the observations for any given reflection, 
and is reported to be a more accurate means of determining which data are useful, 
particularly at higher resolution than R factors (139). The CC can be separated between 
CCwork and CCfree, which are correlation coefficients between calculated and experimental 
intensities. The CCwork for this data at 2.27Å is 0.925, with a CCfree of 0.887, which 
according to Diederichs and Karplus (143, 144) is an acceptable value at this resolution. At 
higher resolution the acceptable values for CC drop and a proposed acceptable cut off is 
0.125, however performing a Student’s T test can determine if the data, when compared to 
0, is statistically significant and can therefore be included in the dataset (143). 
The output of the MR was placed directly in to REFMAC and 20 cycles of TLS with 
restrained refinement were performed. Translation, Libration, Screw (TLS) is a means of 
deriving anisotropic motion for collective groups of atoms. The definitions relate to 
biologically relevant domains or regions of a structure that then allow the modelling of 
correlated thermal motion that will be common to all atoms within that domain or region. 
This refinement adds many fewer parameters than anisotropic refinement but can 
R = Σ || Fobs |− | Fcalc ||
Σ | Fobs |
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significantly improve the R and Rfree, The R factor of the input coordinates was 38.07% with 
an Rfree of 36.93%. After the 20 cycles the R factor had been reduced to 25.27% and the 
Rfree had been reduced to 29.13%. Using the software COOT (145) in combination with 
REFMAC, backbones and side-chains that were not within the visible electron density were 
either modified (such as by rotation or by using an alternative rotamer) or completely 
removed in order to generate coordinates that better matched the density provided. The 
electron density was contoured to 2.0σ. These coordinates were then saved and were put into 
REFMAC for a second run of 20 cycles of restrained refinement. REFMAC was run a total 
of 14 individual times, all running 20 cycles. This number of cycles was performed as 
refinement is an iterative process, and only when the R factor and Rfree values remain 
relatively static is it known that no further improvements can be made and the structure best 
represents the data collected. The final R factor after all refinement was 21.6% with an Rfree 
of 27.55%. Generally the difference between the R factor and Rfree should be no larger than 
5%. Although the difference between the R factor and Rfree generated for this dataset being 
greater than 5%, any issues would become apparent during the structural validation. 
4.1.4.5 – Validation 
The goal of refinement is to generate a model that is stereochemically sound and that 
best describes the data. This is characterised by a low R factor that remains at the same level 
after continuous attempts at further refinement. Once this has been achieved, the 
coordinates have to be validated to ensure that they are correct. All validation of the 
structure was performed using COOT (145) and the various validation tools it has at its 
disposal. The first, and possibly most powerful means of validating the structure is the 
Ramachandran plot. It was first used as a means of visualising dihedral backbone torsion 
angles (φ, ψ) of the amino acids present in the structure (146). The φ angle relates to the 
torsion between the N and Cα and the ψ angle relates to the C and the Cα. The 
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Ramachandran plot is a powerful tool used to visualise the torsion angles for each individual 
amino acid in the structure.  
There are six individual plots that are used together with one another and they vary 
based on the particular amino acid. Firstly there is a general plot, which covers every amino 
acid and plots ψ along the x-axis with φ along the y-axis. It then highlights regions within a 
+180° to -180° range that are favoured energetically. There is also a plot for all isoleucines 
and valines, aliphatic residues that have moderate length side chains that are more 
permissive than proline, but more constrained than glycine. There is then a plot dedicated to 
every glycine within the structure. This is due to the fact that glycine has no side chain. This 
therefore means it has a greater range of acceptable torsion angles, shown by the larger 
allowed regions on the plot. Next there are two plots dedicated to every proline within the 
structure. One for Cis prolines and one for Trans prolines. Proline contains an aliphatic side 
chain that is covalently bonded to the nitrogen atom of the α-amino group, forming an 
imide bond and leading to a constrained 5-membered ring. This constraint is visualised by 
the very small allowed regions. In fact it is so restricted in its torsion angles that it has a 
tendency to affect the amino acid prior to it in the structure. This gives rise to the pre-proline 
plot, which shows every amino acid in the structure that directly precedes a proline. 
The Ramachandran plot for this dataset showed that, of the 542 amino acids present 
in the structure, there were 535 (98%) in the preferred regions, and all 542 (100%) being 
within the allowed regions with 0 as outliers.  
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Figure 4.13 - Ramachandran plot generated by MolProbity (147) for this 2.27Å structure of 
Pab FEN 1. It indicates 98.7% of residues were in favoured regions and 100% of residues 
being in allowed regions.  
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4.1.4.6 – Conclusions 
There are two molecules in the AU, which are organised into an orthorhombic unit 
cell, as seen in figure 4.15. The secondary structure shows 12 α-helices and 6 β-pleated sheet 
strands, arranged within the core of the structure, as well as several unstructured loop 
regions. The core and ‘head’ of the protein have more of the residues forming more complex 
secondary structures such as sheets and helices, whereas these secondary structure elements 
are less well defined in the lower ‘tail’ region, which could potentially imply that the lower 
portion of the protein has greater flexibility, and could theoretically move to allow 
incorporation of the DNA. Using the online software PDBSum (148), a schematic of the 
secondary structure can be generated. 
 
Figure 4.14 - Schematic of the secondary structure elements of the 2.27Å structure of FEN 1 
from Pab, highlighting unstructured regions, alpha helices and beta sheets. Highlighted in the 
red box is the location in the structure, between K87 and K124, which is missing. 
This schematic serves to illustrate how the head region, from the first half of the 
protein has a greater number of secondary structure elements, whereas the latter half of the 
protein, referring to the tail region has a greater number of unstructured regions. This could 
however be due to disorder within structure meaning regions of the protein couldn’t be 
accurately built. 
The region between K87 and K124 is missing from the structure. This is could not be 
modelled due to poor electron density, therefore it has been excluded from the structure. 
Based on the construct map in figure 4.1, this is within the internal (I) domain of the protein. 
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It is believed that this domain of the protein contains the active site (136) and this particular 
area of the domain encodes for the helical archway (137). Structural disorder is most likely to 
be the reason as to the lack of electron density for this region of the protein.  Examples of the 
helical archway can be observed in both the Pfu structure and the human structure (figures 
4.18 and 4.20 respectively). What can be observed are unstructured regions at the base of the 
activation loop. This therefore has the potential for a great deal of flexibility. It can therefore 
be surmised that when crystallising this flexibility lead to positional disorder within the 
crystal. 
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Figure 4.15 – The upper image shows the two molecules within the AU, coloured green and 
red indicating the two distinct chains, as well as the unit cell. The lower image indicates the 
dimensions of FEN 1 from Pab at the longest and widest points of the structure. Also shown 
in the figure are K87 and K124, the two residues at either end of the missing activation loop, 
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Figure 4.16 – Alignment of FEN 1 from Pab (green) and Sso (2IZO) (yellow), the model used 
as the search model for MR. Highlighted are the two main differences between the structures. 
The yellow text from K334 to F346 indicates the portion of structure present in the Sso 
structure yet absent in the Pab structure. The green text from L261 to D271 is a helical 
portion at the base of the structure that is present in the Pab structure and absent in the Sso 
structure. 
In order to further validate the solution of MR, the refined Pab structure was aligned 
with the structure used as the search ensemble, FEN 1 from Sso (PDB code: 2IZO). In terms 
of sequence the two structures share 55% identity, but using the online software SSAP 
(Sequential Structure Alignment Program) (149) to compare the two PDB coordinates, they 
have 91% structural similarity with an RMSD of 1.43Å. The two main differences have been 
highlighted and exploded in the figure. The first difference is a loss of 17 amino acids from 
K334 to F346. The reason for this is most likely due to it being relatively unstructured. This 
lack of organised structure leads to heterogeneity, evidenced by a lack of electron density 
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applied to the loss of the loop-helix-loop region between L261 and D271, however this is a 
lack of density in the search ensemble and not in the final structure. This will merely be as a 
result of a lack of homogeneity but it does give credence to the fact that the structure has 
limited levels of model bias. 
4.1.4.7 Oligomeric State 
All of the purification steps indicated that FEN 1 behaved as a monomer in solution as 
well as the DLS data, which showed a small proportion of the protein dimerising, however it 
appeared that this dimerisation was concentration dependent.  
The online software PISA (150), a server designed to analyse the interface between 
macromolecules within their crystallographic environment, determined that of the 227 
residues within the protein, 20 belong at the interface between the two molecules. These 
residues have been highlighted in the table below.  
 
Table 4.2 - PISA output showing all 20 residues shown to play a role in the formation of an 
interface. In green are the residues that are predicted to be forming hydrogen bonds to the 
alternate chain. 
This table shows all interfacing residues between the two chains within the PDB 
coordinates for the 2.27Å structure of FEN 1 from Pab. Highlighted in yellow are all of the 
interface residues. In green are the residues on each respective chain that form hydrogen 
Chain A  HSDC   ASA   BSA   ∆iG  Chain C  HSDC   ASA   BSA   ∆iG 
A:TYR  33    H    122.95       52.76  |||||       0.31  C:TYR  33         125.22       45.29  ||||        0.33 
A:LEU  36          49.10       38.47  ||||||||    0.36  C:LEU  36          53.23       40.50  ||||||||    0.29 
 A:SER  37          35.54       25.79  ||||||||    0.40  C:SER  37          42.10       28.11  |||||||     0.44 
A:ARG  40         131.46       48.40  ||||        -0.88  C:ARG  40         125.59       43.39  ||||        -0.35 
A:ASP  43          90.93       41.52  |||||       0.13  C:GLN  41          64.97        2.31  |           -0.03 
 A:GLY  44          43.53       22.18  ||||||      -0.04  C:ASP  43    H    107.65       39.08  ||||        -0.09 
 A:THR  45          55.94       44.42  ||||||||    0.71  C:GLY  44          41.22       26.24  |||||||     0.05 
 A:PRO  46          57.15       52.79  ||||||||||   0.84  C:THR  45          61.32       51.26  |||||||||   0.82 
 A:MET  48          96.21       65.31  |||||||     1.67  C:PRO  46          60.39       54.86  ||||||||||   0.88 
 A:ASP  49          8.99        6.73  ||||||||    -0.03  C:MET  48          95.83       68.16  ||||||||    1.71 
 A:SER  50          97.61       66.95  |||||||     0.43  C:ASP  49          9.72        7.46  ||||||||    -0.03 
 A:LYS  51         151.72       43.34  |||         0.13  C:SER  50          93.97       60.28  |||||||     0.26 
 A:GLY  52    H     51.89       49.55  ||||||||||   0.02  C:LYS  51         145.16       41.97  |||         0.12 
 A:ARG  53          95.28       35.66  ||||        0.57  C:GLY  52    H     52.32       50.48  ||||||||||   0.02 
 A:ILE  54    H     55.31       50.32  ||||||||||   0.68  C:ARG  53         101.72       35.89  ||||        0.57 
A:LYS 126         101.76       22.28  |||         0.28  C:ILE  54    H     57.47       53.65  ||||||||||   0.75 
 A:VAL 127         107.70       64.78  |||||||     0.96 C:LYS 126         210.54       32.24  ||          0.33 
 A:MET 130         132.10       53.88  |||||       0.87  C:VAL 127         100.00       60.64  |||||||     0.96 
 A:LEU 131          12.48        9.30  ||||||||    0.15  C:MET 130         119.83       55.60  |||||       0.90 
A:ASP 309          75.27        3.71  |           -0.00  C:LEU 131          14.34        9.49  |||||||     0.15
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bonds. HSDC refers to interactions between the two chains, as either hydrogen (H), salt 
bridge (S), disulphide bonds (D) or covalent links (C). The ASA is the available surface area, 
measured in Å2. The BSA is the buried surface area, also measured in Å2. The green tally 
marks indicate the buried area percentage, with each tally mark representing 10% of the 
total surface available surface area. The ΔiG is the solvation energy effect, measured in 
kcal/M.  
 
Figure 4.17 – (A) 2.27Å structure of FEN 1 from Pab, including stick representations of the 
residues predicted to be forming hydrogen bonds. (B) Expanded view of the interface 
between the two chains, with hydrogen atoms presented to aid visualisation of hydrogen 
bond interactions. All 20 residues forming the interface have been identified with a stick 
representation in Pymol. (C) An expanded view of the 6 residues on both chains that have 
been predicted to form hydrogen bonds. Residues in chain A are coloured green, residues in 
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The carbonyl group of Gly52 from chain A forms a hydrogen bond with the main 
chain amide group of Ile54 from chain C and vice versa. These interactions fall around the 
symmetry axis for the two chains. Tyr33 from chain A forms two hydrogen bonds with 
Asp43 from chain C as seen in figure 4.17.  An interesting observation from this analysis is 
the fact that, excluding two instances (Gln 41 from chain C and Asp 309 from chain A), each 
residue is present in both chains. PISA calculated that of the interfacing residues, only 5.9% 
is solvent accessible from chain A, with only 6.0% being accessible from chain C. 
PISA awarded the interface a CSS (Complex formation Significance Score) of 1.000, 
implying that the interface plays a significant role in complex formation. Through searching 
the protein data bank for other FEN 1 structures from human, Sso, and Pfu, it is apparent 
that none of these structures exhibit this dimerisation event. As mentioned previously, there 
has been evidence of a concentration dependent oligomerisation during this research. There 
is therefore a strong likelihood that the concentration of the protein during the crystallisation 
process has led to the formation of a dimer during crystal formation. This does not preclude 
the possibility that this dimerisation is biologically significant, however various searches in 
the literature (90, 94, 96, 137, 151) indicate that only one molecule of FEN 1 binds to the 
DNA in order for successful cleavage of the flap.  
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Figure 4.18 – Alignment of FEN 1 from Pab (green) and Pfu (1B43) (magenta). Although Pfu 
FEN1 has 90.3% sequence identity with Pab FEN1, a  MR solution could not be found with 
Pfu FEN1 due to packing clashes. Exploded views of the two main differences between the 
two structures. 
The alignment of the two structures in figure 4.18 are interesting, because the Pfu 
structure shares a 90.3% sequence identity with FEN 1 from Pab. When attempts were made 
to use the Pfu structure as a search model during MR, significant clashes were generated 
during the rotation and translation functions. According to the online software SSAP (149), 
the two sets of PDB coordinates share a structure similarity of 81% with an RMSD of 
0.79Å,. The first difference between the two is the lack of the helical archway in the Pab 
structure compared to the Pfu structure. When looking at the sequences together in figure 
4.19, it can be observed that the Pab sequence does account for this helical archway. 
C C 
N N 
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Figure 4.19 - Multiple-sequence alignment of the region believed to encode for the helical 
archway 
The second difference between the two structures is that the Pab structure is missing a 
loop region containing two β-strands. This is most likely due to increased heterogeneity 
within the crystal caused by the lack of an organised structure.  
The structures seen in figure 4.20 show how the human and archaeal FEN 1 structures 
align with one another. Using the online software SSAP again, the two PDB files were 
uploaded and along with the 42% sequence identity it showed an 80% sequence similarity 
with an RMSD of 2.06Å, when comparing chain A from each structure. The biggest 
difference between the two structures is a difference common with the Pfu structure, in a lack 
of the helical archway. As shown in figure 4.19, the Pab, Pfu and human sequences all possess 
this region and a reason it is lacking in the Pab structure could simply be due to increased 
disorder as a result of a lack of a stabilising effect from the presence of DNA.  
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Figure 4.20 – Alignment of FEN1 from Pab (green) and human (PDB code: PDB code: 
3Q8K) (blue). The two sequences share 42% identity and seem to share higher structural 
similarity. The N termini of the two chains are both identified with the single N in black. Their 
respective C termini are coloured according to the colour of their respective chains .The two 
main differences are shared with the Pfu structure and a purpose for these α-helices seems 
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Figure 4.21 – (A) Electrostatic potential representation of FEN 1 from Pab.  Both the left hand 
image and central image show a wide array of both positive and negatively charged areas. 
The right hand image shows a positively charged channel in an area that could bind DNA. 
This channel has been highlighted with a green dashed box, with the positively charged 
region being coloured blue. The left hand image shows the negatively charged strip, 
highlighted with the yellow box that is postulated to confer some degree of directionality. (B) 
Shows Pab FEN 1 modelled with the DNA coordinates from the human structure (PDB code: 
3Q8K) as a theoretical binding mode for DNA, binding in the same proposed area based on 
surface charges. Due to only taking the DNA coordinates from the human PDB code: 3Q8K 
structure and overlaying this to the Pab FEN 1 structure, the helical archway cannot be 
observed. 
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Using the software Pymol, the surface of the protein was shown, giving rise to the basic 
shape seen in figure 4.19. Using an external plugin through Pymol known as APBS Tools 
2.1(152), it is possible to determine the surface electrostatic potential. The PDB coordinates 
were first converted to PQR format, a modified version of the PDB that contains both the 
charge and radius parameters, using the in-built software within APBS Tools. Then using the 
macro ‘Set Grid’ the software determines the grid spacings for its calculations. Once 
completed various parameters can be altered to produce an image such as the one in figure 
4.19. The surface electrostatic potential is measured in kbTec-1, where kb is the Boltzmann 
constant, T is temperature in Kelvin and ec-1 is the charge of an electron. 
What is noticeable about the charge distribution for this structure are the two charged 
regions that run parallel with one another either side of the ‘head’ of the molecule, most 
visible in the far left and far right images from figure 4.21 (A). One theory could be that the 
positively charged strip is the means by which the DNA binds to FEN 1 in order for it to 
perform its function. To counter that the negatively charged strip adjacent to that could be 
charged in this fashion in order to confer a level of directionality to the protein, ensuring it 
can only bind in one orientation. This however is merely supposition and further 
experimentation is required. 
A hypothetical model of the interaction with DNA is shown in figure 4.21 (B), using 
the DNA coordinates from the human FEN 1 structure, PDB code: 3Q8K after its alignment 
with the Pab structure. With this region being highly conserved, it is likely to have a similar 
mode of action elsewhere. A further aim of this thesis is to empirically determine the binding 
mode of Pab FEN 1 to DNA, to determine if it is in fact similar to the human interaction. 
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4.2 FEN 1 / DNA Complex Structure 
4.2.1 – Introduction 
Leading on from the information presented in the previous section, it is apparent that 
in order to prove the hypothesised binding mode of DNA with FEN 1 from Pab, they have to 
be co-crystallised and the complexed structure has to be solved. 
Firstly the absence of the helical archway that can be seen in the Pfu FEN 1 structure 
but perhaps more importantly the human FEN 1 structure could be significant. However as 
previously alluded to, the sequences for this portion of the structure match up with both the 
Pfu and human sequences, implying its presence. A working hypothesis to explain its absence 
is a high degree of disorder, with a lack of organised structure at the base of the loop, it has 
fewer structural constraints and is therefore very flexible, meaning that it is unlikely to 
remain in one orientation in every unit cell within the crystal. Solving the crystal structure in 
the presence of DNA however could alleviate this issue. With DNA in place, this could act to 
stabilise the helical archway into a single conformation and therefore generating electron 
density. 
4.2.2 – Oligonucleotide Design 
The Tainer group crystallised human FEN1 and DNA using synthetic oligos and 
solved for the structure of the complex (PDB code: 3Q8K) (137), this was taken as an initial 
model for oligonucleotide design. For the protein to efficiently perform its function, it is self 
explanatory that it will not be sequence specific, however it has been shown that it acts in a 
structure specific manner (153), recognising the 5’ flap that it cleaves. 
The DNA needed to be long enough to be able to physically bind but not significantly 
longer than the protein itself, which would hinder crystal growth. As shown in figure 4.13, 
the length of FEN 1 from Pab is approximately 62 Å. The distance between two bases of 
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DNA is approximately 3.4 Å, which means that approximately 18 nucleotides will equate to 
the length of the protein (154). The template strand was therefore made to be 18 nucleotides 
long. 
 
Figure 4.22 – (A) Oligonucleotide design used by Tsutukawa et al (137) including the 
introduction of a non-hydrolysable phosphoramidate, indicated by an asterisk (*). (B) 
Oligonucleotide design including the template, downstream and upstream portions that were 
ordered as single stranded DNA that annealed to one another for this study. A standard 
phosphate at the scissile phosphate position was used in this study. 
 
The Tainer group replaced the phosphodiester bond of the 5’ flap oligonucleotide 
with a 3’ phosphoramidate group, thus meaning that the flap could no longer be cleaved.  
This was due to the fact that they were attempting to capture the complex, intermediate 
steps and products. The phosphoramidate was present as a control to additional base 
removal (137) (figure 4.22 (A)). In this study the initial complex was the structure to be 
determined and the experiments were designed in order to trap the complex before any 
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cleavage occurred, in order to determine binding mode and to increase likelihood of uniform 
crystal production. 
4.2.3 – Annealing 
Using the protocol mentioned in chapter 2, the three single stranded oligos were 
combined to form the double stranded sequence of DNA that contained the designed ‘flap’, 
in order to test its interaction with FEN 1 and ideally to crystallise the complex and gain 
structural insight into the mechanism. 
After the annealing process, checks were performed to determine a successful protocol 
and formation of the desired product. One theoretical method would be to run the samples 
on an agarose gel. This however would be an issue when running such small oligos (6nt, 
15nt, 18nt) and it would be extremely difficult to differentiate between them, especially the 
15mer and 18mer. The other possibility would be to run a non denaturing acrylamide gel, 
which would allow the resolution required to detect the difference in size of the oligos, but to 
get accurate results for the single stranded DNA, the gel would have to be denaturing to 
inhibit duplex formation, which would vary greatly depending upon the sequence.  
This therefore means that there is not really a technique that can be performed to 
check both the relative size of the individual oligos as well as the complex. However the 
samples were analysed via high performance liquid chromatography (HPLC) using a Mini-Q 
PE column (GE Healthcare). Each individual component was run over the column to 
determine both the elution volume and elution conductivity. Once values were obtained for 
each component, the complex was passed over the column to determine if the complex had 
in fact formed, or if it was simply a mix of the constitutive parts. The results of this 
experiment can be seen in figure 4.23. 
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Figure 4.23 – Chromatography traces of each individual oligonucleotide, as well as the formed 
complex passing down a mini-Q PETM column. Orange peak – 6nt Upstream, Red peak – 
15nt downstream, Purple peak – 18nt template, Black peak – DNA complex. 
 
As can be seen by the chromatogram, the smallest oligo (6 nt - upstream) is eluted first 
at 2.95 mL and a conductivity of 32.49 mS/cm. The next smallest oligo (15 nt - downstream) 
is eluted at 4.56 mL and 53.77 mS/cm. The largest of the three (18 nt – template) is then 
eluted at 4.75 mL and 56.25 mS/cm. It stands to reason that the two oligos with only 3 nt 
difference will elute at similar times and conductivities, especially in relation to the 6 nt oligo. 
The complex of all three eluted at 5.51 mL and 65.79 mS/cm. With its length being the 
same as the template the observable shift can be attributed to the fact that this is now double 
stranded, complexed DNA, rather than the single stranded DNA seen in the template.  
Although this is the case it can be seen that in the DNA complex sample (Black trace), 
has a smaller peak that correlates to the same elution volume (2.95 mL) and conductivity 
(32.49 mS/cm) as the upstream only. One possible reason could be that the 6nt upstream 
fragment hasn’t annealed and the complex is merely template and downstream combined. 
Although this is possible it is more likely that this peak can be attributed to an excess of 
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final concentration 100 µM and if there was no annealing event involving the upstream then 
the peak size would correlate with the upstream only peak, whereas it is significantly smaller. 
For the template strand there is also a small peak that correlates with the same elution of the 
complex. This is most likely going to be some self-complementarity of the template strand, as 
indicated in figure 4.24. 
 
Figure 4.24 – A diagram showing the areas where the template strand could dimerise with 
itself 
 
The fact that there are two peaks adjacent to one another for each sample could 
possibly be indicative of minor nucleotide errors in the synthesis and purification of the oligo 
from the manufacturer (Sigma Aldrich). This could be in the case of the 18 nt template that 
there is either some 19 or 17 nt variants present in the sample. For future experiments this 
HPLC could be used as a purification step rather than an analytical one, and the correct 
peaks could be collected and used in subsequent experiments. This however will most likely 
not be an issue due to the fact that a one nucleotide discrepancy at either the 5’ or 3’ end of 
the complexed DNA is unlikely to affect the central ‘flapped’ portion of the complex and it is 
this structure, rather than the sequence, that is required for effective binding to the FEN 1 
protein. 
4.2.4 – Binding to FEN 1 
Once a complex containing the three oligos had been produced, it was then taken and 
added to purified FEN 1 in order to form the protein-DNA complex. The DNA was added 
to the protein in slight excess, in order for the equilibrium to favour the formation of the 
complex if the interaction is transient, which is most likely due to the proteins mode of 
action. This also correlates with previous examples in literature for similar protein-DNA 
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complexes (137). The final molar ratio of protein to DNA was 1:1.2. This was worked out 
using the following calculations: 
MW of FEN 1 = 38949 (Da) 
Concentration = 6.4 mgmL-1 
n = 1.643 x 10-4 moles 
= 164.3 µM 
Therefore to maintain the molar ratio required for the slight excess of DNA as 
previously mentioned: 
164.3 x 1.2 = 197.2 µM 
The complexed DNA was concentrated to a final concentration of 100 µM. Therefore 
for every 1 µL of FEN 1 added, 1.97 µL (~2 µL) of DNA was added. Once the desired 
amount of FEN 1 and DNA were added together, EDTA was added at a final concentration 
of 5 mM.  
Mg2+ has been shown to bind to sites of two metal acidic residue clusters within 
archaeal FEN 1, known as M-1 (Asp-27, Asp-80, Glu-152, Glu-154) and M-2 (Asp-173, Asp-
175, Asp-236), shown to be essential for catalytic activity. It is theorised that the M-1 site 
engages in nucleophilic attack of the scissile phosphodiester bond at the junction of the flap, 
whereas M-2 induces conformational changes resulting in the formation of the active 
complex (155). By chelating the Mg2+ with EDTA the theory is that the FEN 1 will no longer 
be catalytically active and therefore it will be easier to trap the protein and nucleic acid in 
complex with one another. 
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The mixture was then incubated for 1 h at 25°C at which point it was then centrifuged 
for 60 seconds at 13,000g to remove any precipitated protein and particulate matter ready 
for further experiments. 
The first of these experiments was a native-PAGE gel in order to detect any changes in 
running height of the FEN 1 band +/- DNA. The results of this experiment can be seen in 
figure 4.25. 
 
Figure 4.25 – (A) 15% Native-PAGE gel testing a possible change in the height of the protein 
+/- DNA. (B) Repeat of the gel to confirm a potential increase in size after complex formation.  
Two lanes were filled with half of the protein solution so the final concentration was 50 µM to 
reduce the smear levels often seen with native gel electrophoresis. The arrows indicate 
proposed FEN 1 bands based on their migration and theoretical molecular weight. The 
molecular weight of the double stranded DNA is approximately 11.1 kDa therefore the MW of 
the complex is approximately 49.9 kDa. 
 
Based on gel A in figure 4.25, it could be concluded that the band assumed to be FEN 
1 (38.9 kDa) does in fact shift upward, indicating a larger complex, upon addition of the 
DNA. This however could be refuted due to the fact that each of the other ‘contaminant’ 
bands present in the solution also shift upward implying that this is merely an artefact of the 
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gel, simply a running anomaly. Identical samples were then analysed on another freshly cast 
15% native-PAGE gel which can be seen as gel B in figure 4.25. In this gel there is no 
upward shift of any bands in the gel upon addition of the DNA, either contaminant or FEN 
1. This therefore implies that there is no complex formation. 
This can be further corroborated by the presence of the over-saturated bands < 20 
kDa. For reference purposes there are lanes dedicated to each individual oligo as well as the 
complex. The bands present in all 3 FEN 1 + DNA lanes are of a similar intensity to these 
reference lanes. Although the presence of these bands could indicate an excess of DNA, at 
these similar intensities it is more likely that it is the entirety of the DNA sample. 
Another experiment that was performed on the FEN 1 + DNA sample was analytical 
size exclusion chromatography. Using a Superdex 200 10/300 GL column (GE Healthcare) 
a small volume of the sample was loaded and the chromatographic trace was recorded. 
Samples of FEN 1 apo, as well the DNA only as comparisons were also loaded. The results of 
this experiment can be seen in figure 4.26. 
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Figure 4.26 - A chromatogram showing the results of an analytical size exclusion 
chromatography experiment with FEN 1 +/- DNA as well as the DNA only. 
 
As can be seen in figure 4.26, the purple FEN 1 only peak had an elution volume of 
17.93 mL, which, based on previous results and calibration curves created in the same 
conditions, indicate that this is monomeric FEN 1 and is the control that will act as a 
comparison at the point when the DNA is added. The orange DNA only trace has two peaks 
at 18.95 mL and 21.61 mL. The presence of two peaks is most likely due to two different 
species. The first peak corresponds to a molecular weight of ~ 9.1 kDa, which is smaller than 
the double stranded complex, but this is based on calibration data for globular proteins, not 
double stranded DNA in a helical arrangement. The smaller peak at 21.61 mL roughly 
corresponds to ~ 2.3 kDa, again, which is smaller than single stranded template but based on 
calibration data that is not suitable for helical DNA. Future work will include a size exclusion 
chromatography trace for nucleic acids to help determine the identities of these two peaks. 
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Perhaps if the sample had been purified when performing the mini-Q experiment in 
figure 4.21 this secondary peak would be removed, a hypothesis that can be tested in future 
experiments. 
When looking at the FEN 1 + DNA trace in red it can be observed that the elution 
volume of the large peak is at 18.15 mL. Although this is shifted very slightly right of the 
FEN 1 apo sample, the elution actually begins at the same point, and the largest DNA only 
peak is also contained under the peak. The increase in mAu can also be attributed to the fact 
that the two species are combined in a mixture rather than a complex. It would make sense 
that if the higher DNA peak were the complex, and the lower peak was either single stranded 
template or some other incorrect complex, then even if the FEN 1-DNA complex were 
forming, this second peak would be present in the FEN 1 + DNA sample, which can be seen 
in the trace. Overall this chromatographic trace further suggests that no complex has been 
formed. 
Another means of detecting complex formation is to perform a thermal denaturation 
assay. When comparing a melting profile of FEN 1 apo and the FEN 1-DNA complex, the 
complex should theoretically be more stable than the apo protein and therefore melt at a 
higher temperature. If this shift is observed it will indicate complex formation. The inherent 
problem with this technique is the fact that Pyrococcus abyssi is a thermostable organism and 
the protein is less susceptible to thermal denaturation than human proteins. This problem 
can be observed in figure 4.27.  




Figure 4.27 - Thermal denaturation assay showing both the relative fluorescent units and their 
derivative values. 
 
Based on the information in both the raw data as well as the derivative data, at various 
concentrations from 18 mgmL-1 to 0.12 mgmL-1 there does not appear to be a suitable melt. 
At both ~80°C and ~89°C there appears to be signs of initial melts but they aren’t 
significant enough to be considered the melting point of the protein. This therefore hasn’t 
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provided any more conclusive information regarding the formation of a FEN 1:DNA 
complex. 
4.2.5 – Crystallisation 
After performing the previous experiments, and determining neither positively nor 
negatively if the FEN 1-DNA complex had indeed formed, a sample of the mixture was used 
in an attempt to produce crystals containing the complex. The FEN 1-DNA solution was 
used at its current concentration of 2.2 mgmL-1. Using the Gryphon LCP liquid handling 
robot, the precipitant and FEN 1-DNA solution were placed in a sitting drop orientation in a 
1:1 ratio in two 96 well plates testing the Structure Screen 1 + 2 (Molecular Dimensions) and 
the Nucleix (Qiagen) screens. The first screen was chosen due to the previous success with 
the FEN 1 apo crystal formation. The Nucleix screen was chosen due to its apparent 
increased likelihood of growth of crystals containing protein-DNA complexes based on 
previous successful examples, such as from within the PDB, checking for RNA, DNA and 
protein/nucleic acid complexes, analysing the crystallisation conditions and checking for 
how recurrent the components were (156). Crystals grew in 7 days in 200 mM zinc acetate, 
100 mM sodium cacodylate, 18 % PEG 8000, pH 6.5. These crystals grew in the same 
conditions as the FEN 1 apo crystals. 
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Figure 4.28 - Crystals in sitting drop, containing FEN 1 + DNA grown in 200 mM Zinc 
Acetate, 100 mM Sodium Cacodylate, 18% PEG 8000, pH 6.5 
The crystals take the form of a triangular prism and all possessed small inwardly facing 
growth defects. This was reproducible but an adequate reason for this has not been 
determined. The crystals were harvested and cryo-cooled in liquid N2 without the use of 
cryo-protectant due to the high concentration of PEG 8000 thought to be suitable to reduce 
cooling damage and the presence of ice rings in data collection. The data were collected 
remotely using the I04-1 beam-line at the Diamond Light Source Synchrotron. 
4.2.6 – Crystallography 
4.2.6.1 – Space Group Determination 
The crystals seen in figure 4.28 were shot and diffracted to 2.83 Å resolution. Prior to 
any crystal growth refinement, the data were processed to determine the presence or absence 
of DNA within the structure.  
The data were collected and processed using MOSFLM (113) in the space group 
P3112. As mentioned previously the space group for the FEN 1 apo was C2221. The 
reflections were scaled using SCALA (109). Although the crystal diffracted to 2.83Å, the 
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Rmerge in the outer shell at this resolution was 4.776 and the Rpim was 3.519. The Rpim has 
within it an additional weighting accounting for multiplicity, which the Rmerge doesn’t, and 
can therefore be considered a more accurate guide to the quality of the dataset. It is believed 
that a value for Rpim of 0.5 is an acceptable cut-off for data quality. The value obtained for 
the I/σI in the outer shell at this resolution was 0.2, where an acceptable cut off for this is 
approximately 2.0. 
The resolution was therefore manually cut back until acceptable values for these 
statistics were obtained. At a resolution of 3.62Å, the Rmerge was 0.519, the Rpim was 0.370 
and the I/σI was 2.3. This resolution limit was then used for the remaining data processing. 
The crystal gave a total of 82395 observed reflections. The unit cell dimensions were 
shown to be a = b = 127.21 Å, c = 177.47 Å; α = β = 90°, γ = 120°. The Rmerge values 
were 11.7%. The Matthew’s Coefficient was calculated for both the protein alone as well as 
the protein in complex with the DNA. The value for the protein alone was 2.66 Å3/Da, 
calculating 4 molecules in the AU with a solvent content of 53.8%. By assuming that the 
molecular weight of the protein-DNA complex is 38.9 kDa (FEN 1) + 11.2 kDa (DNA) = 
50.1 kDa, the Matthew’s Coefficient was 2.76 Å3/Da, predicting three molecules in the AU 
with a solvent content of 55.5%. The data were collected to a completeness of 92.8% 










 FEN 1 FEN 1 + DNA 
Data collection   
Space group C2221 P31 2 
Cell dimensions     
a, b, c (Å) 65.23, 86.40, 238.99 127.21, 127.21, 177.47 
     	α, β, γ (°) 90, 90, 90 90, 90, 120 
Resolution Range (Å) 50.26 - 2.27 51.34 – 3.62 
Rmerge 0.143 (0.317) 0.117 (0.519) 
I/σI 6.0 (2.7) 6.1 (2.3) 
Solvent Content (%) 43.1 53.8 / 55.5 
Molecules / AU 2 4 / 3 
Completeness (%) 96.1 (99.8) 92.8 (79.9) 
Redundancy 4.2 4.7 
Table 4.3 - A table comparing the data collection statistics for FEN 1 apo crystals and crystals 
containing FEN 1 in complex with the DNA. Values in parentheses indicate the statistic for the 
highest resolution shell 
 
The table shows that despite the two sets of crystals growing in the same conditions, 
they have in fact changed upon addition of the DNA. The space group has changed from a 
centred orthorhombic space group to a primitive trigonal one. The unit cell is considerably 
larger when the DNA is added when compared to the protein only. This has allowed 4 
molecules within the asymmetric unit compared to 2 previously. The presence of the DNA 
could have allowed the protein to adopt an alternate conformation, meaning it packs very 
differently leading to these outcomes. 
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Figure 4.29 - Diffraction pattern of the FEN 1+ DNA crystals shown in figure 4.28, which 
diffracted to 2.83 Å resolution. The pattern indicates one partial ice ring and another very feint 
one, indicating the lack of cryo-protectant during crystal harvesting was not too detrimental, 
however crystal quality could have been improved by including this step. 
 
4.2.6.2 – Molecular Replacement 
The FEN 1 apo structure solved to 2.27 Å was the first search model used in order to 
solve the phase problem using PHASER. A single molecule was used, searching for 4 
moleucles within the AU, based on the Matthew’s coefficient. The cell content analysis 
revealed similar values for the Matthews coefficient as the values obtained prior to any MR. 
The rotation function generated a top RF score of 60.47 with a Z-score of 6.2. The 
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translation function was then performed, generating a TF score of 143.3 and a Z-score of 
8.9. Packing analysis was performed and there were 2 possible orientations, both of which 
were deemed acceptable. Automated molecular replacement was then carried out and the 
best solution obtained had an LLG of 1536.4 with an R factor of 41.45% prior to any 
refinement. 
The output from PHASER was then used to perform TLS and restrained refinement 
using isotropic B factors, using the program REFMAC. 10 cycles of TLS refinement were 
performed, followed by 10 cycles of maximum likelihood restrained refinement to a 
maximum resolution of 3.62Å. The R factor after this round of refinement was 29.47%, with 
an R free of 37.25%.  
 
 
Figure 4.30 - Electron density map (2Fo-Fc) of a portion of the 3.62Å structure of FEN 1 
contoured to 1.8σ. The density strongly correlates with the atomic coordinates. 
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The electron density shown in figure 4.30 is a representative example of the density 
throughout the structure. It correlates well with the coordinates of the protein structure 
meaning that any conclusions drawn from the structure in its current form can be done so 
with a certain degree of confidence. At 3.62Å however side chain positions and rotamers 
cannot be accurately identified leading to levels of ambiguity. The purpose at this stage of the 
process is to determine the presence or absence of DNA within the structure and at this 
resolution density for a double helix should be observable. 
The four molecules within the asymmetric unit, seen in figure 4.31 (A), are coloured 
according to their chain ID, with the N and C termini highlighted on chain A (green). Chain 
A and chain B (cyan) sit end to end within the AU, whereas chain C (yellow) and chain D 
(magenta) sit side by side facing inward toward one other. However, packing of asymmetric 
units within the unit cell allows for chains A and B, which sit end to end in the AU, to 
effectively pair with their corresponding chain from the adjacent AU. This allows them to 
















Figure 4.31 - (A) The 4 molecules within the AU coloured by chain. Chain A (green), chain B 
(cyan), chain C (yellow), chain D (magenta). (B) - Inclusion of molecules from adjacent AUs 
showing how each asymmetric unit packs within the unit cell. 
A 
B 
  Chapter 4 
 196 
 
Figure 4.32 - 2Fo-Fc map contoured to 1.8σ in blue showing atomic coordinates from FEN 1 
as well as unoccupied density adjacent to the protein. Fo-Fc map contoured to 2.8σ showing 
positive density in green. 
Adjacent to the protein coordinates is a region of positive density that runs alongside 
the protein in a manner similar to that of DNA binding to human FEN 1 in the PDB PDB 
code: 3Q8K (137). This positive density is approximately 18Å in length and 8Å at its widest 
point, which is not wide enough to contain a DNA double helix, which is approximately 
20Å, and not long enough to contain even one helical turn, which is 10.5 base pairs, the 
equivalent to 34Å (157). It also doesn’t exhibit any helical nature that could be attributed to 
DNA. It does exhibit features of an α helix, however a helix in this position would not relate 
to any residues within the sequence of FEN 1 from Pab, including the missing activation loop 
previously discussed. 
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Figure 4.33 - The left hand image shows the PDB coordinates for FEN 1 from Pab at 3.62Å. 
The 2Fo-Fc map in blue, contoured to 1.2 σ, is adjacent to the protein. The right hand image 
is an expanded version of the first image highlighting both the 2Fo-Fc map and the Fo-Fc 
map, contoured to 2.8σ. Also shown in the density are the symmetry atoms indicating that 
any density in these regions is due to symmetry mates from adjacent unit cells within the 
crystal. 
In the lower left hand corner of figure 4.31 as well as the right hand image of figure 
4.33 additional regions of density can be seen to occupy space surrounding the protein, as 
well as areas of positive density. They can be seen to be containing symmetry mates of the 
visible AU. The particular symmetry mates seen in figure 4.33 were previously pointed out in 
figure 4.31 when discussing how the chains interact with one another, whether it be through 
symmetry mate interactions or with alternative chains within the AU. Symmetry atoms 
account for a significant proportion of density adjacent to the protein, however there are 
distinct regions that cannot be attributed to this, a prime example of which is the positive 
density in figure 4.30. Before making an attempt to fit nucleic acids to the density, modelling 
was performed to determine if there was space for DNA to bind to the protein whilst it 
occupied this particular orientation within the AU. 
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Figure 4.34 – model of the coordinates from the 3.62Å structure of FEN 1. In the figure the 
coordinates from the human FEN 1 structure (PDB code: 3Q8K) were aligned to chain C 
from the Pab structure. Making the assumption that the DNA will bind to Pab FEN 1 in the 
same manner as it does in human, it is apparent that there is insufficient space when the 
protein adopts this orientation within the crystal for double stranded DNA. This lack of space is 
apparent when observing the clashes between the DNA and chain D (magenta)   
In order to theoretically determine if this AU could allow for DNA to form a complex 
with the protein, the coordinates from the human FEN1-DNA complex (PDB code: 3Q8K) 
(137), shown in red, were aligned to one of the four molecules within the AU.  FEN 1 binds 
to DNA in a structure-specific manner rather than a sequence-specific one (153). Assuming 
that the FEN 1 from Pab binds to DNA in the same manner as it does in humans, this 
suggests that due to the protein packing in this particular orientation within the crystal, there 
is not enough space in between the two chains to allow for this particular DNA. Meaning 
that even if only one double stranded molecule of DNA occupied the space between the 
chains, it would bind to one of the two chains but, as can be seen in the figure, the clashes 
observed from this alignment indicate a distinct lack of space.  
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4.2.6.3 – Refinement 
With an initial R factor after one round of TLS and restrained refinement of 29.47% 
it can be surmised that the phases obtained through molecular replacement accurately relate 
to the experimental data obtained.  
The purpose of collecting data from these particular crystals was to determine a 
binding mode for DNA with Pab FEN 1, in order to empirically determine if the binding 
mode is similar to that proposed for human FEN 1 by Tsutakawa et al (137).  As discussed in 
the previous section however, there is a lack of evidence for any DNA to exist within the 
crystal structure, therefore this aim cannot be met.  
Due to the fact that the data was only collected to 2.83Å, but was manually cut back to 
3.62Å to ensure only suitable data was used, any data obtained from this experiment, has a 
lower resolution than the 2.27Å achieved when crystallising Pab FEN 1 apo. This 
combination of a lack of electron density for any DNA, as well as significantly lower 
resolution than previous experiments means that further refinement of this structure would 
serve little purpose and therefore was discontinued. 
4.2.7 – Concluding Remarks 
Based on the results discussed in chapter 4.2, it is believed that the FEN 1 and DNA 
are not co-crystallising in complex with one another. One possible reason could be that the 
interaction is transient and although a complex may be forming, it may be breaking away 
again due to the fact that either the released DNA has had the flap removed or perhaps the 
interaction is not strong enough to maintain the complex. 
Another possible reason is that the concentration of EDTA is not high enough to 
chelate all the divalent cations present in the solution. If the Mg2+ concentration is sufficient 
for the enzyme to turn over ATP and cleave the flap, releasing the cleaved DNA product 
then it won’t be visible in either the assays or the crystal structure. 
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It could also be that the DNA being used was not pure enough for crystallisation 
purposes. If the doubling of peaks present in figure 4.21 indicates several species, perhaps this 
heterogeneity meant that crystals could not pack effectively and only crystals without the 
DNA could grow.  
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4.3 FEN 1 High Pressure Crystallography 
4.3.1 – Introduction 
The replicative machinery of Pab is poorly understood at the high pressures that the 
piezophilic archaeon thrives at, but structural studies could generate valuable insight (158). 
That being said it has been shown that Photobacterium profundum, another piezophilic archaeon, 
and Xenopus cell-free systems, which can survive at pressures up to 80 MPa, both halt DNA 
replication at high pressure (158, 159). One previous example of an HPMX experiment, 
using the enzyme urate oxidase from Aspergillus flavus, showed that upon pressure being 
applied at 150MPa, they observed a conformational sub-state, where the uric acid substrate 
binding pocket increased in size at the expense of a localised hydrophobic pocket, which the 
authors suggest was required to be able to accommodate both intermediate and final 
products (160). This therefore could be a useful technique to determine potential structural 
changes that occur within FEN 1 from Pab at high pressure. 
The mechanisms by which the Photobacterium profundum replicates under pressure in 
these highlighted studies indicate a role of both DiaA and SeqA (positive and negative 
replication regulators respectively) in controlling levels of replication at high-pressure. 
However once replication has been initiated at pressure, what changes in the replicative 
machinery occur to allow it to continue error free? By studying FEN 1 at pressure, one can 
determine if there are structural changes that could affect function, or at least show that it is 
tolerant to these pressures. 
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Figure 4.35 - (A) Photograph taken of the DAC during the data collection experiment. 
Highlighted are the Tungsten gasket, the Diamond Anvil and the Sample Chamber. Also seen 
in the image is a brass ring that encircles the sample chamber. This plays a role in the 
temperature regulation of the DAC. (B) Schematic showing the DAC and how it contains the 
sample during data collection. 
Pressure was measured using the ruby shown in Figure 4.35, as discussed in section 
2.2.9.1. Due to the position in which the DAC sits in relation to the beam, there was only a 
90º rotation possible from -45º to +45º around the vertical axis. This meant that in order to 
generate a complete data set in order to produce a structure, more crystals had to be used, 
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and they were placed within the sample chamber in as many varied positions as possible. 
Upon processing the data, due to the necessity for a greater number of crystals being used, 
there are more images to merge from different crystals, which led to greater Rmerge values. 
The intensity of the spots collected is also considerably smaller than that of standard cryo 
data collection. The Mar555 detector is sensitive enough to detect this reduction, but 
MOSFLM is not powerful enough to process the data and therefore XDS was used (108). A 
total of 12 crystals were shot in order to collect a complete dataset. The first crystal was used 
as a precursor to determine the maximum pressure to which these particular crystals could 
be subjected to, whilst still diffracting X-rays. This value was 8.6 kBar. Using this value as a 
benchmark the pressure for the remaining crystals was set at just below 50 % of this value, 
which was 3.2 kBar. 
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4.3.2 – Data Collection 
 
Figure 4.36 - (A) One of the crystals used for the high-pressure data collection housed within 
a capillary used for transport. (B) The same crystal after being loaded within the DAC prior to 
the data collection 
The crystals were transported in 1 mm capillaries in order to ensure minimal damage 
to the crystal, whilst maintaining the surrounding mother liquor that it grew in to potentially 
increase the crystal’s stability. Figure 4.36 (A) shows a typical example of the crystal within 
the capillary. Extraction from the crystal was performed by placing a small drop of mother 
Crystal
Ruby 
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liquor onto a cover slip allowing capillary action to move the crystal out, where it was then 
picked via a loop and placed within the DAC. An image of the same crystal placed within the 
DAC can be seen in figure 4.36 (B), which also highlights the ruby used for pressure 
measurements.  Data collection was then performed as described in the chapter 2. 
4.3.3 – Data Processing 
Figure 4.37 - Typical example of collected data during the high-pressure experiments. This 
particular image is from the 7th crystal shot during the experiment. The resolution limit was 
approximately 3.5 Å. 
The crystals used in this experiment were grown in 50 mM MgCl2, 100 mM 
imidazole/maleate buffer pH 6.5, 15% PEG 8000. Crystals appeared after one week. 
Although 12 crystals were shot, they had varying degrees of success and a final solution could 
not be obtained. A large factor in this was the fact that the crystals that were taken for the 
experiment had larger dimensions than could be accommodated within the DAC. In order 
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to attempt data collection they were manually broken up into smaller pieces, that were 
placed inside the chamber one at a time. This introduced significant structural damage and 
inherent internal damage that affected the quality of the data. 
Promising data were collected from one crystal and the statistics for this particular 
crystal will be discussed. The unit cell dimensions for this particular crystal system were a = 
65.18, b = 83.04, c = 235.64, α = β = γ = 90° with the space group C2221. There was a 
resolution range from 14.8 to 3.3 Å. The total number of observed reflections was 3436, of 
which 2607 were unique. It was collected to a completeness of 26.1% with an I/σI of 3.2. 
The data had an observed R factor of 12.7% with an Rmeas value of 17.5%.  
These preliminary high-pressure experiments proved to be a good stepping-stone for 
further experimentation. Conditions were determined that yielded crystals amenable to both 
the high pressures and ambient temperatures. Optimisation could include crystal harvesting 
at an earlier stage, resulting in crystals with the same unit cell dimensions, but smaller overall 
to fit within the DAC chamber. 
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Chapter 5 
Conclusions & Future Work 
5.1 DNA-PKcs 
5.1.1 – Overall conclusions of this work 
What can be observed based on the results presented throughout this thesis, is that 
these particular DNA-PKcs constructs are inherently insoluble and even with archetypal 
techniques employed to increase the solubility; no improvement could be obtained. One 
particular method that is frequently used to improve the solubility of proteins is to use 
alternative expression systems. These include yeast, which has the advantage of being a 
eukaryotic system. Baculovirus infected insect cells can also be used, which are able to 
process more complex post-translational modifications, which E. coli cannot perform. 
Mammalian cells such as HEK or CHO cells can also be used. They have the ability to offer 
increased productivity and less variation, however expression levels are lower and the process 
is more time consuming. Future work would certainly involve the use of alternative 
expression systems to potentially increase levels of soluble protein. Despite these problems, 
relative levels of success were achieved using a denature-renature approach to refold the 
protein in the absence of cellular components in favourable conditions.   
Based on the structure published by Sibanda et al (47), shown in figure 1.3, it can be 
seen that the purple kinase domain is nestled within the surrounding domains and it could be 
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postulated that the outer portions of this domain are actually hydrophobic, preferring to lie 
within the folded structure. Therefore if this domain is isolated from the surrounding 
domains, its hydrophobic regions will be exposed to the aqueous buffer and would fold 
inward on itself in an attempt to avoid the buffer. In order to test this theory, one could 
generate considerably larger constructs to potentially contain these surrounding regions. One 
possible new domain boundary could be from S2883 rather than P3600. This would contain 
the entirety of the FAT domain, rather than approximately half of it in the case of A1. 
Taking a domain in its entirety like this is more likely to lead to successfully folded protein as 
the areas in between domains can often be disordered and it can be considered a lot more 
preferable to start a protein from an unstructured region such as this, rather than from the 
middle of a structured region, such as an α-helix.  
Although solubilisation experiments failed to yield any improvement this result can still 
be built upon. This is due to the fact that these failed options can be removed from future 
experiments as variables to be tested. Although a considerable number of solubilisation 
techniques were tested to no avail, soluble domains have been produced, evidenced by Sajish 
et al (126), discussed in chapter 3.3.3, although these results could not be replicated in this 
study, through various attempts. 
Another result that requires further analysis is the co-purification of both the 60 kDa 
chaperonin as well as GroEL with the two codon optimised constructs used in this thesis. It 
stands to reason that within the cellular environment, if a protein requires assistance to 
maintain its conformation they would exist as some form of complex, but for this complex to 
be maintained out of the cellular environment and after a barrage of stringent conditions is 
an interesting observation.  
One method that was not performed during this research that could be employed to 
remove this contamination was described by Rohman et al (161) and it involves the addition 
of denatured host protein to the lysate. The theory being that the unfolded protein will 
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compete for the binding of the chaperone and therefore allow the chaperone to dissociate 
from the codon optimised construct.  
In future, experiments could be performed to ensure catalytically active protein is 
refolded. An ATPase assay monitoring the turnover of radio labelled ATP into ADP 
detecting the release of the γ-32P could be used. Stability assays could involve testing the 
thermal shift profile at various stages after the purification to determine the stability of the 
protein over time.  
5.1.2 – Optimisation of the purification protocol 
As mentioned in chapter 4, a protocol was developed that allowed for the denaturing 
and refolding of the longest A1 construct (P3600 – M4128). Preliminary biophysical 
characterisation also showed that one of the refolded species was approximately the same 
size as the theoretical size of that particular construct. However there were several issues with 
this protocol, mainly the low yields obtained. 
The initial concentration of A1 in the presence of AMP-PNP and 8M Urea was 
around 38 mg/mL but after refolding this was reduced to 0.3 mg/mL in approximately 100 
µL, thus not being enough to perform important biophysical experiments or crystal screens. 
The largest rates of attrition were consistently seen during the dialysis steps and even though 
various modifications were tested this could not be improved upon. That being said, there 
was some degree of improvement by using a combination of drop-wise dilution into an 
intermediate buffer, containing 2 M guanidine, and then using a Ni-Sepharose HisTrap 
column as a scaffold for the remaining refold. Time constraints limited the levels of 
improvement that could be performed on this step but future work would include this 
optimisation. By decreasing the levels of protein loss at this stage will lead to greater amounts 
of seemingly correctly folded protein. Adequate biophysical characterisation could then be 
performed as well as crystal growth trials.  
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The other issue with this protocol was also the 260 nm/ 280 nm ratio after treatment. 
This was still at high levels, typically indicating contamination, either from nucleic acids or 
from pyrimidine nucleotides such as ATP. The former of which however, would be unlikely 
due to the procedure that the protein went through. Normal protein-DNA interactions 
would not be able to withstand denaturing, purification and then refolding. The other 
observation seen during this research was a high 260 nm / 280 nm ratio in relation to 
chaperone contamination, although a solution to this problem could not be determined. This 
too is highly unlikely for the same reasons mentioned previously. Therefore this would 
require adequate investigation, to both determine the source of this 260 nm / 280 nm ratio 
as well as removing it.  
ATP contamination is a more likely in this scenario due to the fact that AMP-PNP is 
required as a scaffold for the successful refolding of the protein. Due to the protocol failing in 
the absence of AMP-PNP it will be difficult to test if this hypothesis is correct. One possible 
technique could involve a radiolabelled AMP-PNP in the refolding process, and subsequent 
testing of the protein to detect its presence as a reason for the high 260 nm / 280 nm ratio. 
5.2 FEN 1 
5.2.1 – Overall conclusions of this work 
Also presented in this thesis is a novel X-ray crystal structure of FEN 1 from Pyrococcus 
abyssi at 2.27 Å.  The structure had two molecules of FEN 1 in the asymmetric unit with each 
molecule being 44 Å at its widest dimension, and 62 Å at its longest dimension. The results 
showed that in solution the Pab FEN 1 behaves as a monomer. This result was evidenced by 
both size exclusion chromatography, as well as dynamic light scattering experiments. 
Although this is an in vitro result it would make sense that this is observed in vivo too, based on 
the theorised mode of action. Due to FEN 1 being a structure-specific endonuclease, then 
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only one FEN 1 molecule will be able to bind to one particular flap at any given time, 
therefore if it were a dimer, the second copy of the FEN 1 would not be able to interact with 
the DNA at the same time as the first, in fact being a large globular protein it is more likely 
that it would in fact sterically hinder the FEN 1 from accessing the DNA, a reason that could 
potentially indicate why no FEN 1 – DNA complex was being seen in this research. This 
theory however is something that would require experimentation.  
Subsequent improvements on this structure would start with attempting to generate a 
structure containing the helical archway. This portion of the structure was observed in the 
Sso and human structures and is thought to be integral to the function of the enzyme, 
specifically the DNA recognition and binding. The lack of this region has been attributed to 
disorder. 
Future work will include further attempts at using the coordinates from Pfu FEN 1 as a 
search model for MR. Due to the 90.3% sequence identity it stands to reason that this would 
have been the most suitable search model, however when attempts were made during this 
research, significant clashes were observed during rotation and translation functions. This 
will most likely be due to the presence of the two regions shown in figure 4.18 in the search 
model, but with no corresponding density obtained from the experimental data. By removing 
these portions from the search model prior to performing the MR the phases from the 
remaining structure would correlate better with the experimental data, when compared to 
the Sso structure used. The removed regions could then be replaced during the iterative 
cycles of refinement to potentially improve the final structure. 
Structural alignments between the Pab structure and the human showed that they 
potentially share their mode of interaction with DNA with one another. This theory was 
strengthened based on the surface charge distribution, which showed a positively charged 
channel running along the proposed region where the DNA would interact with the protein. 
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This theory would therefore need to be validated, which was why attempts were made to 
generate a FEN 1–DNA complexed crystal structure. 
5.2.2 – Determining a crystal structure of FEN 1 in complex with 
DNA. 
The results in this thesis show that pure FEN 1 was being produced and that a DNA 
complex was being formed from the three oligonucleotides designed, based on similar DNA 
published by Tsutakawa et al (137). However the required complex could not be formed 
between the protein and nucleic acid species. There could be a variety of reasons for this.  
One of these reasons could be that the DNA being used was not pure enough for 
crystallisation purposes. The doubling of peaks present in figure 4.21 most likely indicates the 
presence of several species and this heterogeneity could lead to ineffective crystal packing. 
Future work would include an additional purification step after the DNA complex formation 
prior to any crystallisation.  
Future work would also include additional analysis performed on the crystals being 
tested in order to determine whether or not any DNA was actually present within the crystal. 
This analysis would include mass spectrometry on a dissolved crystal as well as detecting the 
260 nm / 280 nm ratio, also of a dissolved crystal to detect the presence of nucleic acid.  
The data presented in chapter 4.2.6 shows the data collection and processing strategy 
to solve the structure for a FEN 1-DNA complex. After molecular replacement the top 
solution had a Z-score of 8.9, with an LLG of 1536.4. This in combination with an R factor 
after one round of TLS and restrained refinement of 29.47% indicates that the solution is 
correct. In light of this, it can be stated with confidence that the structure lacks electron 
density for DNA. Theoretical models using coordinates from the human FEN 1 structure 
containing DNA also showed that there was not enough space for a DNA double helix, 
assuming that the binding mode of action is similar.  
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One interesting aspect of this solution, however, is that even though a complex 
between the protein and nucleic acid did not form, the crystal grew in an alternative space 
group upon addition of the DNA even though they were grown in identical conditions. This 
is also something that can be expanded upon in future work. 
5.2.3 – Determining a crystal structure of FEN 1 at high 
pressure. 
The crystallography experiments performed at high pressure were only preliminary, 
and they serve as a springboard for future work attempting to solve the structure at high 
pressure. Important results obtained included the determination of crystals that favoured 
ambient high-pressure data collection but were poor for cryo data collection and vice versa. 
Although the crystal growth conditions were different for both the ambient and high-
pressure experiments, the initial statistics indicated that they had the same space group and 
unit cell dimensions. That being said the high-pressure conditions should be subjected to 
further optimisation in any future experimentation.  
Aside from archetypal optimisation, whereby slight modifications in the conditions are 
made to generate more suitable crystal types, optimisation could include an earlier crystal 
harvest. The crystals that were harvested for these preliminary experiments had dimensions 
larger than that of the DAC sample chamber. This led to the crystals having to be manually 
broken up to fit into the chamber. This introduced cracks and other deformities that 
compromised the integrity and quality of the data collected. Harvesting the crystals earlier 
would mean that the crystals would be smaller, and therefore more likely to fit within the 
chamber. This would mean that no damage is introduced to the crystal before the data 
collection generates radiation damage potentially increasing the quality of the data as well as 
the lifespan of the crystal. 
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Alternative methods to solve the phase problem 
Isomorphous replacement works on the principle of detecting visible changes in 
intensity as a result of soaking the crystal in a solution containing ‘heavy’ atoms, by which 
they are atoms with a large atomic number. 
The presence of the heavy atom significantly changes the structure factors associated 
with the data.  
 
Figure A.1 - Harker constructs demonstrating both single isomorphous replacement (SIR) and 
multiple isomorphous replacement (MIR). Fp relates to the structure factor for the protein, 
which remains unknown, FH relates to the heavy atom structure factor and FPH relates to the 
structure factor for the derivative crystal containing the heavy atom. 
Making use of this phenomenon to collect both a native data set and a derivative set 
containing a heavy atom set allows direct comparisons to be made and a location for the 
heavy atoms within the structure to be identified. This in turn then allows for the 
determination of the structure factor for the heavy atoms (FH).  
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Combining this information with the amplitude information about both datasets into a 
Harker construct as seen in figure 2.5, where FPH is the structure factor for the derivative 
crystal containing the heavy atom and FP is the as yet unknown structure factor for the 
protein.  
𝐹!" = 𝐹! + 𝐹!  
Because of this formula, the only possible phase outcomes for the FP are where the two 
circles intersect with one another, giving two possible results. In this diagram, the circles 
represent the maximum amplitude for the data collected and all possible phases.  
If a second heavy atom derivative dataset was collected, the structure factor for the 
second heavy atom could be determined (FH’) and therefore a third circle could be drawn, 
leading on to only one possible phase outcome for the protein structure factor as seen in 
figure 2.5. In practice, the result is seldom as clear cut, but the principle works in theory 
Anomalous dispersion is another technique that can be used to determine the phases, 
and works on similar principles to isomorphous replacement. One way it improves on SIR 
and even more so MIR, is that the levels of isomorphism are preserved due to the fact that 
only one crystal is used. In MAD, the data are collected at several wavelengths, which are 
shown in figure 2.6 and of which, λ1 and λ2 are most important.  
With a change in the wavelength there is an alteration in the structure factor 
amplitude, which can be plotted either on a phase diagram or again on a Harker 
construction. In SAD only one wavelength is used. 
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Figure A.2. - A modified graph that illustrates the variation in anomalous scattering against the 
incident X-ray energy. Showing f’ – dispersive term, f’’ – absorption term, λ1 – absorption 
peak, λ2 – maximum dispersive difference, λ3 + λ4 – remote wavelengths (162, 163) 
In order to perform anomalous dispersion, atoms with anomalous scattering are 
needed. One way is to use a heavy atom that has been incorporated into the structure, such 
as by replacing the methionine amino acids present in the structure with selenomethionines, 
replacing the S atoms with Se atoms, which have a significantly larger atomic mass and 
therefore scatter electrons considerably more. 
Wavelength tuning is essential for AD, therefore the data has to be collected at a 
synchrotron. The anomalous scattering relates to the scattering of both the hkl values as well 
as the –h-k-l values, which one would expect to be identical. However they are in fact slightly 
different. 
Once the data have been collected, the structure factors are known for all the atoms. 
The anomalous scattering component of all the atoms then needs to be determined. Once 
this is known the difference in phase angle between the normal and anomalous data can be 
determined and the phase of the data can be calculated. 
 
